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Abstract 
Decoration of nanoparticle surfaces with receptor-specific ligands can improve functional drug 
delivery to cancer cells.  Our ligand of interest is a short peptide, U11, sequenced to show 
high affinity for the Urokinase Plasminogen Activator receptor (uPAR), a receptor 
overexpressed on the surface of many tumours.   We prove that the presentation of the 
peptide ligand, along with the nature of the liposomal platform, play synergic roles in the 
exhibition of the nanoparticle’s targeting effect. 
 
U11 peptides were loaded onto PEGylated liposomal nanoparticle surfaces by covalent 
conjugation.  In vitro pDNA transfection and uptake studies established the viability of the U11 
peptide as a ligand for cancer cell targeting.  Circular dichroism and fluorescence 
spectroscopy methods were used to examine the secondary and tertiary conformations of the 
surface peptides. siRNA encapsulation assays, nanoparticle turbidity and in vitro gene 
silencing experiments were used to optimise the targeted nanoparticle for in vivo delivery.  In 
vivo siRNA (luciferase) experiments were performed on mice carrying uPAR-positive (DU145-
luc and MDA-MB-231-luc) and uPAR-negative (PC3-luc) cancer xenografts.   Biodistribution 
properties of the nanoparticles were examined by administrating fluorescently-labelled or 
microRNA-encapsulated nanoparticles.   
 
U11-targeted nanoparticles were able to enhance gene delivery (pDNA and siRNA) to uPAR-
positive cells.  Nanoparticle platforms of lower zetapotential reduced non-specific electrostatic 
interactions with cell membranes, hence allowed enhanced exhibition of the ligand’s targeting 
effect. Adding further percentages of PEG increased nanoparticle stability, and maximised 
ligand exposure by forcing the U11-associated PEG chains into a brush conformation.  In vivo, 
U11-nanoparticles indicated enhanced delivery efficacies of siRNA to models bearing small, 
uPAR-positive tumours.  In larger, uPAR-negative xenografts, the accumulation of both 
targeted and non-targeted nanoparticles (by the enhanced permeation and retention effect) 
into tumours was equal, and indicated reduced protein expression to the same extent.  24-
hours post-administration, accumulation into the liver and the spleen of targeted nanoparticles 
was higher compared to non-targeted nanoparticles, most likely a result of increased 
recognition of the nanoparticles by organ-specific macrophages.   
 
Without doubt, the introduction of surface ligands can enhance nanoparticle deliver to cancer 
cells, although careful organisation is required to maximise their effect.  Low ligand densities, 
ligand extension via a PEG spacer, high platform PEGylation and low zetapotentials can aid 
the maximum exhibition of the ligand’s targeting effect.  Such a presentation of surface-
ligands can increase nanoparticle interaction with cancer cell receptors, although it can also 
lead to greater accumulation into the liver and spleen. 
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The translation of novel molecular medicines into viable options for cancer therapies 
is dependent on the progression in the development of efficient vehicles in which 
they can be delivered.  The main reasons for which molecular medicines require 
encapsulation into carrier vehicles are related to both the toxicity of the medicines, 
plus the integrity of the molecular structure of the drug before arrival at the site of 
interest.  Many chemotherapeutic agents have the major disadvantage in that their 
toxicities can have considerable detrimental effects on healthy cells.  The toxicities of 
such drugs hinder their administration at higher concentrations, and their use at 
repeated doses.  For example, doxorubicin, a recognized agent used clinically for 
cancer treatment, is limited in its application due to the toxic effect it has on the heart 
and the immune system after its systemic delivery into the blood stream [1].   This 
has led to the development of Caelyx (or Doxil), a formulation of Doxorubicin 
encapsulated in a liposomal carrier, which has shown to have significantly diminished 
cytotoxicity issues without the reduction of anti-tumour efficacies [2-3].   Other 
macromoecular drugs, such as therapeutic nucleic acids, need to be protected in a 
carrier due to their sensitivity to modification or digestion by nucleases.  Particularly 
for cancer therapy, successful arrival of macromolecular drugs, at therapeutic 
quantities, to the tumour sites requires longer circulation time, hence a prolonged 
exposure to such enzymes for extended periods of time.   
 
Examples of anti-cancer drugs are plenty, and injectable colloidal formulations of of 
varying characteristics have been formulated to accommodate their differences.  
Upon systemic delivery, the pathway through which these nanoparticles arrive at 
cancer sites is via the neovasculature.  Therefore, the scaffolds of the nanoparticle 
delivery systems share common components crucial for proper pharmacokinetics 
and for successful delivery. 
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A     B    C  D
A= drug material
B= nanoparticle envelope
C= Stealth layer
D= Targeting layer  
 
Figure 1-1: Cross sectional representation of general structure of nanoparticles for drug 
delivery to cancer cells.  Systems consist of drug material (A) which is protected within a core 
of material capable of encapsulation (B).  Another layer of stealth polymer (C) aids the 
biocompatibility of the nanoparticle for systemic delivery.  Finally, the exterior of the 
delivery system, D) can include targeting ligands to encourage specificity and enhance 
internalisation into cancer cells. 
 
A functional delivery system to cancers generally consists of several layers, where 
each layer serves a purpose for overcoming barriers to delivery (Figure 1-1).  Firstly, 
the core interior comprises of the molecular drug that exhibits anti-cancer abilities.  
Immediately enclosing the drug core is the main encapsulation platform, employed to 
protect the molecules from external environments.  The materials that make up such 
a layer are generally based on polymers or lipids, which can self-assemble around 
the drug core and form colloidal structures when suspended in aqueous solutions.  
Although this layer of molecules can effectively encapsulate the drug core, the 
resulting colloidal system is still vulnerable to physiological conditions inherent to 
systemic delivery.  Consequently, a further exterior layer is required for ultimate 
protection of the composite nanoparticle construct.  Otherwise termed the stealth 
layer, this layer is composed of hydrophilic polymers, commonly polyethylene glycol 
or sugar-based polymers such as dextran or chitosan, and its introduction into the 
nanoparticle system has been proven crucial to overcome a series of biological 
barriers.  To further functionalise such a system, the ultimate exterior layer can 
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consist of targeting ligands that have high affinity to cancer-related receptors.  The 
incorporation of such ligands onto nanoparticle surfaces has been shown to enhance 
selective delivery and internalisation into cancer cells. 
 
1.1.  Delivery to cancer cells 
 
Each layer within a delivery system is recruited to aid the nanoparticle to overcome 
the many biological barriers the delivery process poses.  The hurdles that 
nanoparticles encounter are plentiful and can be categorized into two main classes: 
the systemic and cellular barriers.  The systemic barriers refer to the succession of 
obstacles met during the transport of the nanoparticles, between administration into 
the blood stream and arrival at the cancer cells.  As the vasculature provides the only 
route to the tumour site, the nanoparticles must be engineered with the 
characteristics of blood circulation in mind.  The cellular barriers describe the 
challenges faced during the cellular internalisation process, after arrival at the target 
site.  Upon internalisation, the nanoparticles can release their cargo, after which the 
anti-tumour effect is dependent on the potency of the drug.  Described below is a 
detailed discussion of the biological barriers, and the design of the nanoparticle 
system to overcome them. 
 
1.1.1. Systemic barriers 
 
The systemic barriers are representative of the difficulties nanoparticles encounter in 
blood circulation, en route to the tumour site.  Intravenous administration of cancer 
medicines is the ultimate method of delivery, preferred over other means such as 
intratumoral or intraperitoneal, in terms of ease of injection, tumour-homing and 
efficiency.  Particularly for treatment of ovarian cancer, delivery methods by 
intraperitoneal injection have proven effective, although the accumulation of high 
concentrations within the peritoneal cavity can be toxic [4]. Termed the enhanced 
permeation and retention effect (EPR effect) [1-2], nanoparticles arrive at cancer 
cells through the network of tumour vasculature, a result of angiogenesis which 
occurs once tumour growth reaches a size of 2-3mm3 (Figure 1-2) [3].  The 
angiogenic vasculature serving the tumour differs from the vasculature of other 
organs in the structure and organisation of the endothelial cell layer.  The lining to 
these blood vessels are not smooth and well-ordered, as they are normally, but are 
disordered and ‘leaky’, providing various holes and fenestrae through which small 
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particles can pass.  These fenestrations have been measured to be within 100-
400nm in width, a size range that demonstrates one of the requirements for 
nanoparticle design [1].  The diameters of nanoparticles have been proven crucial for 
tumour accumulation.  Smaller nanoparticle sizes exhibit higher diffusional rates into 
the tumour interstitium, due to enhanced passage through the vasculature 
fenestration. For nanoparticles less than 100nm in diameter, the rate of extravasation 
into tumour sites is inversely dependent on nanoparticle sizes [8-13].  The lymphatic 
drainage system of the tumour tissue is also impaired, which results in the retention 
of macromolecular species within the tumour, whilst extravasation continues [4-5].  
The challenge in systemic delivery is to maintain the small nanoparticle diameter 
whilst in circulation, required eventually to allow their diffusional transport across 
tumour-vasculature fenestrations. 
.   
 
 
Figure 1-2: Representation of the systemic barriers based on the EPR effect.  Accumulation 
of macromolecular species into tumour sites is through the leakage into the fenestration 
within the endothelial layer. Reproduced from Dan Peer et al. Nature Biotechnology, 2009 
[16].   
 
After intravenous injection and dispersion into circulation, nanoparticles are 
immediately exposed to a highly ionic environment, containing a variety of plasma 
proteins.  The combination of high salt and high protein concentrations poses an 
environment that threatens the stability of colloidal systems.   The loss of stability can 
lead to nanoparticle aggregation and increased surface-adsorption of plasma 
proteins.  Aggregation of nanoparticles is unfavourable due to the increase in particle 
diameter, plus surface-adsorption of proteins can mark the nanoparticles for 
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macrophage recognition.  Aggregated nanoparticles are also limited to localisation in 
the lung and the liver, as the pulmonary capillary bed is the first site intravenously 
administered molecules pass over.  This becomes a problem when the cancer to be 
treated is located in organs other than the lung, highlighting the importance of 
inducing anti-aggregation properties to the nanoparticles.  Adsorption of plasma 
proteins onto surfaces can occur for the majority of nanoparticles, but the 
phenomenon is enhanced when the surface curvature is reduced [6].  Adsorption of 
opsonins, proteins involved in the immune-response mechanism of the reticular 
endoplasmic system (RES), leads to identification by the mononuclear phagocyte 
system, followed by removal from circulation [7-8].  Once removed from the blood 
stream, the nanoparticles are unable to be transported to tumour sites.  Therefore, 
preventing nanoparticle aggregation and reducing protein adsorption are the two key 
factors to consider during nanoparticle design.  The introduction of the stealth layer, a 
layer of hydrophilic polymers, is one of the most important components of a 
nanoparticle system.  
 
The nanoparticles must be dispersed and remain non-aggregated in order to by-pass 
the small fenestrations of the tumour vasculature.  Colloidal stability is therefore 
essential for bypassing systemic barriers.  According to the DLVO theory (Derjaguin 
and Landau, Verwey and Overbeek), a theory that describes the stability of colloids 
in solution, resistance of aggregation and flocculation is achieved if the repulsive 
forces between the nanoparticles are greater than the attractive forces (Figure 1-3) 
[7-9].  The attractive forces are essentially the Van der Waal potential between the 
nanoparticles, and the repulsive forces are those generated by electrostatic and/or 
steric repulsion.  In biological fluids, the effect of charge screening, achieved through 
the introduction of steric factors, is important for the generation of a stable colloidal 
system.  In terms of biological applications, the systemic delivery of highly charged 
particles, specifically positively charged particles, is likely to result in a rapid 
clearance from circulation.  This is a consequence of recognition by the RES, again 
an undesirable outcome, as accumulation of nanoparticles into tumours is dependent 
on their extended residency in circulation.   
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Figure 1-3: Representation of the DLVO theory- where the net energy is a sum of the 
repulsive and the Van der Waals attractive forces, a).  Colloidal stability is only maintained 
when the repulsive forces are greater than that of the attractive forces.   b) Colloids 
stabilised by electrostatic repulsion (left), and steric repulsion (right).  Electrostatically 
stabilised particles contain a highly charged double layer surrounding the particle, whereas 
sterically stabilised particles are surface-functionalised with polymer chains.   
 
Therefore, to induce colloidal stability in a situation where inter-particle electrostatic 
stabilisation is not feasible, the introduction of steric chemical components is crucial.  
Steric stabilisation can be achieved by the functionalisation of particle surfaces with 
hydrophilic polymers, such as poly-ethylene glycol (PEG).   These PEG chains not 
only reduce Van der Waal attractions between the nanoparticles, but also provide a 
stealth-like quality to the nanoparticles, by preventing the adsorption of proteins 
encountered in biological fluids (Figure 1-3).   
b 
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Incorporation of a polymer coat onto the surface is anticipated as a method to shield 
the nanoparticles from external stimuli presented in circulation.  The second of the 
two major benefits of conjugating a stealth polymer layer is its role in repelling 
plasma proteins.   
 
The plasma component of blood contains a plentiful variety of proteins.  Antibodies 
and opsonin proteins can adhere to nanoparticle surfaces, to act as marker tags for 
macrophage recognition.  Once tagged, the nanoparticles are recognised by 
mononuclear phagocytes, macrophage cells that can be free entities within 
circulation, or fixed within tissues such as the Kupffer cells of the liver and the 
sinusoidal cells of the spleen [18, 23-24].  On recognition, the nanoparticles are 
sequestered by the macrophages and hence unable to localise into tumour sites.  
Inclusion of the stealth layer is therefore important to minimise such an occurrence 
by preventing the adsorption of opsonin proteins.   PEG molecules are particularly 
effective as a steric barrier due to their flexibility and hydrophilicity [10].  Highly 
hydrophilic and flexible molecules are able to cause higher degrees of water 
disturbance, allowing the movement of water molecules out of the PEG cloud, 
rendering it impermeable to protein adsorption [11]. To maximise the steric effect of 
the stealth layer, the length of the PEG monomers plus the density of their grafting 
can be varied.  The surface density of the PEG polymers ultimately affects the 
conformation they adopt.  At lower concentrations, the PEG chains fold into spherical 
mushroom-like clouds, each with a gyration radius depending on the number of 
monomers within the chain [12].  At higher concentrations, the lateral pressures 
between the PEG mushrooms force the chains to extend form the nanoparticle 
surface, forming brush-like conformations (Figure 1-4).  Both types of PEG 
configurations can still allow protein adherence, although it is generally accepted that 
higher PEG densities (brush conformations), in conjunction with high surface 
curvature (small diameter) are able to reject protein adsorption most effectively [13-
15].  Interesting is also the phenomenon of anti-PEG IgM antibodies, which are 
produced in the spleen 4-5 days after the administration of the 1 dose of PEGylated 
nanoparticles [31-34].   
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Figure 1-4: Representation of mushroom and brush conformations of PEG polymers on the 
surfaces of nanoparticles.  At low densities, PEG chains fold into mushroom-type clouds, and 
at high densities, they are forced into brush-type configurations. 
 
As nanoparticles are appropriately prepared to avoid aggregation and clearance from 
circulation, they can overcome systemic barriers and eventually arrive at tumour sites 
through the tumour vasculature.  On arrival within proximity of the external layer of 
cancer cells, nanoparticles require further internalisation within the cancer cells for 
the exhibition of their effect.   However, it is unfortunate that the said characteristics 
required to bypass systemic barriers are those that pose problems for overcoming 
cellular barriers.  Entrance into cancer cells through mechanisms of endocytosis is 
maximized when the nanoparticles are high in cationic charge.  The presence of 
surface-polymers also reduces the association of nanoparticles to cancer cells, 
hence further limiting their cellular internalisation.  The presence of PEG chains also 
affects the nanoparticles’ ability to disrupt endosomal compartments [35].  
 
To overcome the series of systemic barriers, the nanoparticles must resist inter-
particle aggregation, and they must oppose surface adsorption of proteins.  
Bypassing these obstacles leads to nanoparticle accumulation into tumour sites, after 
which the therapeutic function of the delivered drug is dependent on overcoming the 
cellular barriers.  Further components in a general nanoparticle delivery system are 
recruited to challenge these hurdles. 
 
 
 
 
 
Chapter 1- Introduction 
26 
 
Table 1-1: List of systemic barriers and their implications for nanoparticle drug delivery to 
cancer cells. 
 
Systemic Barriers 
to overcome 
Implications Prevention 
Nanoparticle 
aggregation 
 Large diameters prevents nanoparticle 
diffusion into tumour sites through 
fenestrations in vasculature (<500nm). 
 Larger sizes creates decreased 
curvature for increased protein 
adsorption 
 Introduce polymer 
stealth layer to induce 
steric repulsion. 
Surface 
adsorption of 
plasma proteins 
(opsonisation) 
 Opsonin proteins act as recognition 
tags for macrophages, which withhold 
and prevent re-entry of nanoparticles 
back into circulation.  
 Protein adsorption increases overall 
size of nanoparticle 
 Introduce polymer 
layer. 
 Low-charge (neutral) 
nanoparticle platform. 
 
1.1.2. Cellular Barriers 
 
Entry of anti-cancer nanoparticles into cancer cells is generally through the 
mechanism of endocytosis, an internalisation mechanism where extracellular species 
are engulfed by the lipid cell membrane to be contained within the cell’s 
cytoplasm.  Electron microscopy studies have suggested that the internalisation 
mechanism of nanoparticles is dependent on Clathrin, a well-characterised protein 
involved in membrane-folding for endocytosis [16-17]. The specificity of cell uptake is 
therefore a result of the selectivity of cell-binding, where the internalisation of a 
receptor-targeted nanoparticle occurs by receptor-mediated endocytosis 
(RME).  Once internalised, the lipoplex is contained within an endosomal structure, a 
vesicle formed from lipid and protein material gathered from the cell membrane 
(Figure 1-5, Table 1-2).    
 
The endosome essentially acts as a ‘filtering’ mechanism, recycling reusable material 
such as receptors back to the cell surface, or degrading harmful material via fusion 
with a lysosome.  The fate of an internalised nanoparticle is dependent on its ability 
to disrupt the endosome barrier, which must occur in timely order to avoid 
degradation or re-delivery to the cell surface.  A successful disruption of endosomal 
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encapsulation, either through the de-acidification of the enodosmal pH or the fusion 
of endosomal lipids with the nanoparticle lipids, would result in the release of genetic 
material from the nanoparticle into the cytoplasm.  For nuclear translocation, DNA 
must overcome the diffusional barrier of the cytosol and resist metabolic degradation 
in order to successfully enter the nucleus [18].  siRNA molecules can function in the 
cytoplasm, obliterating the extra obstacle of nuclear entry.  
 
However, before they are faced with cellular delivery, nanoparticles must 
successfully arrive at the cancer cells, after overcoming the series of hurdles 
presented by the systemic barriers. 
 
 
 
 
Figure 1-5: Schematic representation of cellular barriers encountered by nanoparticles.  
Firstly, nanoparticles must attach to the cell membranes through non-specific or receptor-
specific binding (a).  Then the nanoparticles are internalised into the cytoplasm through non-
specific or receptor-mediated endocytosis (b).  Once internalised, the nanoparticles are 
trapped in endosomal compartments (c), which they must escape in order to release their 
therapeutic cargo (d).  For nucleus-mediated drug delivery, the released drugs must cross 
the nuclear membrane (e). 
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 Table 1-2: List of cellular barriers and their implications in nanoparticle drug delivery to 
cancer cells. 
 
Cellular Barriers Considerations 
Cellular binding Initiates cellular internalisation.  Nanoparticles can be 
prepared to induce receptor-specific binding for cell 
specificity. 
Cellular internalisation Entry of nanoparticles into cells.  Generally through 
endocytosis or receptor-mediated endocytosis.  
Endosomal escape Endocytosis into cells results in nanoparticles contained 
within endosomes. Escape from such compartments 
releases therapeutic drug into cytosol. 
Intercellular transport For therapies targeting DNA of the genome, drugs must 
travel to the nucleus through the nuclear membrane.  
Nuclear-localisation strategies can be adopted. 
 
1.2. Types of nanoparticle drug delivery systems 
 
The objective for nanoparticle based-therapies is to enhance the pharmacokinetics 
and the biodistribution of the therapies for cancer cells.  The nanoparticles used for 
such purposes are generally comprised of molecular units that self-assemble in 
aqueous solution to form nano-sized entities.  These entities are macomolecular 
structures that form as specifically-designed molecules interact through non-covalent 
interactions.  The properties of such synthetic platforms are therefore dependent on 
the structure and the composition of the monomers, which can be manipulated by 
chemical methods.  Components that are adopted for the preparation of 
nanoparticles are generally classified into three main types, protein/peptide-based, 
polymer-based, and liposome-based.  Sub-classes include the chemical and covalent 
combination of these i.e. lipopeptides, polymer-peptides, lipid-polymers.  Molecular 
therapies chemically associate into the interior of such nanoparticle systems, hence 
should be protected from exposure to blood and cellular components before the 
target site is reached.   
 
Described below are examples of different types of nanoparticle delivery platforms.  
These systems differ in the nature of their material, which is chosen for their 
compatibility with the drug they encapsulate.  Although these delivery systems differ 
in many ways, they share the same aim in delivering the anti-cancer drugs to the site 
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of the tumour.  Therefore, the pathway through which they reach the tumour tissue, 
which is via the leaky fenestrations of the tumour vasculature, is the same.     
1.2.1. Protein and peptide-based nanoparticles 
 
Protein and peptide-based nanoparticles exploit the encapsulation efficiencies and 
the immunogenicity of naturally occurring proteins and peptides.  In the case of 
protein-based systems, one main example is that of albumin-associated delivery, 
human albumin being an abundant plasma protein that is a natural carrier for 
lipophilic compounds such as hormones [19].  Human albumin proteins are naturally 
dispersed as nanospheres, and function as transport agents, which prompted its 
application as a drug delivery agent.   Already in market is Abraxane, an albumin- 
nanoparticle delivery system encapsulating paclitaxel, an anti-cancer drug that acts 
by affecting the cellular microtubules to induce apoptosis [20].  
 
Triple helix of  collagen peptide- with 
immunogenic telopeptides removed by 
enzyme digestion
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Figure 1-6:  Examples of protein and peptide-based nanoparticle delivery systems for cancer.  
Left, Abraxane formulation- paclitaxel anti-cancer drug encapsulated within albumin 
proteins (www.abraxane.com).  Right, atelocollagen particles- assembled from collagen 
peptides that have been treated to remove the immunogenic telopeptide components.  
Atelocollagen particles have been used to deliver siRNA.   
 
Peptide-based nanoparticles have also been employed for their antigenicity and their 
ease of preparation.  The peptides used have high intermolecular interactions and 
are generally derived from naturally-occurring proteins through enzyme digestion.  
One example is that of atelocollagen, a digested product of collagen without the 
telopeptide components to minimize immune recognition.  Atelocollagen has shown 
high efficiencies for the delivery nucleic acids, for the induction of gene therapy 
against cancer [21].  On encapsulation of short interference RNA (siRNA), 
atelocollagen nanoparticles were able to functionally inhibit the expression of 
oncogenic proteins [22].  Although functional, nanoparticles formulated with these 
materials are not easily manipulated by chemical methods, hence limiting their 
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flexibility for improvement. The functionalisation of such nanoparticle delivery 
systems with additional modalities, such as imaging probes, or targeting ligands is 
also important for optimising the delivery effect.  Materials such as polymers and 
liposomes are extensively used for their ability to accommodate extra chemical 
functionalities for improved drug delivery.    
 
1.2.2. Polymer-based nanoparticles 
 
Polymeric materials have been popular as platforms for drug delivery due to the ease 
of their synthesis and manipulation.  Essentially, this means that nanoparticles can 
be developed accordingly to their application, through rational design and chemical 
modification of the monomeric species.  Polymers, as well as liposomes, are 
particularly useful as gene delivery systems, as they can be prepared to exhibit 
cationic features, for electrostatic binding with negatively charged nucleic acids.  An 
example of a well characterised and highly functional delivery polymer is that of the 
polycation modified cyclodextrins [23].  Cyclodextrin-based polycations can associate 
electrostatically with nucleic acids, encapsulating them with their hydrophilic cores 
(Figure 1-7) [44].  Furthermore, the pores within the dextran molecules provide 
regions into which PEG-associated hydrophobic anchors (adamantane) can dock.  
Anchoring of additional targeting ligands such as PEG-transferrin has allowed 
enhanced nanoparticle internalisation into cancer cells [45-48].  This example of 
nanoparticle delivery systems for siRNA delivery is one of few to be studies in clinical 
trials [43, 45, 49-50].  
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Figure 1-7: Representation of polymeric cyclodextrin-based nanoparticle delivery systems, as 
developed by Davis ME et al.  The cationic 7-membered cyclodextrin polymer can 
encapsulate siRNA by electrostatic interactions.  The hydrophobic pores within the cyclic 
rings provide anchoring points for PEG or transferrin-PEG components [23].   
 
Polymers are not always prepared by polymerisation of the same monomeric units.  
They can also be copolymers, synthesized to include a hydrophilic part and a 
hydrophobic part in the same molecule.  This therefore allows the amphiphilic block 
copolymers to self-assemble into micellar tertiary structures upon hydration in 
aqueous solutions.  Many examples of polymeric micelles have already been 
featured in clinical trials, one of which is NC-4016, or DACH-platin micelle.  This 
nanoparticle delivery system consists of amphiphilic polymer units synthesized to 
include hydrophilic PEG chains at one end, and hydrophobic peptide chains at the 
other [24-25].  The hydrophobic moiety of the polymer coordinates and binds with 
cisplaitin, a platinum-based anti-cancer drug, and the hydrophilic part protects the 
interior with the PEG chains (Figure 1-8, right).   
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Figure 1-8: Representation of polymeric nanoparticle delivery systems.  Anti-cancer 
molecular drugs or nucleic acids (represented by purple circles) can be encapsulated into 
simple polymer chains (left) or into polymeric micelles (right). 
 
1.2.3. Liposomes 
 
Formed from the assembly of amphiphilic lipids, liposomes, like their micellar polymer 
counterparts, can encapsulate macromolecular therapies within their interior core.  
Liposomes exhibit many advantages over cationic polymers as delivery vehicles for 
gene therapy, one of which is the lower levels of toxicity.  Composed of the same 
material as cell membranes, the lipidic moieties of the liposomes can easily be 
cleared from the cells after internalisation, whereas long polymeric chains such as 
PEI, induce cell toxicity through their disinclination for degradation [26].  
 
The lipids involved in these delivery liposomes are either natural lipids or synthetic 
lipids, consisting of a positively charged hydrophilic head group with a lipid-based 
hydrophobic tail.  On exposure to aqueous environment, amphiphilic lipids self-
assemble into a variety of macrostructures, dependent on the geometrical shape and 
the concentration of the lipid in solution (Figure 1-9).  The flexibility of liposomes as 
drug delivery vehicles is even greater than that of polymers, as the lipidic content can 
be added and tuned according to the application of the particle.  The structure of the 
liposomal particle is dependent on the geometrical shapes of the lipids recruited for 
formulation. Contrary to micellar polymer nanoparticles, liposomes can encapsulate 
Chapter 1- Introduction 
33 
 
hydrophilic molecules such as nucleic acids.  The ability of liposomes to encapsulate 
DNA and RNA lies in its capability to express cationic nature, through the 
incorporation of cationic lipids.  On addition of negatively charged genetic material, 
encapsulation of the genes occurs in the aqueous core and between the aqueous 
layers of the liposomes, to render an increase in entropy (through the release of 
counter-ions associated with the cationic head groups) and system stability [27].  
Termed ‘lipoplexes’, these nucleic acid-liposome structures range between 50-
500nm in diameter size, and can consist of a variety of different lipids.  The main 
advantage of liposomal nanoparticle delivery systems is their ease and ability for 
functionalisation.  Fluorescent, radioactive or metallic-lipid amphiphiles can all be 
incorporated into liposomal structures easily, to render tracking and probing ability to 
the nanoparticle. 
Liposome 
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Figure 1-9: Representation of liposomal drug encapsulation.  Liposomes are firstly formed 
through self-assembly of lipidic components (left).  Hydrophilic drugs or nucleic acids 
(purple) can then be encapsulated into the aqueous core if the liposome (right). 
 
Mentioned is the example of Caelyx, a liposomal formulation of the anti-cancer drug 
Doxorubicin.  The nanoparticle used in this example is in fact a combination of 
liposome and polymers, where a layer of polyethylene glycol (PEG) chains are 
incorporated onto the surfaces of the drug-encapsulating liposome.  Encapsulation of 
doxorubicin into this type of nanoparticle increases its circulation time by 100-fold, 
hence enhancing the accumulation of the molecular drug into cancer sites [28].  This 
example demonstrates the flexibility of liposomes for modification, as the PEG layer 
was easily included through the addition of PEG-lipids into the liposome formulation.   
 
In regards to gene delivery, liposomes have proven to be the nanoparticle of choice, 
in comparison to the other methods described here.  The most well-known example 
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being Lipofectamine®, the standard in vitro transfection agent used widely in 
biological protocols.  Encapsulation of therapeutic nucleic acids into such liposomal 
nanoparticles has also shown promise as a method of gene therapy for cancer [29-
30].  
 
1.3.  Principles of Gene Therapy 
 
Defined as the delivery of genetic material for purposes of therapy, the aim of gene 
therapy is to correct the consequences of a defective gene by the administration of a 
therapeutic one.  The theroretical advantages of gene therapy over traditional 
chemotherapeutic reagents lie in their reduced side effects and lower toxicity issues.  
Gene therapy measures aim to treat disease at the genetic level, eradicating the 
potential for disease development in the future.   For cancer gene therapy, nucleic 
acids can be delivered to either promote the expression of tumour suppressors, or to 
inactivate the expression of oncogenic proteins.  Two limiting factors are therefore 
posed in this quest for success. Firstly, the discovery of defective genes associated 
with corresponding cancers is important for the identification of therapeutic genes for 
treatment.  The other main hurdle lies in the delivery method of such genes to the 
cancer cells.   Success from the Cancer Genome Project has propelled the 
understanding of disease at the genetic level, which leaves the therapeutic step of 
gene therapy as the real challenge for scientists [31-33].  With also over 80% of 
clinical trials entering subsequent phases (www.wiley.co.uk/genetherapy/clinical/), 
the potential of gene therapy as a standard treatment for cancer is becoming 
increasingly recognised.     
 
Since cancer is a disease that is expressed on damage or mutation within the 
genome, the use of DNA or RNA as a therapeutic agent aims to correct the disease 
from the root of the cause.  The development of tumours is caused by genetic 
defects associated with cell growth, which leads to the uncontrolled proliferation of 
cancer cells.  The delivery of DNA in such therapies is proposed to enhance the 
expression of proteins involved in growth suppression, otherwise known as tumour-
suppressors.  One major example is that of the p53 gene, which codes for the 
transcription factor that regulates the cell cycle and initiates apoptosis [34-36].  In 
many types of cancers, a damaged p53 gene results in the expression of defective 
p53 proteins that are unable to arrest cell growth.  Many researchers have therefore 
focused on the development of p53-based therapies for cancer treatment.  In fact, 
Chapter 1- Introduction 
35 
 
the first approved genetic therapy for head and neck cancer (China, Genedicine, 
Shenzhen SiBiono Gene Technologies Co Ltd) is based on the use of p53 DNA, 
which is delivered to the disease site through the use of viral-based adenovirus 
vectors.   
 
More recently there has been an increase in research concerning the delivery of RNA 
for cancer gene therapy.  In contrast to the effect induced by the delivery of DNA, the 
use of RNA is employed to inhibit the translation and expression of proteins 
associated with cancer growth.  The potential of RNAs as a form of cancer therapy 
began with the discovery of the pathway RNA interference pathway in 1998 [37-38].  
RNAi proceeds by the administration of segmented, double-stranded RNA molecules 
(either short-interference RNA or micro RNA) into cells, which eventually leads to the 
inhibition of the protein for which the RNA codes.  Once in the cell, the short RNA 
strands can bind to complementary mRNA strands and hence inhibit its further 
translation.  Therefore, this strategy has been adopted to treat cancer by knock-down 
of oncogenic proteins that lead to tumour growth.  Many studies have focused on 
inhibiting the expression of vascular endothelial growth factors (VEGF), as a method 
of RNAi-induced cancer therapy.  VEGF is a growth factor protein secreted by 
tumour cells to signal for angiogenesis, the formation of vasculature to supply the 
growing tumour.  By hindering the expression of such growth factors, angiogenesis 
around the tumour tissue is also limited, hence affecting the increase in tumour 
growth.  Using the peptide-based nanoparticle delivery system, atelocollagen, the 
administration of anti-VEGF siRNA was shown to suppress both tumour 
angiogenesis and tumour growth [66].  
 
What is evident is that all genetic therapies require a suitable carrier through which it 
can be delivered to the tumour sites.  A variety of delivery methods have been 
developed, the most effective being the use of viral vectors.  With the advantage of 
millions of years of evolution, viruses have evolved to infect host cells with 
remarkable efficiency.  Genetic modification of wild type viruses allows the 
replacement of natural viral genes, which are detrimental to the host cells, with genes 
of a therapeutic nature.  Common viruses adapted for gene therapy include 
retroviruses, adenoviruses and adeno-associated viruses [39-40].  Although 
acclaimed for their high efficiency in transfection, a modest understanding of the 
activity of these viral vectors poses a number of potential problems.  The least of 
these disadvantages include the high costs and the difficulty of their production in 
large quantities, whereas the more dangerous side effects include insertional 
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mutagenesis [41], development of leukaemia [42], high levels of toxicity and 
immunogenicity [43-44].  Without a sound understanding of the mechanism and 
manipulation of viral vectors, their action could potentially be more detrimental than 
therapeutic.   
 
This therefore leaves the use of non-viral nanoparticles as a safer and a more viable 
option for gene delivery.  Liposomes are by far the most versatile and flexible 
nanoparticle delivery system, due to the ease at which the properties of the 
nanoparticle can be manipulated through the adjustment of lipidic content.  Described 
earlier is the EPR effect, the mechanism through which nanoparticle drug delivery 
systems can accumulate into tumour sites.  Additional components are therefore 
required within a liposomal delivery system to overcome the biological barriers posed.   
Aside from the obvious inclusion of nucleic acids, the other main constituents for the 
assembly of liposomal nanoparticles are generally listed as: 
 
1) Liposomal lipids 
2) Stealth polymers 
3) Targeting ligands 
 
Here, we follow by dissecting the function and optimisation of each component, for 
the formation of an ultimate nanoparticle for cancer delivery. 
 
1.4. Nanoparticle constituents- liposomal lipids  
 
The main purpose of recruiting cationic liposomes for delivery purposes is to utilize 
their ability for encapsulating and protecting the nucleic acids during the delivery 
process.  The liposomal bilayers are formed from amphiphilic lipids, which consist of 
a hydrophilic head group, and a hydrophobic lipidic tail.  Liposomes are hence 
formed when the mixture of lipids are suspended in aqueous solution, rearranging to 
minimize contact of the hydrophobic tails with the surround H2O.  The liposomal lipids 
generally consist of a mixture of cationic lipids, plus that of helper lipids, recruited to 
aid phase transition of the bilayers during post-internalisation endosomal escape.   
 
The cationic lipids described for liposomal gene delivery have headgroups containing 
one or multiple amine sites for protonation.  The first cationic lipid to be used for gene 
delivery is that of N-[1-(2,3-dioleyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium 
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chloride (DOTMA), as described by Felgner et al [45] (Scheme 1-1).  DOTMA itself 
has a mono-amine head group, conjugated to a dioelic lipid chain.  DOTMA, along 
with many other cationic lipids, is generally formulated with DOPE (dioleoyl-L-α-
phosphatidyethanolamine), a neutral lipid incorporated for its fusogenic properties.  A 
small polar headgroup plus a larger lipidic fraction renders the geometry of DOPE to 
be inverted hexagonal (HII), a shape that aides the destabilisation of endosomes after 
cellular internalisation (Figure 1-10). 
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Figure 1-10: Formation of inverted hexagonal phase by DOPE to aid endosomal escape. 
Adapted from Koltover et al- (1998) Science, 281, 78-81 [46]. 
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Scheme 1-1: Molecular structures of common lipids used in liposomal gene delivery: a) 
DOTMA, cationic lipid part of commercially available transfection agent, Lipofectamine®, b) 
CDAN: cholesterol-based cationic lipid, and c) DOPE- phosphatidyl ethanolamine-based 
fusogenic neutral lipid.  The 1:1 ratio of CDAN:DOPE is the transfection reagent commercially 
known as Trojene™. 
 
Other classes of cationic lipids have been developed based on the anchor structure 
of cholesterol, a natural component of biological membranes.  One particular 
example from this group of lipids is that of N-cholesteryloxycarbonyl-3,7-
diazanonane-1,9-diamine, more commonly known as CDAN (Scheme 1-1) [47].  In 
conjunction with DOPE, CDAN has been proven to be as efficient as DOTMA in 
transfecting DNA and siRNA, moreover with reduced toxicity [48].  Aside from being 
cholesterol-based, CDAN also differs from DOTMA in that its polar headgroup 
possess three amine groups, with a distribution of pKa, rendering it able to 
accommodate more cationic charge for the encapsulation of genetic material.  The in 
vitro efficiency of CDAN combined with DOPE has led to its commercialisation as the 
transfection agent, Trojene™ (Avanti Polar Lipids).  
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On addition to negatively charged DNA molecules, the liposomal structures undergo 
further rearrangement, resulting in the sandwiching of the DNA within the aqueous 
layers of the multilamellar membrane.  Many examples using siRNA report similar 
findings, where the short RNA molecules also become entrapped in between 
liposomal bilayers on electrostatic interaction with cationic liposomes.  The 
encapsulation of nucleic acids into the layers of the liposomes is propelled by the 
replacement of the counter ions from the lipid surface by the nucleic acids, a 
mechanism associated with an increase in entropy (Figure 1-11) [49].  
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Figure 1-11:  Representation of proposed model of DNA encapsulation by cationic liposomes.  
The liposomes wrap around the supercoiled plasmid DNA and fuse to encapsulate it 
completely within its bilayers. Adapted from Templeton NS, Nat Biotech, 1997 [27] . 
 
The mechanism for the encapsulation of shorter nucleic acids, siRNA or microRNA 
appears similar [50].  These types of nucleic acids can also be sandwiched between 
layers within the multilamellar liposome, although the effect of encapsulation can be 
reduced when polymer-lipids are introduced [51].  It has been suggested that the 
encapsulation efficiencies of siRNA in PEGylated liposomes can be enhanced by 
optimising its encapsulation method.  Instead of adding siRNA to pre-formed PEG-
liposomes, which results in a high % of siRNA trapped within the exterior PEG layers, 
instead, hydration of lipid films with siRNA-containing solutions can ensure their 
localisation within the interior of the liposomes [51].   
 
The formulated lipoplex-type nanoparticles show high transfection efficiencies in vitro, 
most likely a function of the hexagonal arrangement of the lipids [52].  These gene-
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nanoparticles are however, vulnerable to removal from circulation by the RES, due to 
their excessive cationic charge, and the lipophilic nature of their surfaces.  The 
cationic nature of these gene delivery systems only enhances their interactions with 
plasma proteins which can result in very short circulation lifetimes [14, 53-54]. Ideally 
the cationic lipid content in the liposomal formulation would be as low as possible, to 
minimise the nanoparticles’ positive charges, but not at the expense of reducing gene 
encapsulations.  In addition to the protective effects of a stealth layer, a layer of 
surface polymers can also shield the extra cationic charges of the encapsulated 
nanoparticle from plasma proteins, allowing longer circulation times and enhanced 
tumour uptake by the EPR effect. 
 
1.5. Nanoparticle constituents- Stealth polymers 
 
This protective layer is formed by the incorporation of a hydrophilic polymer layer.  
PEG molecules are commonly adopted for the stealth function, due to their enhanced 
hydrophilicity and flexibility [10].  Inclusion of such a layer is primarily to enhance the 
nanoparticle’s lifetime in circulation, by preventing their interaction with plasma 
proteins [55-58].  The coating of liposomal nanoparticle systems with a protective 
PEG layer can be achieved through 3 main methods.  The main technique of doing 
so is through the inclusion of PEG-lipid conjugates into the lipid film of the liposomal 
formulation.  Upon hydration, the liposomes are formed with PEG polymers exposed 
on the surfaces. The other techniques are based on the formation of the liposomal 
platform before the addition of PEG polymers.  One of which is the method of post-
conjugation, where the PEG molecules are covalently attached to the pre-formed 
nanoparticle platforms through corresponding functional groups.  Post-insertion, on 
the other hand, is performed by incubating the preformed liposomes with PEG-lipid 
conjugates in aqueous solution [59].  The amphiphilic nature of the PEG-lipid 
conjugates render them into micellar structures, and their insertion into liposomal 
surfaces is perceived as a method of relieving the relative instabilityof high-cruvature 
structures.   
 
However the method of preparation, the configuration and the effect of the PEG layer 
is dependent on the PEG chain length and their surface densities.  The role of the 
stealth layer on enabling systemic delivery of nanoparticles to tumour sites is crucial.  
The effect of such a layer depends on its optimisation of the organisation of the PEG 
chains [60-63]. Although the inclusion of PEG onto liposomal surfaces improves their 
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efficiencies for transport to the tumour sites, it is important to remember that their 
presence hinders their binding to and uptake by cancer cells. 
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Scheme 1-2: Structures of PEG-lipid conjugates used in preparing stealth liposomes.  Both 
lipids shown are formed with a PEG chain of 45 monomers, correlating to a molecular weight 
of approximately 2000 Da.  PEG units in both lipids are capped at the distal end with a 
methoxy group, and conjugated to a DSPE lipid (a), or a DPPE lipid (b). 
 
The incorporated PEG-lipid conjugates need to be able to render steric stability of the 
nanoparticles and be able to prevent surface adsorption of opsonin proteins.  Higher 
coverage of liposomal surfaces is achieved by introducing higher densities of PEG-
lipids [12]. However in the case of liposomes, there is a maximum molar percentage 
that the PEG-lipids can be incorporated into the lipid formulation before they become 
detrimental to systemic delivery.  A liposomal membrane is held together by non-
covalent interactions, therefore the PEG-lipid conjugates are susceptible to 
dissociation from the liposomal bulk if the PEG density is sub-optimal.  Methoxy-
capped PEG2000-lipid conjugates such as MeO-PEG2000-DPPE (1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) or MeO-
PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000]) are common PEG-lipid amphiphiles used in 
liposomal formulations for systemic delivery (Scheme 1-2) [86, 92].  When presented 
on a liposomal surface, individual PEG chains exhibit a Flory dimension, Rf, which 
represents the volume that each flexible PEG cloud occupies (Figure 1-12).  Longer 
polymer chains (i.e. 2000Da) have larger Rf, although studies have shown that the 
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PEG density on a liposome surface is more important that the size of the polymer 
[93].  The Rf of a PEG2000 chain is approximately 5.6nm, and in conjunction with 
grafting density, affects the resultant conformation of the PEG chains.  Increasing the 
amount of PEG-lipids within a liposomal formulation increases the PEG grafting 
density, which ultimately reduces the distance, D, between each PEG molecule on 
the nanoparticle surface.  When D> Rf, the PEG chains will self-assemble into a 
random-coil like mushroom cloud.  When D< Rf, the lateral pressure between the 
overcrowded PEG mushroom clouds will force the PEG chains to stretch and extend 
into a brush conformation [64-65].  The brush regime results from the increased 
lateral pressure between the PEG chains, which forces the extension of the polymers 
away from the surface, into more linear conformations. 
 
Rf
D D
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Figure 1-12: Representation of different PEG conformations, formed through their 
incorporation onto surfaces at different densities.  When the distance between the PEG-
lipids, D, is greater than the Flory diameter of the PEG (D> Rf), the polymer will collapse into 
a mushroom configuration.  When D< Rf, the PEG chains will be extended from the surface 
to form a brush-like conformation.  In the case of PEG2000, mushroom conformation occurs 
when the PEG2000 molar ratio is <5 mol% of total lipid content, and brush conformation 
forms when the mol ratio is >5mol%. 
 
Once the brush regime is achieved, further inclusion of PEG-lipids results in 
increased Van Der Waal repulsion between the PEG chains, consequently leading to 
dissociation of the PEG-lipids from the main liposome bulk [27, 96-98].  When using 
PEG2000-lipids, it is found that a 5-7 mol% of the total lipid molar content is the 
maximum loading density, before the PEG-lipids dissociate from the liposomal 
membrane.  The dissociation process involved the removal of the PEG-lipids into 
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separate micellar-like structures, leaving a partially protected liposomal surface [93, 
97, 99-100].  These micellar structures can be either spherical, containing only PEG-
lipids, or they can recruit other lipids stripped from the main liposomal bulk to form 
disk-like shapes (Figure 1-13) [97, 101-103].  This occurrence is disadvantageous to 
the delivery properties of the liposome, as the dissociation of PEG-lipids leaves the 
remaining liposomes partially protected with a lower molar % of PEG chains.   
 
 
 
Figure 1-13: Cryo-TEM images depicting the dissociation of PEG-lipids from liposome 
membranes on increasing concentration of MeO-PEG2000-DPPE lipids in DPPC liposomes.  
Images are of liposomes containing PEG2000-lipid at a) 4.5 mol%, b) 9.5 mol%, c) 19.5 mol% 
and d) 30.2 mol%.  At PEG-lipid concentrations above 4.5 mol%, the majority of PEG-lipids 
dissociate from the main liposome bulk to form micellar disks.  At even higher PEG 
concentrations, the PEG-lipids dissociate to form PEG-lipid-exclusive spherical micelles. 
Arrows point to disk formation and bar represents 100nm.  Adapted from [66]. 
 
What prolongs a liposomal nanoparticle’s retention time in circulation is its ability to 
avoid interaction with plasma proteins [67].  The arrangement of surface PEGs into 
brush configurations generates greater protein repulsion, and generally enhances a 
liposome’s lifetime in circulation [28, 105-106].  Another phenomenon related to 
protein adsorption is the recognition of PEGylated liposomes by anti-PEG antibodies 
[68-70].  This effect has been reported to occur between 2-4 days after the first 
administration of PEG-liposomes, and leads to the event of accelerated blood 
clearance of further PEG-liposomes administered at repeat doses [71-73].   As 
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techniques of overcoming this event have yet to be identified, the time points of 
administration of repeat doses will have to be cooperative. What is left is therefore 
the optimisation of a delivery system with an optimal amount of PEG lipids, where too 
little does not provide enough coverage to evade protein adsorption, and too much 
results in removal of the PEG-lipids.    
 
Although an appropriate coverage of liposomal surfaces with a stealth PEG layer can 
greatly enhance accumulation into tumour sites, their presence also greatly 
diminishes the delivery system’s ability to internalise into cancer cells.  To overcome 
this cellular barrier, further functionalisation of the delivery system is required.  Such 
a method includes the triggerable detachment of the PEG component from the 
liposome on interaction with an external source such as pH or tumour-specific 
enzymes [109-113].  Particularly in the case of enzyme-activated bond dissociation, 
triggerability can be difficult due to the steric obstacles posed by the PEG chains.  
Another method of enhancing cellular internalisation is through the introduction of 
another layer on top of the stealth layer, consisting of receptor-specific ligands. 
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1.6.  Nanoparticle constituents- targeting ligands 
 
= Antibody (full)
= Antibody (Fragement)
= Small Molecule
= Peptide
= Aptamer
Non-targeted nanoparticle Targeted nanoparticle
 
 
Figure 1-14: Representation of targeted and non-targeted nanoparticle systems.  The 
targeted nanoparticles are functionalised with an outer layer of receptor-specific ligands, 
which can be of an antibody (full or fragment), small molecule, peptide or aptamer nature.   
 
The addition of a targeting moiety onto the surface of nanoparticles aims to increase 
selective cellular internalisation through receptor-mediated endocytosis.  Without the 
incorporation of targeting ligands, lipid-based nanoparticles rely on non-specific 
interactions with cell membranes, which can be minimal when covered in a layer of 
PEG polymers.  Exhibition of the targeting effect of the surface-grafted ligands is 
dependent not only on the nature of the ligand itself, but on a variety of factors that 
require cooperative optimisation.  Discussed in this section are many examples of 
ligand-targeted liposomal nanoparticle systems.  These examples differ from each 
other in many ways, including liposomal lipid content, type of ligand, method of ligand 
loading, degree of PEGylation and ligand density.  With attention to the physical and 
biological effects of differently prepared nanoparticle system, patterns that lead to 
enhanced drug delivery to cancers, through the effect of targeting ligands, can be 
derived.   
 
1.6.1. Type of ligand 
 
One challenge of targeting cancers and tumours is that the defective cells are often 
very similar in characteristics to its surrounding healthy tissue.  To differentiate such 
cells, the ligands can be designed to have specificity for receptors that are over-
expressed on cancerous cells, but are normally or minimally expressed on normal, 
healthy cells.  These molecules should have high affinity to their cognate receptors, 
plus have innate abilities to induce receptor-mediated endocytosis.  The targeting 
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layer poses as the outmost exterior of the nanoparticle delivery system, where 
targeting ligands are generally presented on top of the stealth layer [74].  Structures 
such as antibodies, antibody fragments, proteins, small molecules, aptamers and 
peptides have all demonstrated abilities to induce nanoparticle-targeting to cancer 
cells.   
 
Antibodies HER-2, the transferrin receptor (TfR) and the prostate specific antigen 
receptor are common examples of receptor targets, due to their over-expression on 
cancer cells [115-118].  These antibodies generally exhibit strong interactions with 
corresponding receptors, with dissociation constants in the nanomolar range.  
Antibody fragments, consisting of only the Fab binding regions, have also been 
studied as targeting ligands [75-76].  The advantages of such structures is that they 
are smaller, and do not contain the Fc region of the antibody which can induce 
immunogenicity and antigenicity when present on liposome surfaces [121-123].  Like 
antibodies and antibody fragments, the use of whole proteins is also commonly 
considered as targeting ligands for their increased affinity for target receptors.  For 
example, the natural ligand for TfR, transferrin, binds to its receptor with a 
dissociation constant of around Kd=40nM.  On overcoming systemic barriers to arrive 
in tumour vicinities, targeted liposomes have greater opportunities for binding to 
cancer cells if the ligand has naturally high affinities for the corresponding receptor.  
Another protein that has shown potential for cancer targeting is the urokinase 
plasminogen activator, uPA, a natural ligand for the urokinase plasminogen activator 
receptor.  Examples have used protein fragments, containing only the binding region 
of uPA for targeting the over-expressed receptors on colon cancers and breast 
cancers [124].  
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Scheme 1-3:  Structures of ligands commonly used to functionalise nanoparticle surfaces, for 
inducing their specificity and internalisation characteristics to cancer cells.  Top, cyclic RGD 
peptide, has used to target αvβ3 and αvβ5 integrins, which are over-expressed on tumour 
vasculature.  Bottom, folic acid, a ligand used to target the folate receptors on ovarian 
cancer tissue.  
 
Peptide sequences represent even shorter and smaller versions of antibody and 
protein fragments.  Derived from phage display assays and X-ray crystallography 
studies, short peptide sequences with receptor-afiinity have been used for 
nanoparticle targeting.    For uPAR, peptides such as the U11 peptide were identified 
from examination of the binding region of uPA [125-126].  Our work has focused on 
promoting this peptide for targeting prostate and breast cancer cells [77].  Another 
prominent example of peptide ligands is the RGD peptide, identified through phage 
display to have high affinity to αvβ3 and αvβ5 integrin receptors over-expressed on 
angiogenic vasculatures (Scheme 1-3) [128-130].  Other types of shorter ligands 
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include small molecules such as anisamide, a ligand for sigma receptors over-
expressed on lung cancer cells [131-132], and folic acid, specific for the folate 
receptors on ovarian cells [78-80], are more examples of targeting moieties for 
nanoparticle targeting (Scheme 1-3).   
 
Ligands chosen for receptor-targeting should have function for inducing receptor-
mediated endocytosis.  Depending on the type of ligand-receptor interaction, the rate 
of cellular internalisation would differ.  This is an important factor as rates of 
internalisation could affect the accumulation of nanoparticles in tumour sites.  Some 
ligand species, such as folate, have been shown to have fast internalisation rates into 
tumour cells [81].  On binding, ovarian cells, characterised to express 3 to 18 × 106 
folate receptors per cell, each cell can internalise 3x105 molecules of folic acid/hr.  
This inherent property of the ligand-receptor conjugate could enhance accumulation 
of nanoparticle by faster clearance of the tumour interstitium through faster 
internalisation of ligand-conjugated nanoparticles.  Creating greater diffusion 
gradients would encourage faster diffusion of nanoparticle through the tumour 
vasculature.  The ligands also need to be conjugated onto nanoparticles in an 
optimal fashion, as to maintain their structural integrity and affinities for their 
corresponding receptors.  For example, the measured dissociation constants for 
immunoliposome-coupled HER-2 antibodies were similar to free antibodies, around 
12-15nM, depending on the surface PEG density [82-83].  The targeting layer is 
presented as the ultimate exterior of the nanoparticle, the surface that interacts 
primarily with cell membranes.  Irrespective of their nature, the ligand must have high 
affinities for corresponding receptors, and be able to exhibit high rates of cellular 
internalisation.  Furthermore, the loading and presentation of the ligand on 
nanoparticle surfaces must be cooperative with the stealth layer.   
 
1.6.2. Methods of incorporation 
 
Like the PEG layer, the targeting ligands can be incorporated onto nanoparticle 
surfaces by a variety of methods.  Pre-modification and post-insertion methods 
require the pre-synthesis of a ligand-PEG-lipid or ligand-lipid conjugate, which is then 
included in the lipid film along with other co-lipids (e.g. fusogenic and cationic).  
Particularly when PEG molecules are involved, the synthetic pathway to such 
conjugates can be complicated.  The main difficulties lie in the solution-phase 
conjugation to a sterically hindered functional group, and in the separation step 
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between conjugated and non-conjugated PEG species. The pre-modification 
technique, where the ligand-PEG-conjugate is included in the lipid film, exhibits 
another handicap in its inability to control the amount of ligands presented on 
nanoparticle surfaces.  When the molar ratio of other PEG species (for stealth) in the 
liposome formulation is minimal, the percentage of succesfully anchored ligands on 
the exterior of the liposome can be as low as 60% of the amount of functionalised-
PEG component.  Post-modification methods of post-conjugation and post-insertion 
are therefore more commonly used for ligand loading [138-142]. These methods offer 
more control in ligand loading, ensuring maximum percentages of ligand exposed on 
the nanoparticle exterior. 
 
1.6.3. Effect of loading ligands onto PEG-brush scaffold 
 
Previously discussed is the importance of incorporating PEG chains at densities that 
allow optimal coverage, which means inducing brush conformations on nanoparticle 
surfaces.  As the brush conformation allows the extension of the PEG chains away 
from the nanoparticle surface, presenting targeting ligands on such a platform should 
allow increased interactions with corresponding receptors.  The use of antibodies as 
targeting ligands has been widely studied due to their high affinities cognate 
receptors.  A prominent example has been the use of HER-2 antibodies, which target 
the receptor HER-2, which are over-expressed on a range of breast cancer cells [84-
86].  Incorporation of anti-HER2 antibodies onto the surfaces of PEGylated 
liposomes has indeed shown greater efficiency for drug delivery compared to non-
targeted PEG-liposomes [87].  Treatment of tumour models with doxorubicin-
encapsulated liposomes enabled complete depletion in subcutaneous tumours, when 
the antibodies are conjugated onto a liposomal platform of optimal PEG2000 density (6 
mol%).  In this case, and in most examples of targeted nanoparticles, increased 
therapeutic effect of targeted nanoparticles is a result of increased tumour cell uptake, 
and not tumour accumulation.  Both targeted and non-targeted nanoparticles arrive at 
the tumour vicinity via the EPR effect, after which the mechanism of tumour cell 
internalisation is enhanced by the presence of surface ligands. 
 
Although the presentation of ligands on a PEG-brush surface enhances their binding 
to receptors, their improved exposure can decrease the nanoparticle lifetimes in 
circulation.  Using an RGD-targeted stealth system, the delivery of encapsulated 
doxorubicin was found to accumulate faster and in higher concentrations in the liver 
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and the spleen [88].  Faster clearance from circulation generally corresponds to a 
higher and faster accumulation into the liver and the spleen.  In this example, the 
total amount of PEG2000 content was included at optimal brush densities, at 6.5 mol%.  
The ligands are incorporated as RGD-PEG-lipid conjugates, which indicates their 
extension from the nanoparticle surface as a consequence of the brush-like state.  
Presentation of the ligand in a PEG-brush fashion reveals the targeting molecules 
increasingly to plasma proteins, hence their faster clearance from circulation could be 
a result of Fc-mediated RES uptake into liver and spleen-associated macrophages 
[89-90].   When ligands are loaded onto liposomes of ambient PEG2000 density (5-7 
mol%), what is generally observed is a faster clearance from circulation, 
accompanied by a higher accumulation and internalisation into cancer cells [138, 142, 
146, 150].   
 
1.6.4. Effect of loading of ligands onto nanoparticle surfaces with 
excessive or sub-minimal PEG 
 
As discussed earlier, the over-loading of PEG-species can cause their dislodgement 
from liposomes.  A density of PEG2000 chains over 5-7mol% causes the dissociation 
of the PEG-lipid conjugates, an event that could be applied to stealth liposomes 
presenting surface ligands.  Using a peptide sequence derived for fibroblast growth 
factor receptor specificity as a targeting ligand, the effect of increasing peptide-
PEG2000-lipid densities has been studied. It was found that an over-loading with 10 
mol% of peptide-PEG2000-lipids was less effective at increasing cell targeting 
compared to nanoparticles decorated with 5 mol% of such a conjugate [151].  This 
suggests that the use of increased percentage of PEG2000 (10 mol%) causes the 
stripping of peptide-PEG-lipids from the main liposome bulk.  Such an action would 
then reduce the ligand density on the nanoparticle surface, hence limiting their 
binding to and uptake into cancer cells.  Other reports investigating targeted delivery 
systems have also described this observance.  PEGylated (9 or 18 mol% PEG2000) 
liposomes targeted with the HIV-derived TAT cell-penetrating peptide showed 
maximum cell-association when the PEG density was high enough to induce brush 
conformation, but low enough to prevent PEG dissociation (9 mol% > 18 mol%) [91].  
However, cryo-TEM and size exclusion chromatography studies would be required to 
confirm the removal of ligand-PEG-lipids on introduction of high PEG mol%.  An 
under-loading of ligand-PEG-lipids into liposomal formulation is also not ideal for both 
systemic protection and for cellular binding.  Low PEG densities (>5 mol% PEG2000) 
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result in the increased exposure of the liposomal surface to plasma proteins, plus, 
their extension of the ligand is limited due to its shielding within the mushroom clouds.  
However, many examples of targeted nanosystems with low PEG densities still 
exhibit enhanced tumour binding, suggesting the flexibility of the PEG chains to 
reveal the ligand out of the mushroom barrier [92].  
 
Comparing liposomal platforms of medium and low PEG densities (7mol% and 
1mol%) in dox-encapsulated immunoliposomes (against HER-2), the effect of tumour 
accumulation and tumour reduction is apparent with both types of PEGylation, 
although at a lower extent when the surface PEG density is low (1 mol%).  A low 
PEG density relates to the organisation of the PEG chains into mushroom 
conformations, burying the attached antibodies within the collapsed cloud.  Because 
of the reduced exposure of ligands coupled to a mushroom-PEG, the circulation 
lifetime and liver/spleen-uptake is the same as non-targeted low-PEG nanoparticles.  
Interaction of such particles with opsonin proteins can be high, due to the minimal 
coverage of the nanoparticle surface with PEG molecules.  On the other hand, high-
PEG immunoliposomes still exhibited longer lifetimes and less liver/spleen-
accumulation than the low-PEG immunoliposomes.  Therefore, ligand presentation 
on a brush-like PEG layer is important for increasing interactions with cancer cells . 
 
1.6.5. Effect of PEG spacer between ligand and nanoparticles surface. 
 
Most examples that describe successful targeting use targeting ligands that are 
loaded onto nanoparticle surfaces via a PEG spacer.  The rationale for such an 
action lies in the extension of the ligand from the nanoparticle platform, enhancing its 
flexibility and interaction with receptors.  Our own work has examined the effects of 
presenting a ligand without a PEG spacer [77].  Through the synthesis of a peptide-
lipid conjugate, we were able to functionalise the surfaces of liposomes with peptide 
ligands specific for the urokinase plasminogen activator receptor.  These targeted 
systems were able to induce enhanced cell binding and gene delivery compared to 
non-targeted nanoparticles.  However, these ligands are exposed at reduced 
proximities to nanoparticle surfaces, an event that becomes problematic when long 
PEG chains are included.  Addition of PEG2000 molecules at optimal densities for in 
vivo delivery is essential, but results in the steric shielding of the short peptide-lipids, 
hence preventing their interaction with cellular receptors.  Similar studies, using a 
RGD-type peptide for targeting αvβ3 integrins, also describe this finding.  This report 
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showed that short peptide-targeted nanoparticles exhibited lower cell-binding abilities 
when higher mol% of PEG2000 was included into the formulation [116, 154].  As a 
sufficient PEG coating is essential for avoiding recognition by the RES, ligands 
should be extended away from nanoparticle surfaces, to avoid shielding by the 
polymer chains.   
 
Our worked continued in the quest to optimise peptide-targeted nanoparticle systems, 
by post-conjugating U11 peptides onto low-charge PEGylated nanoparticles.  
Conjugation of the U11 peptide through a PEG spacer allowed the cell binding, 
uptake and gene delivery efficiencies of targeted nanoparticles to be enhanced 
further (see chapter 3).  Extension of ligands on the distal end of PEG chains is 
suggested as providing higher flexibilities for the ligand to interact with cell receptors.     
 
Arrangement of the stealth layer into brush conformation can allow enhanced 
extension of the PEG-associated ligand from the nanoparticle surface.  However, the 
chain length of the PEG spacer between the ligand and the nanoparticle surface also 
requires consideration.  When the chain length of the PEG spacer is longer than the 
other PEG chains involved in the PEG brush, the conjugated ligand can become 
buried within the brush layer (Figure 1-15) [93].  The extra units of a longer PEG 
spacer are subject to mushroom-like folding, which results in the limited exposure of 
the ligand.  Implications of this effect have been described with a folate-targeted 
liposome.  Conjugation of the folate through a PEG3400 spacer, when the rest of the 
stealth content is comprised of PEG2000, the effect of the ligand is not apparent.  The 
folate-targeted nanoparticles were unable to increase tumour accumulation, plus they 
did not exhibit long circulation lifetimes, a consequence commonly accompanying an 
effectively exposed ligand [90].  The ligand-conjugated PEG spacer therefore needs 
to the same length as the other PEG constituents in the nanoparticle. 
 
Another feature that stems from this observation is the importance of inherent or 
additional spectroscopic function in the targeting ligand [93].  The exposure from or 
burying of targeting ligands in PEG conformation was observed using fluorescent 
tags conjugated at the distal ends of PEG spacers.  In our work, the targeting peptide, 
U11, contains a Tryptophan residue that allowed the probing of their 
microenvironments by fluorescence spectroscopy (see chapter 2, 3, 4 and 5).  The 
nature of the amide bonds in proteins and peptide sequences can also be examined 
by circular dichroism or infra-red spectroscopy for their change in secondary or 
tertiary structures upon nanoparticle conjugation. 
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Figure 1-15: Effect of PEG spacer length on the organisation and presentation of the 
conjugated ligand.  If the PEG spacer between the ligand and the nanoparticle surface is of 
the same length as the other PEG species within the formulation, the distal ligand will be 
exposed through extension (A).  The ligand will also remain extended if its PEG chains are 
shorter than the other PEGs (B).  However, when the PEG spacer is shorter than other 
stealth PEGs, the ligand cannot extend to be exposed to the exterior environment, as the 
extra PEG length folds into mushroom-type conformation (B, E) [93]. 
 
1.6.6. Effect of ligand densities on the surfaces of nanoparticles 
 
Concentration of surface ligands is another parameter that affects the exhibition of 
the ligand’s targeting effect [156].  A higher ligand density (multivalency) is 
envisioned as a method of increasing the probability of nanoparticle interactions with 
cell receptors.  However, the presence of increased non-PEG-like material on 
nanoparticle surfaces can be more detrimental than advantageous to delivery.  A 
study using aptamers as a targeting ligand for prostate cancer-specific antigens 
(PSMA) demonstrated that higher densities of surface ligands resulted in greater 
accumulation of nanoparticles into the liver and the spleen [157].  Localisation of 
such nanoparticles in tumours was also at lower concentrations compared to 
nanoparticles functionalized with lower densities of aptamers.  This is suggesting that 
higher coverage of the PEGylated nanoparticl’es surface with targeting ligands 
further shields the effect of the PEG layer, hence resulting in greater recognition by 
tumour and spleen-associated macrophages. Later studies using a HER-2 targeting 
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system enhances this argument, where heavy-ligand loading led to higher clearance 
rates from circulation [94].  High surface coverage of ligands therefore renders the 
PEG layer obsolete, an occurrence that needs to be avoided in order to reduce 
interactions with plasma proteins.  Although the physical implications of ligand 
loading were not studied, the biological effects demonstrate the importance of 
optimising ligand densities for maximising their targeting abilities [95]. 
 
Presenting ligands directly on nanoparticle surfaces, without a PEG spacer 
demonstrates another disadvantage to using ligands at high densities.  Our own work 
has described the intermolecular aggregation of surface ligands, when they are 
incorporated at higher concentrations (chapter 2).  In this study, a peptide-lipid 
conjugate U11-Palm (palmitoylic lipid chain, no PEG spacer) to functionalise the 
surface of cationic liposomes, U11 being a peptide specific for the urokinase 
plasminogen activator receptor.  We found that inclusion of higher mol% of peptide-
lipid not only induced inter-ligand aggregation on the liposomal surface, but also 
caused excessive inter-particle aggregation.  The peptides were aggregated into β-
sheet like structures, hence reducing the particle’s ability to enhance in vitro activity.  
We hypothesized this to be a function of attraction between the peptides, in the form 
of hydrogen bonding, when they are loaded at close proximities. However, when the 
peptide-lipids were incorporated at lower densities, the ligands were presented in a 
more monomeric form, and were able to significantly enhance cellular binding and 
gene delivery.  The effect of particle-aggregation on high peptide-loading has also 
been described for an APRPG peptide-targeted liposomal targeted system, where 
targeted nanoparticles aggregated at greater extents in serum and high salt solutions 
[96].  This finding is highlighting the importance of avoiding inter-ligand aggregation, 
an occurrence resultant of high ligand densities.  Other ligand molecules can be 
highly hydrophobic, such as folate, which are highly sensitive to π-π stacking 
between the aromatic rings on higher ligand loading densities [97]. 
 
Even if a high concentration of surface ligands can be loaded without intermolecular 
aggregation, the consequences of high ligand densities still can raise concern.  
Studies have described the change in liposome shape on receptor-binding, an effect 
that is considerably enhanced when the ligand density is high [98].  As targeted 
liposomes bind to cellular receptors, the tangent between the spherical liposome and 
the cell membrane changes depending on the ligand density.  It was found that for 
liposomes, high ligand loading induces tangents of shallow gradients, indicating an 
elongation of liposomal shape, which can ultimately result in liposomal disruption.   
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An elimination of liposome structure would result in extracellular drug release, a 
consequence that could be undesirable if the loaded drug requires is only effective 
intracellularly (e.g. DNA or RNA).    
 
1.6.7. Targeting tumour-homing species in circulation 
 
Contrary to the majority of biodistribuntion studies, some examples of targeted 
nanoparticle drug delivery systems have shown faster and higher concentrations 
accumulation in tumours, compared to non-targeted systems [148, 163].  Generally it 
is believed that the introduction of targeting ligands do not enhance nanoparticle 
accumulation into tumours, but show higher efficacy by enhancing internalisation into 
tumour cells.  However, in some cases of antibody and folate targeted nanoparticles, 
accumulation into tumours was at higher rates than to non-targeted nanoparticles [89, 
99-101]. This occurrence is envisioned as a consequence of recognition of the 
nanoparticles by tumour-associated macrophages (TAM) [90, 102-106].  In response 
to this hypothesis, folate receptors have been identified to be over-expressed on 
TAMs.  This effect of TAM-recognition is pronounced when the folate ligands are 
loaded onto PEG-brushes, a conformation that highlights the exposure of the ligands. 
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Table 1-3: Summary of ligand characteristics for preparation of cancer-targeted 
nanoparticles. 
 
Effect of… Considerations 
Type of ligand  Antibodies, antibody fragments, proteins, peptides, small 
molecules. 
 Ligand should have high affinity for receptors over-expressed 
on cancer cells.  
 Ligand-receptor conjugate should have high internalisation 
rates 
 Ligands including specific antibodies and folate have shown 
affinity for tumour-associated macrophages. 
 Ligands can be prepared to include a spectroscopic probe 
such as Trp to examine changes in conformation. 
Surface PEG 
content on 
ligand 
presentation 
 Loading onto PEG-brush surface- ligands are extended for 
enhanced receptor-interaction.  Can also result in lower 
circulation lifetimes and through recognition by RES. 
 Over-loading- leads to displacement of ligand-PEG-lipid 
species which leads to lower PEGylation and lower ligand 
densities. 
 Mushroom conformation- ligands become buried within PEG 
clouds.  Does not effect circulation lifetime.  
PEG spacer 
between 
ligand and 
surface 
 Should be same length as PEG species in stealth function. 
 If PEG spacer longer, ligands subject to intramolecular 
mushroom-shielding.  If PEG spacer is shorter, ligands 
intermolecularly shielded by longer PEG species of stealth 
function. 
Ligand density  High ligand density leads to intermolecular aggregation of 
ligands on nanoparticle surfaces. 
 High ligand densities can also result in liposome deformation 
on interaction with receptors. 
 
1.7.  Targeting the Urokinase Plasminogen Activator Receptor 
 
In this study, we introduce a novel peptide sequence for cancer targeting, and further 
demonstrate its ability to enhance gene delivery to cancer cells.  The receptor we are 
interested in targeting is the Urokinase-Type Plasminogen Activator Receptor (uPAR), 
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a class of molecules found to be over-expressed on cancer cell membranes, 
particularly those of the breast and prostate [171-172]. Otherwise termed as CD87, 
uPAR is a 313-residue, phosphatidylinositol (GPI)-anchored protein which has 
urokinase plasminogen activator (uPA) as its natural ligand for binding [107].  The 
cellular function of uPA has been described to act as a serine protease, digesting 
components of the extracellular matrix, by activating the zymogen plasminogen into 
its active protease state of plasmin [108].  Before activation, uPA is produced and 
stored in the cell as a single peptide chain termed ‘pro-uPA’, which is converted into 
its active form of uPA upon a single catalytic event.  Once receptor-bound, the 
activity of uPA is inhibited as it complexes with two types of inhibitors, PAI-1 and PAI-
2.  Internalisation by endocytosis is then only mediated on further complexation with 
the low density lipoprotein receptor-related proteins (LDLR), α2-macroglobulin 
receptor (α2MR) and with glycoprotein 330 (gp330) [109].  In regards to the 
mechanism of internalisation, it has been shown that the endocytosis of the LDLR-
uPAR-uPA complex occurs via clathrin-coated pits, through which they enter into 
early endosomes altogether.  The site responsible for the binding to α2MR was found 
to be on domain III of uPAR, a site which therefore cannot be blocked if endocytosis 
is to occur [176].   
 
The structure of uPAR consists of 3 homologous domains, where the functional 
epitope for uPA-binding (Kd< 1nM) is located in the third loop of the N-terminal 
domain (Figure 1-16) [110].  Recently published by Haui et al. is the crystal structure 
of soluble uPAR in complexation with uPA [111].  At the resolution of 1.9Å, it was 
found that all three domains of the receptor participate in uPA-binding by forming a 
concave cone shape, into which uPA inserts.  This cavity is described to have a width 
of 25Å and a depth of 14Å, factors which need consideration when designing uPA-
like ligands for uPAR-binding.   
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Figure 1-16: Top, structure of GPI-anchored Urokinase Plasminogen Activator Receptor.  
Above representation shows the three domains and the amino acid sequence of the 55kDa 
receptor.  Large arrows point to positions of phase-1 introns in the gene structure, and small 
arrows indicate regions sensitive to proteolysis and to GPI-specific phospholipase C (PI-PLC). 
The LU-domains (uPAR-specific domains I, II and III) in uPAR are labelled from the N-
terminus by Roman numerals and the location of their putative loop structures are 
numbered in the model by Arabic numerals (1, 2 and 3).  Adapted from Ploug et al 2002 
[178].  Bottom, molecular surface representation of the ATF (or the GFD, growth factor 
domain) region of uPA (blue) fitting into the wide cavity formed by the three domains of the 
uPAR receptor (green, orange and purple).  The binding cavity is found to have a width of 
25Å and a depth of 14 Å.  Adapted from Haui et al. Science, 2006 [111]. 
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uPA on the other hand is a composite structure of three structurally independent 
regions: the amino-terminal growth factor domain, the kringle domain and the 
carboxy-terminal catalytic domain, the region in which the catalytic properties of uPA 
are exhibited [112-113].  The N-terminal region of uPA is termed the ‘amino-terminal 
growth factor domain’ due to its sequence homology with a part of the epidermal 
growth factor (EGF), found to be in the form of a single-chain peptide with three 
cysteine-bridged loops (Figure 1-17) [114].  The region responsible for binding was 
found to be located in the amino-terminal growth factor domain (residues 1-125), 
specifically in residues 12-32 (U21).  
 
 
 
Figure 1-17: Crystal structures of ATF or growth factor domain (blue) and Kringle (grey) of 
domains of uPA.  The bottom right corner of the ATF domain represents the Ω loop of the 
binding sequence of uPA.  Derived from Haui et al. Science, 2006 [126]. 
 
1.7.1. Binding of uPA to uPAR 
 
Peptide sequence of residues 12-32: 
12                                                                        30   32 
C D C L N G G T C V S N K Y F S N I H W C N C 
It is within the amino acid sequence of 12-32 that studies by Appella et al. have 
shown the presence of two cyclic peptide structures that combine to make the 
binding sequence. The first loop is formed between amino acid residues of 13-20 
LNGGTCV, termed the U7 sequence, and the second loop was found to be between 
residues 19-30, VSNKYFSNIHW, termed the U11 sequence.  These studies further 
describe the binding affinity of the U11 sequence to be higher than that of the U7 
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sequence, although both do not surpass the binding affinity of the U21, which consist 
of both the U7 and the U11, suggesting that the presence of both the first and middle 
loops of the amino-terminal growth factor give increased binding to uPAR.  However, 
using shorter peptide fragments as targeting ligands has benefits, such as ease of 
synthesis and easier control of secondary conformation.  uPA fragments, instead of 
whole uPA as targeting ligands is considered advantageous, as the engineering 
process is greatly simplified, and the effects of the enzymatic properties of the C-
terminal domain of uPA are avoided. 
 
An example of the use of the U-7 peptide as a targeting ligand for uPAR-expressing 
cell demonstrates the incorporation of the synthetic peptide onto the surface of 
adenovirus vectors to retarget airway epithelial cells, which are also shown to 
express uPAR molecules [115].  Exposure of human airway epithelial cells to 
solutions of uPA and U-7 showed to stimulate the endocytosis of the viral vector.   
 
NMR studies have confirmed the dicyclic conformation of the binding sequence, 
where cysteine bridges were formed between Cys11-Cys19, and Cys13-Cys31 [113].  
Particularly the cyclic U11 sequence was able to competitively bind to uPAR at low 
dissociation constants within the nanomolar range [116-118].  It is clear from these 
findings that a loop-shaped structure of U-11 binds to the uPAR with high affinity and 
can therefore potentially be a promising targeting agent for cancer cells 
overexpressing the uPA receptor.   
 
Previous investigators in the field of U11 binding have found a ligand affinity of Kd= 
1.3-1.4μM by a displacement assay using the linear G-U11-G peptide (U11 peptide 
flanked at either terminus with Gly amino acid) as the displacing ligand against a 
fluorescently labelled uPA (uPA-FITC) (Figure 1-18).  This calculated dissociation 
constant was found to be comparable to that of the linear RGD sequence (Kd= 
1.0μM), although is also ten-fold lower than the dissociation constant of the cyclic 
RGD structure, indicating that the preservation of the natural conformation of the 
ligand is important in maintaining high receptor affinity.  However, the targeting effect 
of the ligand is also dependent on characteristics of the nanoparticle onto which it is 
loaded, and not only on the binding affinity of the ligand itself.  The process of 
sulphide cyclisation can be difficult, particularly if a third cysteine is required for 
conjugation onto the liposome.   
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Figure 1-18: Displacement of fluorescently labelled uPA by G-U11-G, found by flow 
cytometry assessment of U937 Human leukaemia cell line incubated with uPA-FITC in 
increasing concentrations of G-U11-G uPAR specific targeting peptide (from PhD thesis of 
Tom Kean, Cardiff Univeristy, 2006). 
 
Having considered the range of information regarding uPAR-uPA interactions, the 
following highlights the advantages of U11 as a targeting ligand for uPAR-targeting: 
 
a) uPAR is highly over-expressed in many types of cancer cells. 
b) The U11 peptide is a relatively short sequence, allowing ease of synthesis 
and handling. 
c) The peptide sequence contains aromatic amino acids (Trp, Phe and Tyr), 
which act as fluorescent probes for further characterisation. 
d) U11 binds to the uPA-binding region of uPAR, therefore not blocking domain 
III of the receptor, the region where binding to α2MR occurs. 
 
1.8.  ABCD Delivery Systems 
 
Appreciation for the complication of the delivery mechanism propels the need to 
formulate the delivery vehicle with equal complexity.  In this report, nanoparticle 
construction will be based on a liposomal platform, which has proven to be a flexible 
template that allows the addition of multi functionalities in an organised form for 
improved cancer delivery.  What is required therefore is the construction of a 
macromolecular system whereby the involvement of each component need be fully 
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characterised and understood. With the ultimate aim for cancer delivery, additional 
layers within the liposomal nanoparticle are required to ensure the defeat of systemic 
barriers.  Finally, the functionalisation of nanoparticle surfaces with the uPAR-specific 
U11 peptides will be aimed for the enhancement of internalisation into cancer cells.  
Described here is a systemic representation of a multi-layered liposomal delivery 
platform, designed to incorporate additional strategies for optimising delivery.    
 
A      B    C   D
A= Genetic material
B= liposomal layer
C= Stealth layer
D= Targeting layer
= A core:  pDNA
= B layer: Cationic and fusogenic lipids
= C layer:  MeO-PEG2000-DSPE
= D layer: Targeting ligand  
 
Figure 1-19:  ABCD nomenclature of liposomal based gene delivery nanoparticles. 
 
Contained in the centre, the A core of the nanoparticle, is the genetic material, 
encapsulated within the liposomal layers for increasing bioavailability.   The liposomal 
bilayer, consisting of a combination of cationic lipids and fusogenic lipids, directly 
surrounds the nucleic acids to form what is known as the B layer.   Shielding the AB 
layer is therefore the C layer, formed mainly of polymeric materials, particularly PEG, 
for inducing sterics-associated colloidal stability.  Finally, the outer D layer 
represents the addition of targeting ligands (U11) on the surfaces of such 
nanoparticles. 
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1.9.  Aims 
 
Considering the discussion on targeting ligands and that of the uPAR receptor, the 
main aim of this project is to engineer a viable nanoparticle system that exhibits 
enhanced gene delivery abilities to tumour cells.  The nanoparticle scaffold will be 
based on the ABCD liposomal paradigm, employing U11 peptide ligands as the D-
layer, for inducing specificity and binding to the uPAR receptors on cancer cells. 
 
Firstly, the ability of the U11 peptides to act as targeting ligands will be examined.  
Once this is established, the optimisation of the U11’s targeting effect can be 
considered. 
 
Many factors concerning the nanoparticle structure will be examined.  Features of the 
ligand moiety, in regards to ligand density and presentation will be investigated.  
Variation of the nanoparticle platform will also be studied, in hope to identify 
favourable characteristics for enhancing tumour targeting. 
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2. Realising the potential of U11 peptides as ligands for nanoparticle 
gene delivery 
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To commence the study of U11-targeted delivery systems, a liposomal platform 
based on the formulation of Trojene® was initially employed.  Trogene is an in vitro 
transfection agent formed by a 1:1 molar ration of CDAN (cationic) and DOPE 
(fusogenic) lipids (developed by Imperial College London and availbile from Avanti 
Polar Lipids, Scheme 2-1, a).  The advantage of such a formulation lies in its well-
characterised transfection efficiencies in cancer cells with minimal toxicities [119]. 
 
To functionalise such delivery systems with targeting peptides, many methods have 
been described.  Here, we firstly consider the technique of post-insertion, which 
exploits the amphiphilic nature of peptide-lipids.  This technique relies on the 
spontaneous insertion of amphiphiles onto the external surface of a liposomal layer, 
a mechanism undertaken to relieve the structural strain of the micellar structure in 
which the amphiphilic molecules are organised [120].  Therefore, peptide-lipids 
based on the sequence of the U11 peptide (U11 peptide plus scramble control 
peptide of scrambled sequence) were synthesised. 
 
Table 2-1: Amino acid sequences of binding epitopes within uPA with specificity for uPAR.  
U7 and U11 indicate specific fragments within the binding region that exhibit high receptor 
affinity as synthetic peptides [111]. 
 
 Peptide Sequence 
Residue 11-32 in EGF domain CDCLNGGTC-VSNKYFSNIHWCNC 
U11 VSNKYFSNIHW 
Scrambled ISKSVYNFWNH 
 
 
 
2.1.  Synthesis of U11 and control peptide-lipids 
 
The U11 peptide-lipids were synthesised on solid phase, using an aldehyde-modified 
(FMBP) resin.  This allowed for the attachment a hexadecylamine lipid chain to the 
resin through reductive amination (Scheme 2-1, b).  After extension of the peptide 
chain through standard Fmoc procedure, the peptide-lipid was cleaved and purified 
to homogeneity (>95%) by high performance liquid chromatography (HPLC).  The 
identity of the U11 peptide-lipid was confirmed by electrospray mass spectrometry 
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([M+H]+, 1774.0).  The scrambled (control, Table 2-1) peptide-lipid was also prepared 
similarly in an equivalent manner to act as a control to compare with U11-targeting.  
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Scheme 2-1: a) Structures of main lipids used in formulation- cationic lipid CDAN, fusogenic 
lipid DOPE and targeting lipid U11 peptide-lipid. b) Synthesis of U11 peptide-lipid on solid 
phase. i) C16H33-NH2, HOAc, NaCNBH3, 80°C, 3hrs. ii) a) Extension of peptide chain using 
standard Fmoc-protocol with 3 eq. Fmoc-amino acid, HBTU (3equiv), HOBt (3equiv) in DMF, 
1hr RT per coupling.  iii) Ac2O, DiPEA in DMF, 1hr. iv) 95/2.5/2.5 TFA/TIS/H2O, 5h RT. 
 
 
a 
b 
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2.2.  Formulation of nanoparticles 
 
The liposomal platform was prepared by the standard method of lipid film hydration, 
followed by sonication and pDNA encapsulation [121].  Included in the formulation 
were the lipids CDAN and DOPE (1:1 mol/mol), which were used to encapsulate 
pDNA (pEGFP-Luc SV40 promoter, see material and methods for map of plasmid) at 
a standard ratio of 12:1 w/w.   To introduce the U11 ligand onto the nanoparticle 
surfaces, U11 peptide-lipids (or scrambled peptide-lipids) were incubated (at 37°C, 
1h) with nanoparticle platforms at varying molar percentages.  This procedure 
allowed the insertion of the lipid moieties of peptide-lipids into the outer leaflet 
membrane of the core nanoparticles (Figure 2-1) [122].  The peptide-lipids were 
added to the liposomal dispersion in relatively high concentrations, at concentrations 
beyond the critical micelle concentrations. Incubation temperatures of 37oC were 
used to increase the fluidity of the liposomal membrane, rendering it more gel-like for 
ease of peptide-lipid insertion.   Removal of excess, non-inserted peptide-lipids was 
carried out by centrifugal filtration (MWCO=30kDa, Microcon Millipore).  The U11 
peptide sequence contains a Tryptophan residue, which allowed the quantification of 
peptide-lipid insertion by fluorescence spectroscopy.  Analysis of the centrifugal 
filtrate led to the conclusion that a high level of peptide-lipid insertion (>90%) occurs 
after post-insertion.  Accordingly, no further nanoparticle purification steps were 
considered necessary in future formulations prepared with this method. These 
purified particles were characterised by HPLC and Stewart assay (for phospholipid 
content) to verify that CDAN and DOPE compositions respectively were unaltered 
(comparable to initial molar ratios) by the centrifugation process.  Peptide-lipid 
content was confirmed by fluorescence spectroscopy (excitation wavelength: Iex 298 
nm; emission maximum: Imax 349nm) and pDNA content was quantified by UV-visible 
spectroscopy (using A0.1260 value of 30).  PEGylated nanoparticles were formulated 
along similar lines by the addition of pDNA to CDAN/DOPE/MeO-PEG2000-DSPE (50-
x:50-x:2x, mol/mol/mol; x is 0.25 to 2.5) cationic liposomes (prepared as before) with 
rapid vortex mixing (final lipid:pDNA ratio 12:1, w/w, final pDNA concentration 
0.1mgmL-1).  
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Non-targeted nanoparticle 
(ABC)
U11-targeted nanoparticle 
(ABCD)
Micellar insertion of 
U11 peptide-lipids,
37oC, 1hr
 
 
Figure 2-1: Representation of preparation of U11-targeted nanoparticles, through the post-
insertion of U11 peptide-lipids into preformed ABC-like nanoparticle platforms.  Liposomal 
scaffold consisted of CDAN and DOPE lipids at 1:1 molar ratios along with small % of MeO-
PEG2000DSPE, encapsulating pDNA at 12:1 w/w ratio.   
 
2.3.  Optimising mol % of U11 peptide-lipid: using circular dichroism  
 
The incorporation of peptide-lipids into lipid membranes for presentation of peptide 
ligands has been used widely in the literature [123-127], although few studies 
consider the effect of the anchoring procedure on the ligand’s secondary structure 
[128-129].  Ligand conformation on the surface of the nanoparticle is important as 
this affects its recognition and binding properties with its specific receptor.  Here, we 
investigated the effect of introducing peptide-lipids at high and low molar percentages 
into the outer leaflet membrane of cationic liposomes platforms.  The CD spectra of 
the U11 peptide-lipids (1 or 5 mol %) were recorded before and after incubation with 
nanoparticles (without pDNA), to compare their change in secondary or tertiary 
organisation (Figure 2-2).  Before insertion into nanoparticle surfaces, 1 and 5 mol % 
of peptide-lipids in H2O alone gave rise to spectra with significant negative maxima at 
λ=216nm.  This is indicating the organisation of the peptide-lipids into β-sheet 
aggregates, stabilised by both hydrophobic interactions between the lipidic parts of 
the amphiphiles, and by hydrogen-bonding between the peptide moieties [130-131].  
However, on insertion at low concentrations (1 mol %), the peptide-lipids appear to 
rearrange into more separated structures, as indicated by the reduction in λ=216nm 
in the CD spectrum (Figure 2-2).  Individually presented surface ligands on the 
surface of nanoparticles, as opposed to aggregated ligands, is more favourable for 
receptor-binding.  This disruption in β-sheet conformation is only observed with 
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peptide-lipids at low molar percentages, as the introduction of peptide-lipids into 
liposomes at 5 mol % showed β-sheet aggregation to the same extent as that 
observed in aqueous solution alone.  The use of higher densities of targeting ligand 
was originally proposed to increase the probability of nanoparticle interaction with 
surface receptors.  However, according to our in vitro data, over-loading the 
nanoparticle surfaces with ligands did not furnish any benefits for transfection (Figure 
2-6).     
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Figure 2-2: Circular dichroism spectra of U11 peptide-lipids alone and when incorporated on 
the surface of optimised nanoparticles (CDAN/DOPE/MeO-PEG2000-DSPE 49.75:49.75:0.5, 
mol/mol/mol) (BC system). a) Peptide-lipids incorporated at 5 mol% on nanoparticles (▲) 
and in H2O at equivalent concentration (■); the spectrum of liposomes without peptide-
lipids are shown for comparison (○). b) Peptide- lipids incorporated at 1 mol% on 
nanoparticles (■) and in H2O at equivalent concentration (♦). Negative maximum at 
λ=216nm indicates presence of β-sheet aggregates.  
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This highlights the importance of incorporating peptide-lipids at lower concentrations, 
where intermolecular aggregation on nanoparticle surfaces is prevented.  
Nanoparticle transfections using this formulation were clearly superior to all control 
transfections (including transfections with nanoparticles prepared with scrambled 
control peptide-lipid) (Figure 2-6), thereby suggesting that the U11 peptide-lipids 
were adopting appropriately active conformations to enable functional receptor-
mediated uptake of nanoparticles where uPAR were presented. Indeed, other 
reported studies on ligand loading have shown that lower loading rates of RGD 
peptide-lipid (<1mol%) on DSPC vesicles did not reduce the binding effects of the 
ligand, nor was there reduction in the ability of RGD moieties to induce cell 
adhesions on HUVEC (Human umbilical endothelial) cells [132].   
 
2.4.  Preventing inter-particle aggregation of U11-targeted nanoparticles 
 
Nanoparticles, targeted or non-targeted, were incubated in transfection medium, or in 
50% foetal calf serum (to mimic in vivo circulation conditions) and the increase in 
particle size was observed as a function of time. 
 
It was found that un-PEGylated nanoparticles were prone to aggregation in solutions 
of high salt concentrations, where particle diameters were measured to exceed 
1000nm in size.  The effect of aggregation was even greater when the concentration 
of peptide-lipids increased (Figure 2-3).  On dispersion into buffers, counter ions can 
associate with the protonated amines of the cationic headgroups, hence masking the 
positive charges of the nanoparticle.  This promotes colloidal destabilisation as the 
electrostatic repulsion between particles is reduced.  The size of the nanoparticles 
affects a variety of steps that lead to successful delivery into cancer cells, one of 
which being the step of cellular internalisation.  uPAR-associated endocytosis 
proceeds by clathrin-mediated endocytosis, an internalisation process that appears 
to be dependent on the size of the endocytosed material [17].  It has been reported 
that only particles that are smaller than 500nm in diameter have the ability to be 
internalised by clathrin-mediated endocytosis.  Those that are larger than 500nm in 
diameter are internalised through a different mechanism, namely by claveolin-
mediated endocytosis [16].  Therefore due to their increased sizes, non-PEGylated 
liposomes are unsuitable as nanoparticle platforms to examine U11-mediated cell 
targeting.  The incorporation of PEGylated lipids into the formulation was therefore 
essential for maintaining nanoparticle stability in buffered media used for transfection.  
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By increasing the percentage of MeO-PEG2000-DSPE from 0.5 mol% to 5-mol%, 
nanoparticle stability was indeed observed in transfection media over time (Figure 2-
4).  However, transfection experiments on the DU145 cell (uPAR positive cell line) 
indicated no substantial difference in transfection levels achieved by excessive 
PEGylation (Figure 2-5).  The addition of PEG2000-lipids at molar ratios above 1 mol% 
did not allow the exhibition of the U11-ligand’s targeting effect.  This is most likely a 
consequence of the PEG chains shielding the short U11-surface peptides, inhibiting 
its recognition by its corresponding receptors.  Therefore, 0.5 mol% of MeO-PEG2000-
DSPE was concluded as the optimal amount of PEGylated lipid that could be 
incorporated without sterically hindering the presentation of the U11-peptides.  The 
difficulty in this formulation process lied within striking a balance between the molar 
percentages of the stealth lipid and the targeting peptide-lipid.  
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Figure 2-3: Effect of insertion of 0, 1 or 5% U11 peptide-lipid on the sizes of un-PEGylated 
nanoparticles (comprising CDAN/DOPE 1:1, mol/mol: and pDNA, lipid:pDNA ratio 12:1, w/w) 
incubated in (a) Optimem® and in (b) 50% FCS over 120mins at 37°C, as measured by 
dynamic light scattering.  Non-PEGylated nanoparticles with indicated mol% of U11 peptide-
lipid have greater inclination for aggregation in transfection media, especially systems with 
high peptide-lipid loading.  Diameter errors are plotted as the standard deviation calculated 
by dynamic light scattering.  Measurements of nanoparticle sizes were performed and 
separate samples and were not continued once nanoparticle diameters reached over 
1000nm.   
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Figure 2-4: Effect of inclusion of U11 peptide-lipid (mol% as indicated) on PEGylated 
nanoparticle-size with time.  PEGylated, non-targeted nanoparticle (comprising CDAN/DOPE 
1:1, mol/mol: and pDNA, lipid:pDNA ratio 12:1, w/w, MeO-PEG2000-DSPE, 0.5 mol%) or 
targeted nanoparticles (1 or 5 mol% U11 peptide-lipid) were incubated in Optimem® over 
120mins at 37°C, and measured by dynamic light scattering.  Both non-targeted and targeted 
(with 1 mol% U11 peptide-lipid) nanoparticles were both stable in transfection media, where 
the diameter was maintained under 250nm throughout incubation time.  However, higher 
loading with 5 mol% peptide-lipid was still prone to aggregation.  Diameter errors are 
plotted as the standard deviation calculated by dynamic light scattering.  Measurements of 
nanoparticle sizes were not continued once diameters reached over 1000nm.   
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Figure 2-5: Luciferase transfection studies on DU145 cells with non-targeted and U11-
targeted nanoparticles bearing increasing mol% of MeO-PEG2000-DSPE within the liposomal 
formulation.  Increasing mol% of PEG lipids results in the overall decrease in transfection 
abilities of the nanoparticles.  In these cases, the effect of U11 targeting is non-apparent, 
most likely due to the steric shielding of the U11 ligands by the excessive PEG chains.    
However, minimal PEGylation by in the inclusion of PEG-lipids at 0.5 mol% allowed a balance 
between nanoparticle stability and U11-peptide presentation.  Nanoparticles were 
encapsulated with pDNA at 12:1 w/w and administered to cells at 1ug DNA/well and 
transfected for 3 hours, followed by 48 hour incubation before lysis and analysis for 
luciferase expression.   
 
Importantly, nanoparticle integrity was found to be dependent on the balance of 
surface ligands.  Previously, it was shown that the inclusion of peptide-based 
targeting ligands at higher surface densities (>1 mol %) induced inter-ligand β-sheet 
aggregation (Figure 2-2), a phenomenon that is likely to limit recognition by cell 
receptors.  Another undesirable characteristic of high-ligand densities is their higher 
tendency to induce nanoparticle aggregation.  Nanoparticles decorated with higher 
percentages of peptide-lipids were evidently more prone to aggregation in high-salt 
solutions, where the rates of aggregation were much faster (Figure 2-4).  It is 
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believed that the physicochemical properties of the peptide (size, hydrophilicity) lead 
to particle aggregation on excessive loading. 
 
2.5.  U11-peptide enhanced cell transfection and uptake 
 
Using the stable low PEG (0.5mol% MeO-PEG2000-DSPE) formulation, the 
transfection effects between non-targeted and U11-targeted nanoparticles were 
further studied.  uPAR over-expression is a common trait found in cancers, where 
levels of its expression depends on the cell type (see Chapter 6, Figure 6-6) [133].  
Transfections were performed in two cell lines, namely uPAR positive cells (DU145, 
prostate cancer) and uPAR negative cells (non-cancerous HEK293 human 
embryonic kidney cell line.  Also see material and methods of Chapter 2 for map of 
luciferase-encoding plasmid) [134].  U11-targeted nanoparticles presenting 1 mol% 
U11 peptide-ligand mediated the highest levels of DU145 transfection, nearly 4-fold 
higher than that by non-targeted nanoparticles (Figure 2-6).  Nanoparticles that were 
overloaded with U11 peptide-lipids, at 5 mol%, only induced transfection levels 2-fold 
higher compared to that of non-targeted controls.  In comparison, the highest level of 
HEK293 cell transfection was mediated by non-targeted nanoparticles.   
 
On uPAR-negative cell lines, the U11 peptide sequence becomes non-specific for 
membrane receptors hence functions instead as a steric shield of the surface-
positive charges.  And as with the use of PEGylated lipids, inclusion of non-specific 
polymer chains into the surface of nanoparticles results in their impaired cell uptake 
and transfection efficiency [135].  There is a clear impression with reference to the 
non-targeted nanoparticle transfections, that DU145 transfection mediated by 
nanoparticles presenting 1 mol% of U11 scrambled peptide is on a par with HEK293 
transfection mediated by nanoparticles presenting 1 mol% of U11 peptide ligand.  
Therefore, there appears to be a clear U11 peptide ligand-mediated enhancement of 
approximately one log in U11-nanoparticle transfection of uPAR positive cells 
(DU145) compared with key controls, namely the transfection of uPAR positive cells 
by nanoparticles presenting 1 mol% of U11 scramble peptide, and the transfection of 
uPAR negative cells (HEK293) using nanoparticles presenting 1 mol% of U11 ligand.  
These transfection experiments are demonstrating the effective enhancement in 
gene delivery by U11 targeted nanoparticles consisting of the CDAN/DOPE/MeO-
PEG2000-DSPE/U11 peptide-lipid  lipids. 
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Table 2-2: Lipid composition plus physical characteristics of U11-targeted nanoparticles that 
enhance gene delivery efficiencies to DU145 cells.  Nanoparticles encapsulated pDNA at 12:1 
w/w. 
 
Lipid Molar % of total lipids 
CDAN 48.5 
DOPE 50 
U11 peptide-lipid 1 
MeO-PEG2000-DSPE 0.5 
Size (diameter) 156nm 
Zetapotential (see Chapter 3) +63mV 
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Figure 2-6: Luciferase transfection on uPAR-positive DU145 (a) and uPAR-negative HEK293 
cell lines (b) with nanoparticles (non-targeted, comprising CDAN/DOPE 1:1, mol/mol: and 
pDNA, lipid:pDNA ratio 12:1, w/w, MeO-PEG2000-DSPE, 0.5mol%; ABC) or targeted 
nanoparticles (with 1 or 5 mol% of U11 peptide-lipid or non-specific scrambled peptide-lipid; 
ABCD). Transfection data normalised on value of non-targeted nanoparticle transfections.  
Transfection times for cells were 3hrs in Optimem® after which cells were incubated for 48 h 
before lysis and analysis for luciferase activity.   
 
Cellular uptake and internalisation studies were carried out using fluorescently 
labelled nanoparticles, which were formulated to include 1 mol% of the fluorescent 
probe lipid DOPE-Rhodamine (DOPE-Rho).  After introduction to DU145 cells, cell-
associated rhodamine fluorescence was examined by microscopy at 1 h and 2 h 
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post-administration (Figure 2-7, a, b, c, d).  We observed that fluorescence intensity 
was much greater in cells treated with U11-targeted nanoparticles as compared with 
control non-nanoparticles, again another indication of receptor-targeted delivery by 
uPAR-U11 recognition.  Although the images obtained do not allow us to attribute the 
increased fluorescence intensity solely to cell-internalisation, we can confidently 
conclude that the U11-targeted nanoparticles are nevertheless binding more 
efficiently to the cell membrane than the non-targeted nanoparticles.   
 
FACS studies with DU145 cells further demonstrate the receptor-specificity of the 
U11 peptide.  Compared to controls, the U11-nanoparticles exhibited 15% more 
binding to uPAR over-expressing cells, a result of the U11 peptide’s selectivity.  
Furthermore, the targeting ability of these U11-nanoparticles were shown to be 
reduced to the same levels as control nanoparticles when the uPAR receptors are 
pre-blocked with high concentrations of free uPA ligand (Figure 2-7 e).  The binding 
of the control nanoparticles however, was not affected by the pre-saturation of uPAR 
receptors, again, proving the specificity of the U11 peptide for uPAR targeting.  Other 
groups have described the effect of enhanced endosomolysis exhibited by receptor-
targeted nanoparticles [136-138].  Using antibodies for targeting specific cell-surface 
antigens in leukemic cells, it is shown that the antibody ligands enhance rupture of 
endosomes, the compartment in which liposomes are trapped upon internalisation.  
The mechanism of such an action is considered to be a result of the acidification of 
the ligands, which ends in the release of the liposomal cargo into the cytosol.  Our 
U11 ligand comprises residues such as Lys and His, amino acids which are 
susceptible to protonation in low pH environments such as that of the endosome.  It 
is possible that the presence of U11 ligands on the nanoparticle surfaces can aid the 
de-acidification of endosome pockets, enhancing the release of pDNA cargo into the 
cytosol for translation.  However, the inferior binding and transfection abilities 
exhibited by the scramble-targeted nanoparticles further prove that the efficiency of 
the U11-targeted nanoparticles is due to their increased binding to cancer cells, and 
not by increased endosomolysis.    
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Figure 2-7: Uptake and binding of rhodamine-labelled optimised nanoparticles.  For 
fluorescence microscopy, DU145 cells were incubated with non-targeted, (a, b) and targeted 
nanoparticles (1 mol % U11, c, d) for 1 hr (a, c) and 2 hrs (b, d) before fixing and visualising.  
Images were overlaid with DAPI-nuclear staining.  At 1hr, the cell-associated fluorescence 
appears similar in cells treated with targeted- (c) and non-targeted nanoparticles (a).  The 
difference in fluorescence is more apparent at 2h, where cells treated with uPAR-targeted 
nanoparticles (d) show increased internal rhodamine intensity, compared to corresponding 
control non-targeted nanoparticles (b).  Competitive binding of rhodamine-labelled 
nanoparticles with free uPA, assessed by flow cytometry (e) shows the lower cell-binding by 
scramble peptide-decorated nanoparticles, and demonstrates U11 specificity for uPAR by 
reduced cell-binding of U11-nanoparticles after blocking of uPAR receptors with 40uM uPA. 
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2.6.  Summary of Chapter 2 
 
Overall, the transfection, uptake, and competition studies established the capability of 
the U11-nanoparticles for targeting cancer cells.  Although the increases in 
transfection and in uptake levels by the U11 nanoparticles were higher than the 
control nanoparticles, the amount of enhancement still requires optimisation for 
therapeutic use.  To emphasize the targeting effect of a targeting ligand, the 
background non-specific interaction between the nanoparticle platform and cell 
membranes requires minimisation.   
 
The main cause for these non-specific interactions may well lay in the high overall 
cationic charge of the nanoparticle systems.  Using this CDAN:DOPE 1:1 mol/mol 
platform, zeta potentials were found to be of the order of +60mV, a consequence of 
the high lipid:pDNA ratio of 12:1 (w/w).  This is corresponding to an N/P ratio of 4.25, 
assuming that each cytofectin CDAN presents a net charge of +1.7 at neutral pH [47].  
Cell membranes are typically anionic owing in part to negatively-charged cell surface 
proteoglycans, with which cationic nanoparticles may interact in a non-specific 
manner to trigger cellular uptake by endocytosis without the requirement for receptor 
mediation [139].  Therefore, the discrimination between non-targeted and targeted 
nanoparticle-mediated transfections should be improved by reducing the overall 
cationic charge of both nanoparticles. This could be feasible by engineering of the 
lipid scaffold of these nanoparticles using alternative neutral lipids and lower mol% of 
cytofectins along with a reduction in the lipid:pDNA ratio. 
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3. Optimising the nanoparticle platform to maximise the effect of 
targeting ligands 
 
Established previously is the ability of the U11 peptides to enhance receptor-
mediated uptake and transfection in uPAR-over expressed cells.  The nanoparticle 
platform adopted was based on a lipid formulation optimised for in vitro transfection, 
which are generally high in cationic charge to maximise binding with cell membranes.  
With a lipid platform consisting of 50 mol% of the cationic lipid CDAN, the final 
zetapotential of the nanoparticles were very high, resulting in the high background 
binding to cell membranes driven by electrostatic interactions.   
 
Nanoparticles suspended in solutions are always associated with a proximal layer of 
surface charges termed the Stern layer (Figure 3-1).  Counter ions of the opposite 
charge within the bulk solution then electrostatically interact with the Stern later 
forming another layer known as the diffuse layer.   As the nanoparticles diffuse in 
solution according to Brownian motion, the counter ions within the diffuse layer move 
with nanoparticles at the same velocity.  The zetapotential therefore, is the potential 
at the point in this layer where it moves past the bulk solution.  In the context of 
colloidal systems, the physical characteristic of zetapotentials is used to describe the 
apparent charge exhibited by a nanoparticle’s surface.  In the presence of an electric 
field, the speed at which the charged colloids travel to the electrodes is dependent on 
their apparent surface charge.  Therefore, on application of a laser light source, the 
zetapotentials of the nanoparticles can be calculated according to the phase shift in 
the incident beam.  Although high zetapotentials are associated with enhanced 
colloidal stability, reduction of surface charge in nanoparticles drug delivery systems 
will effectively impair their cell surface association and ultimately their in vitro 
transfection abilities.  However, nanoparticles of lower zetapotentials have longer 
circulation half-times as they are less subject to self-aggregation and protein-
adsorption [140-142].  Here we study the effect of charge on the transfection 
efficiency of uPAR-targeted nanoparticles.  
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Figure 3-1: Representation of zetapotentials of a nanoparticle colloidal system.  The 
measured zetapotential is representative of the difference in potential between that of the 
diffuse double layer, and of the bulk ionic solution.  Diagram modified from Malvern 
Instruments Ltd. 
 
3.1.  Formulating a low-charge nanoparticle platform  
 
The surface charge of a gene delivery nanoparticle is dependent on the ratio of 
positive charges from the cationic lipids (amines) and the negative charges 
(phosphates) from the nucleic acid backbone.  The charge ratio of a nanoparticle 
system can therefore be manipulated by changing the amount of cationic lipid or 
nucleic acids in the formulation.  Reducing the overall amount of cationic charge 
would require a balance of lower molar percentage of cationic lipids in conjunction 
with higher percentages of nucleic acids.  Previously, the CDAN:DOPE formulation 
was optimised to encapsulate pDNA at a weight ratio of 12:1 lipids:DNA (w/w), 
forming nanoparticles of around 200-300nm in diameter and zetapotential of 
approximately 60mV.  In this chapter we aim to formulate a nanoparticle platform with 
reduced amount of cationic lipids. 
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Being cholesterol-based, the cationic lipid CDAN, has implications when used as a 
transfection lipid for purposes of targeted delivery.  Firstly, it was been indicated that 
cholesterol-tailed cationic lipids can be potentially cytotoxic by acting as protein 
kinase C inhibitors [143].  This jeopardises the use of CDAN:DOPE formulations in 
this situation as the cause of cell death within cancer cells would not be entirely due 
to the genes delivered.  Furthermore, the rigidity of the cholesterol tail limits the 
ability of CDAN to be incorporated at a lower molar percentage.  The liposomal 
structures formed with lower ratios of CDAN required the use of higher molar 
percentages of its helper lipid DOPE, resulted in variable lipoplex sizes plus 
unreliable encapsulation efficiencies, most probably a result of the use of higher 
concentrations of DOPE, a geometrically constrained lipid [144].   
 
To overcome the limitations of CDAN, another cationic lipid, 3-[3-(2-Amino-
ethylamino)-propylamino]-N-dioctadecylcarbamoylmethyl-propionamide, known as 
DODAG, was adopted instead (Scheme 3-1).  DODAG relates to CDAN in that they 
share the same cationic head group, but differs in the lipophilic tail, which consists of 
disteroyl lipidic chains instead of a cholesterol group.  Formulations studies were 
carried out using DODAG, plus helper lipids such as DOPC and cholesterol at 
different molar ratios.  DOPC and Cholesterol were chosen to be components in this 
formulation due to various advantages relating to their structures. The geometry of 
the DOPC lipid is more cylindrical rather than inverted hexagonal, which would allow 
the formation of smaller liposomal nanoparticles required for long circulation and 
cancer targeting.  Cholesterol was recruited due to its ability to stabilise the lipidic 
layers, and prevent the mechanical disruption of the nanoparticles on surface-
adsorption of plasma proteins [27].  The main aim was to formulate a low-charged 
nanoparticle system that accommodates a small liposomal diameter along with high 
nucleic acid encapsulation efficiencies.   
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Scheme 3-1: Lipid structures used in formulations for preparing nanoparticle scaffolds of 
lower-cationic charge.  A new cytofection, DODAG is introduced, as an alternative to the 
rigid CDAN used previously in the high-charge formulations.  Other helper lipids, DOPC and 
Cholesterol, were recruited in the formulation for optimising size and stability of the 
nanoparticle.   
 
The inclusion of minimal cationic lipid in the formulation was considered for 
minimising the amount of cationic charge within the nanoparticle platform, and also to 
obviate the potential issues with cytotoxicities that cationic lipids may induce.  Unlike 
the conventional cationic cytofectin, DOTAP, DODAG has a cationic head group 
consisting of 3 amines where protonation can occur [27, 145].  This allows DODAG 
to be used in lower molar ratios without compromising the amount of cationic charge 
within the nanoparticle, required for nucleic acid encapsulation.   
 
Firstly, dynamic light scattering showed that the size of the liposomes was dependent 
on the increasing percentages of DODAG.  Higher percentages of DODAG, which is 
accompanied by lower percentages of DOPC and cholesterol, gave a steady, 
however small, increase in liposome diameter (Figure 3-2, a).  It was on 
encapsulation of pDNA, at the original ratio of 12:1 lipid/DNA (w/w), where there was 
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clear indication that th e minimum of DODAG that could be accommodated within a 
liposome formulation was 20 mol %.  Following this conclusion, the amount of DOPC 
lipids was optimised to be at 60 mol%, which left a remaining 20 mol % for the 
cholesterol component (Figure 3-2, b).  At this liposome formulation of 
DODAG:DOPC:Cholesterol of 20:60:20, the sizes of the nanoparticles were minimal, 
at less than 100nm in diameter, after incorporation of the pDNA.  Again like the 
CDAN:DOPE formulations, a small percentage of the PEGylated lipid, MeO-PEG2000-
DSPE was included for the nanoparticle to resist aggregation in highly buffered 
solutions.   This final liposome formulation consisted of 2.5 times less of cationic lipid 
than the CDAN:DOPE liposomes, which lead to a decrease in the overall cationic 
charge of the nanoparticle.  A lower charged nanoparticle system could potentially 
have less electrostatic interactions with cancer cell membranes, hence reducing non-
specific binding to enhance the effect of targeting ligands. 
 
Table 3-1:  Lipids used in optimised low-charge nanoparticle platform: 
 
Lipid Molar % of total lipids 
DODAG 20 
DOPC 59.5 
Cholesterol 20 
MeO-PEG2000-DSPE 0.5 
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Figure 3-2:  Formulation studies examining the effect of different molar ratios of DODAG, a) 
and DOPC, b). Liposomes were prepared by the lipid film-hydration method and sizes of the 
liposomes were measure by dynamic light scattering.  Smallest diameters and highest 
nanoparticle stabilities were achieved by liposomal formulations of DODAG:DOPC:Chol 
20:60:20.   
 
3.2.  Effect of decoration of low-charge nanoparticles with surface U11 
ligands 
 
To investigate the effect of lower-charged nanoparticle platforms, the DODAG 
formulations were prepared as before to include U11 ligands.  1 mol% of the U11 
peptide-lipid was incorporated by the method of post-insertion and various physical 
characteristics of the nanoparticles were examined.  Dynamic light scattering showed 
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the targeted low-charge nanoparticles to be around 99nm in diameter, a size smaller 
than that of the high charge nanoparticles, due to the difference in lipidic content 
within the liposome.  The zetapotentials were also measured to be lower than that 
measured for the high charge nanoparticles, as the cytofectin content was reduced 
by 2.5 times.  The pDNA encapsulation efficiencies were examined by assays 
utilising nucleic acid-intercalation agents.  Propidium iodide (PI), used generally for 
nucleus-staining in flow cytometry and fluorescence microscopy, was adopted here 
to quantify the amount of pDNA encapsulated within the nanoparticle.  The 
fluorescence of PI increases on intercalation into the major groove of nucleic acids; 
hence the amount of free, non-encapsulated pDNA could be quantified. At the ratio of 
12:1 w/w, the amount of pDNA encapsulated was almost to completion, the same 
level as that encapsulated by high charge nanoparticles.  This is showing that the 
decrease in cationic lipid content within the liposomal formulation does not affect the 
nucleic acid encapsulation efficiencies.  Although a less sensitive method, 
electrophoresis in agarose gels were also used to visualise and confirm the finding of 
the encapsulation assays.  Observed is the complete encapsulation of pDNA within 
the liposomes, as demonstrated by the lack of migration bands after separation 
(Figure 3-3, top right).  
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Lipid Molar % of total lipids 
DODAG 20 
DOPC 58.5 
Cholesterol 20 
U11 peptide-lipid 1 
MeO-PEG2000-DSPE 0.5 
Size (diameter) 99nm 
Zetapotential +43mV 
pDNA encapsulation % 98.8% 
 
Figure 3-3: Top left, representation of targeted nanoparticles with inserted U11 peptide-
lipids.  The low-charge nanoparticle platform consisted of lipid formulation consisting of low 
mol % of cationic lipid (20 mol%), plus a low percentage of MeO-PEG2000-DSPE to prevent 
nanoparticle aggregation in buffered solutions. Top right, gel electrophoresis of targeted and 
non-targeted nanoparticles encapsulating pDNA (lane 1, DNA ladder, lane 2, unencapsulated 
pDNA, lane 3, pDNA encapsulated by non-targeted nanoparticles, lane 4, encapsulated by 
U11-nanoparticles, lane 5, and lane 6, non-targeted and U11-targeted nanoparticles only). 
Bottom, lipid composition plus physical characteristics of low-charge U11-targeted 
nanoparticles that enhance gene delivery efficiencies to DU145 cells.  Nanoparticles 
encapsulated pDNA at 12:1 w/w. 
 
On in vitro transfection, what was firstly observed was a comparably lower efficiency 
in transfection by the low-charge nanoparticles, compared to that by the high-
charged formulations (Figure 3-4).  This result is demonstrating the reduction in 
electrostatically enhanced cell binding and uptake by cationically charged species, an 
effect anticipated by lowering the amount of cationic lipids [146].  However, further to 
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the 4-fold increase observed earlier by the targeted high-charge CDAN:DOPE 
nanoparticles, decoration of the surfaces of lower-charged nanoparticles resulted in 
the dramatic increase in cell transfection.  Using the DODAG low charge formulation, 
the U11-targeted nanoparticles were able to increase luciferase transfection by up to 
20-fold, compared to the non-targeted nanoparticle counterparts.  Here, it is clear 
that a reduction in the cationic charge of the nanoparticle platform limits the non-
specific background binding to cell membranes, and hence allows the effect of the 
targeting ligands to be more prominent.   
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Figure 3-4: Comparison of transfection efficiencies high-charged and low-charged 
nanoparticle platforms, plus the effect of introduction of targeting ligands.  U11-targeted 
nanoparticle systems generally enhance luciferase transfection in DU145 prostate cancer 
cells.  The effect of targeting is significantly more apparent in the low-charged nanoparticle 
systems, where introduction of U11 ligands results in a dramatic 20-fold increase in 
luciferase transfection over that achieved by non-targeted nanoparticles.   
 
Fluorescence binding studies were also used to differentiate the level of cell-
association between cells treated with non-targeted and U11-targeted nanoparticles.  
Nanoparticles were labelled with rhodamine fluorescence by the addition of 1 mol% 
of rhodamine-DOPE into the liposomal formulation and used to encapsulate pDNA at 
12:1 w/w ratio.  As in the case of high charge nanoparticles, the presence of U11 
ligands the surfaces of the low-charge nanoparticles were able to induce greater 
levels of cell-association.  Visualisation of the uptake and binding of the nanoparticles 
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by fluorescence microscopy showed higher rhodamine intensities in DU145 cells 
treated with U11-targeted nanoparticles, compared to those treated with non-targeted 
nanoparticles (Figure 3-5, top).  The difference in the fluorescence intensities 
between non- and targeted-nanoparticles is much more apparent when the 
nanoparticle platform is of lower cationic character.  For flow cytometry, cells were 
incubated with the same nanoparticles and incubated for 1 hr before analysis.  It was 
found that the cell-associated fluorescence induced by U11-nanoparticles were up to 
35 percent higher than that induced by non-targeted nanoparticles (Figure 3-5, 
bottom).  This amount of increase is even higher than that observed by the U11-
targeted high charge nanoparticles, which was found earlier to be around 15%.  
These fluorescence studies are not only indicating the ability of the U11 ligands to 
increase delivery efficiencies, but also emphasisinsg the ability of low charge 
nanoparticle platforms to reveal the full potential of the targeting ligands.   
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Figure 3-5: Cell uptake and internalisation studies using fluorescently labelled low charge 
(pDNA) nanoparticles.  Cell-associated fluorescence in DU145 cells treated with 
nanoparticles was examined by fluorescence microscopy (top) and flow cytometry (bottom).  
For microscopy, cells were examined for rho-fluorescence in cells treated by non-targeted 
(a) and U11-targeted (b) low-charge nanoparticles at 60mins after incubation.  
Accompanying fluorescence images are bright field images of the treated cells.  For flow 
cytometry, cells treated with non-targeted (black) or U11-targeted (black-bold) 
nanoparticles and were analysed for cell-associated fluorescence after 60mins of incubation.  
FL2-H represents relative rhodamine fluorescence intensities. 
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3.3.  U11 peptide organisation on surfaces of low-charge nanoparticles- 
Circular dichorism 
 
The organisation of such ligands on the surfaces of the new liposomal platform was 
examined again by circular dichroism.  Established previously in the case of high-
charged nanoparticle systems is the importance of the introduction of peptide ligands 
at optimal concentrations.  It was concluded that the U11-peptide lipids have a high 
tendency to aggregate into β-sheet like tertiary structures, a consequence of the 
hydrophobic interactions between the lipid moieties of the molecules.  Here, we 
further examined the change in circular dichorism ellipticity pattern of the U11 
peptide-lipids at varying concentrations.  Observed was the dependence on 
concentration for peptide-lipid aggregation into β-sheet like conformations.  At low 
concentrations of 1.5µM in H2O, the elliptical pattern is suggesting a more α-helical 
type conformation of the U11 peptide-lipids, the natural structure of the peptide lipids 
before becoming subject to intermolecular attractions at higher concentrations.  
Increasing the concentrations of the peptide-lipids results in a shift of the elliptical 
pattern, indicating increasing β-sheet-type organisations (Figure 3-6, a).  At 
concentrations above 12µM, the maximum β-sheet aggregation is achieved, where 
higher concentrations of the peptide-lipid all gave identical elliptical patterns.  The 
aggregation profile of the peptide-lipid could be compared to the change in elliptical 
pattern of the peptide-lipid before and after incorporation into the nanoparticle 
surfaces.  The peptide-lipids were incubated with low-charge nanoparticles at a 
concentration of 15µM, which according to the aggregation profile, is a concentration 
at which the peptide lipids should be sensitive to maximum β-sheet aggregation.  
This is confirmed by the elliptical pattern of the peptide-lipids at 15µM in incubation 
with non-targeted nanoparticles at t=0hr.  However, after complete post-insertion into 
the nanoparticle surface, the U11 peptide-lipids showed an elliptical pattern that was 
similar to that of the peptide-lipids in H2O at lower concentrations, or in other words, 
with less β-sheet aggregations (Figure 3-6, b).  This is suggesting that before 
introduction into liposome-nanoparticles, the peptide lipids are indeed organised into 
β-sheet conformations.  However after liposomal insertion, the peptide-lipids become 
more separated into individual strands, as indicated by the decrease in ellipticity at 
λ=216nm.   
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Figure 3-6: Change in tertiary conformation of U11 peptide-lipids as measured by circular 
dichroism.  a) Change in ellipticity pattern of U11 peptide-lipids in increasing concentrations 
in H2O. b) Change in ellipticity pattern of U11 peptide-lipids at 15µM (1 mol% of total lipid 
concentration) before and after incorporation into nanoparticle surface.  Targeted 
nanoparticles consisted of the lipids DODAG, DOPC, cholesterol, MeO-PEG2000-DSPE and U11 
peptide-lipids at ratios of 20/58.5/20/0.5/1.   
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3.4.  Accessibility of the U11 peptides- Fluorescence quenching 
 
Fluorescence properties of the Trp within the U11 sequence was utilised to further 
explore the arrangement of the ligands on the surface of the targeted nanoparticles. 
Fluorescence collisional quenching experiments with increasing concentrations of 
acrylamide were used to examine the accessibility of the peptides to the surrounding 
aqueous environment, in which the nanoparticles are dispersed.  When indole-based 
fluorescent probes such as tryptophan, are promoted into their excited states, 
diffusive contact with acrylamide results in electron transfer to the acrylamide leading 
to return of excitation to the ground state without emission of a photon (Figure 3-7).  
Acrylamide, being a water-soluble quencher, reduces only fluorescence emission of 
the Trp residues that are exposed to the aqueous environment in which the 
acrylamide is dispersed.  Therefore, only the non-aggregated and surface-exposed 
Trp amino acids within the U11 sequence will be quenched in the presence of 
acrylamide.   
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Figure 3-7: Jablowski-type representation of fluorescence emission and effect of quenching 
by addition of quenching reagent such as acrylamide (Principles of Fluorescence 
Spectroscopy, JR Lakowicz). 
 
Introduction of the targeted nanoparticles to increasing concentrations of acrylamide 
resulted in the extrapolation of standard Stern-Volmer graphs, where F0/F is plotted 
as a function of increasing acrylamide concentration. F0 is the fluorescence intensity 
of Trp in the absence of quencher and F is the intensity in the presence of quencher.  
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The KQ is calculated as the gradient of the Stern-Volmer plot, and hence correlates 
with the accessibility of the U11 peptides to acrylamide collision in an aqueous 
solution.  Steeper gradients indicate greater accessibility of Trp residues for collision 
with acrylamide, a result of increased extents of Trp-exposure to the aqueous phase.  
The measurement of KQ is commonly used to assess the lipid membrane-penetration 
abilities of anti-microbial peptides [147-149].  As the peptides are free in solution, 
they exhibit steep Stern-Volmer gradients, due to their easy accessibility to the 
aqueous acrylamide.  As the peptides penetrate the lipid membrane, their Stern-
Volmer gradients decrease considerably, due to their complete shielding within the 
lipid bilayers.  In our case, the measurement of KQ is for assessing the organisation 
of the peptide-lipids once inserted into liposomal surfaces, used to determine if the 
ligand is presented towards the aqueous solution or if it is folded within the lipid. 
 
Before conjugation to nanoparticles, the KQ value of the peptide-lipids is low, 
suggesting that the Trp moiety within the peptide is not well exposed to the aqueous 
environment (Figure 3-8).  This is likely a consequence of the intermolecular stacking 
into β-sheet aggregates.  However, on insertion into the liposomal nanoparticle, the 
KQ values of the U11 peptide-lipids increases, indicating that the Trp residues 
become increasingly exposed to the aqueous surroundings, due to dispersion into 
more monomeric forms.  Other studies concerning peptide-targeting in fact report a 
decrease in KQ after peptide-lipid incorporation into liposomal membranes, 
suggesting the burying of the ligand in either the lipid membrane or within the PEG 
components [150-151].  In our case, an increase in KQ after nanoparticle-association 
is indicative that the peptide moieties are not becoming buried within the lipid layer 
onto which it is anchored.    
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Figure 3-8: Stern-Volmer plots of acrylamide quenching of U11 peptide-lipids before and 
after insertion into nanoparticle surfaces. Plot depicts the increase in quenching constant of 
the ligands after their organisation into the liposomal layer.  Samples were excited at 
λ=289nm and fluorescence emission between λ=300-400nm was recorded for quenching 
constant calculations.  Samples are representative of 1 measurement, with linear plots fitted 
with coefficient determination values, R2, of >0.99. 
 
3.5.  Summary of Chapter 3 
 
In this chapter, the effect of lowering nanoparticle zetapotential is discussed.  The 
organisation of the U11 peptide-lipids on the surfaces of nanoparticles is further 
probed by circular dichroism and fluorescence quenching.   
 
A new, low-charged nanoparticle platform was formulated using a new cationic lipid, 
in conjunction with DOPC and cholesterol lipids.  It was clear that the reduction in 
cationic charge of nanoparticle platforms is important for the maximum exhibition of 
the effect of the targeting ligands.  However, the use of lower-charged nanoparticles 
results in an overall lower efficiency in gene delivery, due to the reduction in 
electrostatic interaction with cell membranes.  Another important observation from 
this experiment is the comparable transfection efficiencies between the high-charged 
non-targeted nanoparticles, with that of the low-charged targeted nanoparticles.  This 
is indication towards the ability of cancer-specific ligands to recover the loss in gene 
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delivery resulting from the use of a lower-charged nanoparticle platform.  
Fluorescence quenching studies further confirmed the dispersion of the U11 peptides 
into more monomeric forms after incorporation onto nanoparticle surfaces.  This form 
of ligand organisation was clearly beneficial for enhancing in vitro transfection levels 
in uPAR-overexpressing cells.  For in vivo purposes, the use of nanoparticles of 
lower cationic charge is highly significant for prolonging circulation time, to allow 
maximum accumulation of nanoparticles into the tumour sites via the EPR effect on 
intravenous injection.  However, lower-charged nanoparticle systems have impaired 
abilities to overcome cellular barriers, on arrival at tumour sites.  These results 
highlight one of the greater challenges of controlled delivery to cancer, in that the 
characteristics that are advantageous to prolonged circulation for enhanced tumour 
accumulation are often detrimental to their eventual gene delivery efficiency.   The 
introduction of receptor-specific ligands is therefore essential to re-establish the 
ability for cancer cell uptake of the low-charged nanoparticle delivery systems.   
 
However, one limitation of this method of surface-functionalisation is the rigidity of the 
U11 peptide-lipid, which limits the peptide extension from the nanoparticle surface.  
For successful accumulation into tumours, nanoparticles must have increased 
circulation half-lives, which can only be feasible on inclusion of at least 5 mol% of 
PEG2000  chains.  0.5 mol % of PEG2000, as used in the present nanoparticles, is not 
enough maintain nanoparticle stability in biological environments, but the use of 
increasing percentages of PEG can sterically limit the exposure of the short U11 
peptide-lipids to cognate receptors (see chapter 2).  It is therefore important to 
present the ligand in a manner where its targeting ability is not affected by the 
presence of stealth polymers. 
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4.  Inclusion of a PEG spacer for extended presentation of U11 ligands 
from nanoparticle surfaces 
Chapter 4- Inclusion of a PEG spacer for extended presentation of ligands from nanoparticle surfaces 
101 
 
On the successful preparation of a low-charge nanoparticle platform, we anticipated 
a further increase in targeted transfection levels by improving the presentation of the 
U11 peptide ligand from the nanoparticle surface.  Considering the ligand-binding 
pocket within uPAR receptor, which has been described to be around 14Å [111], it 
was hypothesised that the receptor-recognition of the U11 ligand could be increased 
by improving its flexibility.  This was carried out by examining the effect of extending 
the distance between the U11 ligand and the nanoparticle surface, by presenting the 
surface ligands through a PEG spacer.  In this chapter, we introduce a different 
technique of ligand-functionalisation of post-conjugation, which involves the covalent 
attachment of the targeting peptides onto the surfaces of pre-formed nanoparticle 
constructs. 
 
4.1.  Conjugation between Cys-U11 and mal-PEG2000-DSPE 
 
Commercially available are functionalised PEG lipids, where a variety of functional 
groups is attached at the distal end of the PEG chain.  Inclusion of these types of 
PEG-lipids into liposomal formulations results in the functionalisation of nanoparticle 
surfaces with reactive groups, such as that of the maleimide molecule.   
 
The maleimide-thiol reaction is ideal for bioconjugaton reactions, as it is very specific, 
and can occur at biological buffered conditions [152-154].  Including maleimide-
PEG2000-DSPE into the liposomal formulation is a means of giving PEG-mal 
functionality to the nanoparticle surfaces.  Previously, the U11-targeted nanoparticles 
were prepared by post-insertion, exploiting the amphiphilic nature of U11 peptide-
lipids.  Here, we examine the application of post-conjugation reactions between a 
free U11 peptide and maleimide groups presented on liposomal surfaces. 
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Scheme 4-1:  a) Nucleophilic attack of the thiol group from a Cys amino acid to a maleimide 
functional group, located at the distal end of PEG chains extending from the nanoparticle 
surface.  b) Structure of U11-PEG2000-DSPE after conjugation of the Cys-modified U11 
peptides (at N-terminal) with mal-PEG2000-PEG. 
 
Firstly, to identify the feasibility of the maleimide-lipid for ligand conjugation, the 
reaction between mal-PEG2000-DSPE and the U11 peptide was studied (Scheme 4-1).  
As the maleimide group reacts specifically with thiols at controlled pHs, the U11 
peptide was re-synthesised to include an extra cysteine amino acid to provide the 
thiol nucleophile for maleimide conjugation.  In the uPA ligand, two Cys residues are 
naturally present adjacent to the U11 sequence, one at the N-terminal and one at the 
C-terminal.  Therefore, two different Cys-modified U11 peptides were prepared, 
where one Cys residue was attached at either end of the peptides (Table 4-1). X-ray 
crystallography has described the U11 sequence in the uPA ligand to be conformed 
into a Ω-loop, which fits into the binding pocket of its cognate receptor uPAR.  The 
binding pocket itself is highly hydrophobic and therefore it is the hydrophobic 
phenylalanine residue within the U11 sequence that is central to the Ω-loop formation 
and recognition by the receptor [111].  As the phenylalanine amino acid lies within 
the middle of the U11 sequence, attachment of the U11 peptide to the nanoparticle 
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by either its C-terminal or its N-terminal should have little, or at least equally 
constraining effect on the vital residues.   
 
Table 4-1:  Amino acid sequences of the Cysteine-modified U11 peptides.  Cys is included at 
either the C-terminal or the N-terminal.  Amino acids were acylated at the amine terminal to 
prevent side reactions.  The U11 components within the peptides are highlighted in bold. 
 
Cysteine-modified peptide Sequence 
C-U11 H2N-C-VSNKYFSNIHWG-OH 
U11-C Ac-VSNKYFSNIHW-C-OH 
C-Scram Ac-C-ISKSVYNFWNH-OH 
 
Reaction between a thiol and a maleimide occurs specifically at pH7, a pH at which 
only thiols, and not other nucleophiles (such as primary amines from the lysine 
residue) are deprotonated enough to allow nucleophilic attack of the maleimide [155].  
Using HPLC to monitor the reaction of the peptide-PEG-lipid conjugation, it was 
found that both peptides, the C-U11 and U11-C were able to covalently attach to the 
maleimide-functionalised lipid over time (Figure 4-1, Figure 4-2, Figure 4-3).  At 
pH6.8, maximum conjugation between the peptide and the maleimide-lipid occurred 
after 8 hours of incubation at room temperature under inert gas.  Other studies that 
utilise this conjugation method have reported a variety of coupling times, up to 48 
hours, depending on the temperature of the reaction [156-157].  Our coupling time of 
8 hours is in aggrement with other studies, which also report conjugation periods to 
be around 8-10 hours at room temperature [158]. In addition, the pH of the buffering 
solution had to be kept as low as possible to avoid thiol oxidation and cysteine dimer 
bridge formation, two side-reactions that Cys-containing peptides are subject to. 
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Figure 4-1: HPLC traces of the Ac-U11-C-OH and mal-PEG2000-DSPE reaction in HEPES 4mM at 
t=0hr, a) and at t=72hr, b). The retention times for the U11-C peptides and the mal-PEG2000-
DSPE lipids are around 14mins, and 36mins respectively.  The decrease in intensity of the 
peak at 14mins over time indicates the conjugation of U11-C peptides to the mal-
functionalised lipids.  
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Figure 4-2: HPLC traces of the Ac-C-U11-OH and mal-PEG2000-DSPE reaction in HEPES 4mM at 
t=0hr, a) and at t=72hr, b). The retention times for the C-U11 peptides and the mal-PEG2000-
DSPE lipids are around 15mins, and 42.5mins respectively.  The decrease in intensity of the 
peak at 14mins over time indicates the conjugation of C-U11 peptides to the mal-
functionalised lipids. 
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Figure 4-3: MALDI mass spectrometry trace of the U11-C-PEG2000-DSPE peptide-PEG-lipid 
conjugate formed by reaction with U11-C peptide with mal-PEG2000-DSPE functionalised 
lipids. 
 
4.2.  Conjugation of Cys-modified U11 peptides to maleimide-functionalised 
nanoparticles 
 
PEG-maleimide-functionalised 
nanoparticle
U11-functionalised 
nanoparticle
Cys-modified U11 peptides
HEPES 4mM, pH7,  21 hrs, rt
post-conjugation
 
 
Figure 4-4: Representation of preparation of targeted nanoparticles by post-conjugation.  
Cys-modified U11 peptides are conjugated onto nanoparticle surfaces via a PEG chain that 
expresses a distal maleimide group.  The nanoparticle platform consisted of the lipids, 
DODAG, DOPC, cholesterol, MeO-PEG2000-DSPE at molar ratios of 20/59/20/1 and the Cys-
U11 peptides were added to the nanoparticle dispersion at 1:1 molar ratio to the maleimide 
groups. 
 
As conjugation between Cys-U11 peptides and mal-PEG2000-DSPE lipids was 
possible, the conjugation reaction on nanoparticle surfaces by the same manner was 
considered (Figure 4-4).  This required the addition of mal-PEG2000DSPE lipids into 
the lipid formulation to firstly functionalise the nanoparticle surfaces with maleimide 
groups. To adhere to the rules of ligand loading, the mal-PEG2000-DSPE lipids were 
included into the liposome formulation at a low concentration, 1 mol%, to avoid 
possibility of aggregation of the peptides on the nanoparticle surface.  The resulting 
nanoparticles consisted of the following lipid composition: 
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Lipid Molar % of total lipids 
DODAG 20 
DOPC 59 
Cholesterol 20 
mal-PEG2000-DSPE 1 
 
After preparation of nanoparticle platforms, Cys-U11 peptides were dissolved in H2O 
at 1mgml-1 and added to the nanoparticle dispersion at 1:1 mol/mol peptide:mal-
PEG2000. The reaction was monitored over time and it was found that the maximum 
conjugation did not amount to 100%, but only 40% could be fully coupled to the 
nanoparticle surfaces.  The coupling time for maximum conjugation to nanoparticle 
surfaces was also much longer than that of the peptides to mal-PEG2000-DSPE alone, 
at 20 hours at room temperature (Figure 4-5).  The total amount of peptides coupled 
was identified by HPLC and by the colourimetric Ellman’s test at a series of time 
points.  The Ellman’s test is based on the reagent 5,5'-Dithio-bis(2-nitrobenzoic acid) 
(DTNB) which absorbs light at 413nm after reaction with free thiols (Scheme 4-2) 
[159-160].  Analysis of size and zetapotential of nanoparticles after surface 
conjugation with peptides showed little change in characteristics to that measured 
before conjugation.   
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Scheme 4-2: Ellman’s test reaction, where the DTNB reacts with free thiols to release the UV 
active TNB molecule.  This assay was performed to quantify the amount of unreacted free 
Cys-modified U11 peptides. 
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Figure 4-5: Maximum coupling of Cys-modified U11 peptides to nanoparticles consisting of 
the lipid composition, DODAG/DOPC/Chol/mal-PEG2000-DSPE 20:59:20:1.  Cys-modified U11 
peptides were added to nanoparticles at 1:1 mole ratio with mal-PEG2000-DSPE and 
incubated for 24 hours at room temperature. a) Coupling of C-U11 peptides to nanoparticles 
as analysed by HPLC. b) Coupling of C-U11 and U11-C peptides to nanoparticles analysed by 
Ellman’s reagent after 24 hours incubation (averaged as n=2). 
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The event of the low percentage of maximum conjugation could be assigned to the 
availability of the maleimide groups for potential conjugation.  The nanoparticle 
platform is based on liposomal assembly, where lipids within the total lipid 
composition form an interior that encapsulates an aqueous core, and an exterior that 
is exposed to the outer aqueous solution.  The arrangement of the lipids within the 
liposome is unknown, therefore it could be estimated that half of the lipid is used to 
make the inner bilayer (the interior) and the other half formulates the outer bilayer 
(the exterior).  This occurrence is highlighted in a study using the pre-modification 
method to include peptide-PEG-lipid conjugates into the liposomal membrane.  It was 
found that the maximum amount of peptide that could be cleaved by an external 
enzyme was 60%, a percentage that reflects the amount of ligands exposed on the 
liposomal surfaces [138, 224].  This is suggesting that the PEG component of PEG-
lipid conjugates can become embedded within the interior of liposomes, if they are 
included in the pre-modification method.  Another factor that could contribute to the 
low % of peptide conjugation is the limited exposure of the externally presented 
maleimide headgroups.  When PEGylated lipids are introduced into liposome, it is 
known that the PEG chains can organise into two types of conformation, the 
mushroom and the brush conformation (Figure 4-6) [161]. The manner in which the 
PEG chains are arranged depends on the concentration, or the molar percentage, of 
the PEG lipids included in the liposomal formulation.   At lower mol % of PEG2000 
lipids, the PEG chains assemble into mushroom type conformation, where the long 
polymer chain is collapsed into singular bulky clouds.  Only on increase of the mol % 
of the PEG2000 lipids can the PEG chains rearrange into a brush-like state, where the 
intermolecular lateral pressure between the long molecules pushes the chains out 
into long extended conformation [27, 96].  In our nanoparticle formulation, only 1 
mol% of mal-PEG2000-DSPE is included, which suggests the organisation of the PEG 
chains into mushroom conformations.  The maleimide groups at the distal end of the 
PEG chains are therefore likely to be folded within the bulky mushroom cloud hence 
minimising their exposure to free U11 peptides.   
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Figure 4-6: Representation of brush and mushroom conformations of liposome-associated 
PEG chains.  On incorporation at low concentrations, the PEG molecules adopt the 
mushroom phase, where the polymer chains collapse into bulky spherical clouds.  PEG 
components can also be embedded within the interior of the liposome.  When included in 
higher concentrations, the PEG chains adopt the brush conformation, where the PEG 
molecules are forced to extend from the nanoparticle surface. 
 
Considering the maximum amount of ligand allowed for coupling to the low PEG 
nanoparticles, formulations were continued to be prepared by addition of Cys-
modified U11 peptides at a 1:0.4 mole ratio to the mal-PEG lipids.   
 
4.3.  Organisation of U11 peptides on the distal ends of nanoparticle 
surfaces 
 
To investigate the conformation of the PEG chains of the surface of the nanoparticles, 
fluorescence spectroscopy was adopted to probe the emission properties of the Trp 
amino acid contained within the U11 sequence.  
 
Fluorescence emission transition energies (π→π*) of Trp amino acids are dependent 
on the polarity of their surrounding environment.  On excitation, fluorophores absorb 
energy to result in the formation of a dipole that has different orientation to that in the 
ground state.  The instability of the new interaction between the dipole of the excited 
fluorophore and the surrounding solvent molecules requires energy from the 
fluorophore to be used for the reorientation of its dipole to match that of the solvent 
molecules.  Consequently, in environments of high polarity, larger amounts of non-
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radiative energy is lost from the fluorophore for dipole ‘relaxation’, which leads to the 
decrease in both the quantum yield, plus the energy of the released photon [162]. 
Therefore, a change in the local environment surrounding Trp residues from 
hydrophilic to hydrophobic results in the shift of the Emmax to lower wavelengths, after 
excitation at the typical wavelengths of λ=298nm.  The Cys-modified peptides were 
therefore probed by fluorescence spectroscopy to understand their arrangement and 
their interactions with PEG molecules on the nanoparticles’ surfaces.   
 
 
 
Figure 4-7: Jablowski-type diagram of fluorescence emission and the effect of the polarity of 
the solvent on the energy of Emmax (Principles of Fluorescence Spectroscopy, JR Lakowicz). 
 
Firstly, the change in emission spectra of U11 peptides as they are dissolved in 
solvents of decreasing polarity was examined.  Increasing concentrations of EtOH 
dissolved in H2O was used to mimic the decrease in solvent polarity.  On addition of 
Cys-modified peptides, observed were the general emission characteristics 
associated with an increase in solvent polarity, which included increases in 
fluorescence intensity and blue shifts in Emmax (Figure 4-8).  This experiment 
provides an indication on the change in the microenvironment, if any, of the peptides 
as they are conjugated onto the surfaces of nanoparticles. 
(10
-10
 sec) 
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Figure 4-8:  Fluorescence emission patterns of C-U11 peptides dissolved in solvents of 
decreasing polarity.  As the solvents increased in EtOH and decreased in H2O, the emission 
spectra of the C-U11 peptides changed in both the Emmax, and in the intensity.  The Emmax 
decreases on increase in solvent polarity along with the fluorescence intensity.  All peptide 
solutions were excited at λ=279nm.   
 
As free peptides in aqueous solution, both C-U11 and U11-C showed similar 
emission patterns, with high Emmax of λ=353nm (Figure 4-9).  This demonstrates the 
peptides’ full exposure to solvents, hence a high degree of hydrogen bonding 
between the peptides and the surrounding H2O molecules.  This state of peptide 
deaggregation is also contrary to that of the U11 peptide-lipids, which shown by 
circular dichroism, was subject to β-sheet type aggregations before incorporation into 
nanoparticles (see Chapter 2-3).  However, upon conjugation to nanoparticle 
surfaces, a clear shift in Emmax to lower wavelengths was observed in both peptides, 
C-U11 and U11-C (Figure 4-9).  Other studies using the fluorescence spectroscopy 
to understand ligand conformations also note a decrease in Emmax on conjugation of 
peptides onto PEGylated liposomes [151].  This blue shift in Emmax is indicative of the 
movement of the peptides into microenvironments of reduced polarity.  Again, the 
data suggest that the U11 peptides are becoming buried within the mushroom-like 
conformations in which the PEG chains are arranged [161, 163].  Along with the blue 
shift in Emmax, an increase in fluorescence intensity was also observed after 
nanoparticle conjugation, demonstrating the increase in quantum yield that is 
associated with microenvironments of lower polarity.  Negative vaules of 
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fluorescence intensities could be a consequence of scattered light from the 
nanoparticle colloids. 
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Figure 4-9: Fluorescence emission spectra of Cys-modified U11 peptides, a) C-U11 and, b) 
U11-C before and after conjugation onto nanoparticle surfaces.  Peptides were excited at 
λ=279nm and emission intensities collected between λ=300nm-400nm.  Spectra shows the 
shift in Emmax towards lower wavelengths after peptide immobilisation onto nanoparticle 
surfaces, indicating peptide transition into more hydrophobic environments within the PEG 
chains. 
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Interesting is also is the difference in emission patterns between the differently 
modified U11 peptides after nanoparticle conjugation.  Both C-U11 and U11-C 
peptides, after conjugation, exhibit similar low Emmax, although the fluorescence 
intensity of the conjugated C-U11 peptides is much higher (Figure 4-10).  This 
suggests that the Trp residues within the conjugated C-U11 peptides are losing less 
energy in the form of non-radiative decay that is not associated with an environment 
of lower solvent polarity. The difference in fluorescence intensity between the 
differently functionalised peptides is likely to be due to intermolecular quenching by 
free carboxylic groups [164-165].    
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Figure 4-10: Comparing fluorescence emission spectra of Cys-modified U11 peptides, C-U11 
and U11-C, before conjugation, a), and after conjugation onto nanoparticle surfaces 
containing 1 mol% PEG2000, b).  Peptides were quenched in 600mM acrylamide and excited at 
λ=279nm.  Emission intensities collected between λ=300nm-400nm.  Values within the 
spectra depict the Emmax of each peptide, and highlight the lower Emmax of the conjugated 
U11-C peptide, after quenching of exposed Trp residues by aqueous-soluble acrylamide.   
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4.4.  Organisation of U11 peptides on the distal ends of nanoparticle 
surfaces- fluorescence quenching 
 
Using the fluorescence-quenching properties of acrylamide, the extent of surface-
exposed or PEG-buried U11 peptides could be estimated.  Firstly the emission 
spectra of the free C-U11 and the U11-C peptides in the presence of acrylamide 
gave significantly lower fluorescence intensities, and both exhibited Emmaxs similar to 
those obtained for peptides in the absence of quencher (Figure 4-11).  This is 
confirming the complete exposure of the peptides to the aqueous solvent, as 
quenching with acrylamide does not reveal ‘masked’ emission patterns of low Emmax.  
Similar results are observed for the conjugated C-U11 peptides, which in the 
presence of a quencher gave emission patterns with comparable Emmax as that 
obtained in the absence of quencher.   On the other hand, emission spectra of 
quenched conjugated U11 peptides showed emission patterns which point towards 
the presence of non-quenchable, ‘buried’ Trp residues.   Assuming that conjugation 
of both the peptides results in targeted peptide-PEG-nanoparticle systems that are of 
identical conformations, the difference in emission maximum between the peptides 
can give insight into the extent of Trp exposure from the PEG clouds. The C-U11 and 
U11-C peptides differ in their location of the Cys amino acid residue within the U11 
sequence.  In the C-U11 peptide, the Cys amino acid is located at the N-terminal of 
the U11, and alternatively, at the C-terminal in the U11-C peptide.  The location of 
the Cys residue determines the direction of the U11 peptide orientation and hence 
changes the extent of exposure of the Trp residues.  The Trp residue itself is found 
naturally at the carboxylic end of the U11 sequence; hence the difference in location 
of the Cys amino acid leads to the difference in distance between the Trp amino acid 
and the nanoparticle surface.  The U11-C peptides are conjugated to nanoparticles 
through the C-terminal Cys amino acid, therefore the Trp residue would be located 
adjacent to the end of the PEG chain (Figure 4-12).  This means that the Trp residue 
of the U11-C peptides is more likely to be in a constant microenvironment of lower 
polarity, due to steric shielding from the PEG chains.  In regards to the C-U11 
peptides, comparing the Emmax of the conjugated C-U11 peptide in the absence with 
that of in the presence of acrylamide shows that the peptide is partially quenchable 
by acrylamide upon nanoparticle conjugation, and hence partially exposed to the 
aqueous environment.  The U11 peptides are therefore either only half buried in the 
PEG clouds, and likely to be in a dynamic process of folding and de-folding out of the 
PEG mushroom.   
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Figure 4-11: Comparing fluorescence emission spectra of acrylamide-quenched Cys-modified 
U11 peptides, C-U11 and U11-C, before conjugation, a), and after conjugation onto 
nanoparticle surfaces containing 1 mol% PEG2000, b).  Peptides were quenched in 600mM 
acrylamide and excited at λ=279nm.  Emission intensities collected between λ=300nm-
400nm.  Values within the spectra depict the Emmax of each peptide, and highlight the lower 
Emmax of the conjugated U11-C peptide, after quenching of exposed Trp residues by 
aqueous-soluble acrylamide.   
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Figure 4-12:  Representation of C-U11 and U11-C peptides conjugated onto nanoparticles 
(plus 1 mol% mal-PEG2000-DSPE) surfaces.  The Trp residues within each peptide differ in their 
distance from the PEG chain, resulting in the difference in fluorescence emission pattern.  
 
Extrapolation of Stern-Volmer plots also reinforces the notion that the U11 peptides 
are folding within the PEG mushroom clouds (Figure 4-13, Figure 4-14).  Quenching 
constants of conjugated-U11 peptides via a PEG chain were considerably lower that 
the free peptide alone, indicating the reduction in exposure of the conjugated 
peptides to the exterior aqueous phase.  The quenching constant of the conjugated 
U11-C peptide was again smaller than that of the conjugated C-U11 peptides, which 
is a result of the near proximity of the Trp amino acid to the PEG portion of the 
nanoparticle.   Since the folding of the U11 peptide within the PEG mushroom cloud 
does not affect its targeting abilities in vitro, it is assumed that the shielding process 
is a dynamic one [166-167], where the peptide can fold and de-fold into the PEG 
chains.   
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Figure 4-13: Stern-Volmer plots of acrylamide quenching of Cys-modified peptides, a) C-U11 
and b) U11-C, before and after conjugation onto the distal end of surface-associated PEG 
chains on nanoparticles.  Plot depicts the decrease in quenching constant of the free 
peptides after their confinement onto the nanoparticle surfaces.  Samples were excited at 
λ=279nm and fluorescence emission at λ=340nm recorded for quenching constant 
calculations.  Lines are representative of one measurement, where linear plots are fitted 
with coefficient determination values, R2, of over 0.95. 
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Figure 4-14: Comparing Stern-Volmer plots of acrylamide-quenched Cys-modified U11 
peptides, C-U11and U11-C, before and after conjugation onto nanoparticle surfaces 
containing 1 mol% PEG2000.  Peptides were quenched in 600mM acrylamide and excited at 
λ=279nm.  Lines are representative of one measurement, where linear plots are fitted with 
coefficient determination values, R2, of over 0.95. 
 
4.5.  Effect of in vitro pDNA transfection activity of targeted nanoparticles 
 
Although the fluorescence data suggest the limited exposure of the peptide ligands 
from the PEG clouds, in vitro transfection experiments proved that this did not hinder 
their effects in cell-targeting.  Targeted nanoparticles prepared by post-conjugation 
were found to encapsulate pDNA at high efficiencies, plus exhibited agreeable 
physical characteristics such as low zetapotentials and small diameters (Figure 4-15).   
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lipid Molar % of total lipids 
DODAG 20 
DOPC 59 
Cholesterol 20 
MeO-PEG2000-DSPE 1 
Size (diameter) 101nm 
Zetapotential +36mV 
% pDNA encapsulation 85.6% 
 
Figure 4-15: Top left: gel electrophoresis of targeted and non-targeted nanoparticles 
encapsulating pDNA (lane 1, DNA ladder, lane 2, pDNA only, lane 3, encapsulated by non-
targeted nanoparticles, lane 4, encapsulated by U11-nanoparticles (with short U11-peptide-
lipid, see Chapter 3), lane 5, non-targeted liposomes only, lane 6, U11-targeted liposomes 
only (targeted with short U11-peptide lipids, see Chapter 3), lane 7, encapsulated by non-
targeted nanoparticles, lane 8, encapsulated by U11-nanoparticles (C-U11 post-conjugated), 
lane 9, non-targeted nanoparticles only, lane 10, U11-targeted (by C-U11 post-conjugation) 
nanoparticles only.  Top right: representation of U11-targeted nanoparticles (low charge 
platform, PEG-extended ligand). Bottom: lipid composition and physical characteristics of 
optimised targeted nanoparticles prepared by post-conjugation.  Cys-modified U11 peptides 
were added to nanoparticle suspension at 1:1 mol ratio to maleimide groups. 
 
The effect of extending the ligand via a PEG spacer on transfection was examined by 
administering nanoparticles carrying pDNA, at a 12:1 lipid:DNA w/w ratio, to uPAR-
overexpressing DU145 cells.  It was found that the transfection levels induced by 
U11-targeted nanoparticles could be increased by up to 30-fold, relative to 
1    2    3    4    5    6    7     8    9   
10 
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transfection by non-targeted counterparts (Figure 4-17).  It was also found that 
targeting by both the C-U11 and the U11-C peptides could increase transfection 
levels by similar amounts, suggesting that the direction of the peptide extension from 
the nanoparticle surface does not affect receptor-interactions.  As mentioned, the 
hydrophobic binding site within the uPAR receptor for uPAR ligand-docking is 
arranged to accept a complementary Ω-loop, which naturally occurs in within the U11 
sequence. The Ω-loop of the U11 peptide centres around the Phe reside which 
resides at the tip of the loop.  This is suggesting that it is the centre residues within 
the U11 peptide that are most responsible for receptor-binding, hence the direction in 
which the peptide is conjugated onto the nanoparticle is not important, as long as the 
middle section of the peptide is exposed.  Further specificity of the U11 peptide was 
demonstrated by the low-transfection levels of nanoparticles targeted by a control 
peptide which is a scrambled U11 sequence.  The amount of transgene expression 
induced by scramble peptide-conjugated nanoparticles was on the same level of that 
by non-targeted nanoparticles, indicating the ineffective function of the scramble-
peptide as a targeting ligand.  The enhanced specificity of the U11-targeted 
nanoparticle systems was further highlighted in fluorescent uptake studies.  
Nanoparticles were labelled with 1 mol% DOPE-Rho and administered to DU145 
cells for 1 hour before analysis.  Fluorescence microscopy showed higher intensities 
of fluorescence in cells treated with U11-targeted nanoparticles, compared to cells 
treated with scram-targeted nanoparticles.  Quantification of cell-associated 
fluorescence by flow cytometry demonstrated enhanced cellular binding and uptake 
by U11-targetd nanoparticles by up to 50% more, compared to control targeted 
nanoparticles (Figure 4-16).  These fluorescence studies are not only indicating the 
specificity of the U11 peptides, but also emphasising the need for their proper 
organisation, as demonstrated by the the effect of PEG-extension of the targeting 
ligand.  Again, the incompetence of scram-targeted (control) nanoparticles to 
increase cell-binding and their inefficiency for transfection demonstrates that the 
effect of the U11 sequence is due to enhanced cell binding, and not enhanced 
endosomolysis. 
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Figure 4-16: Cell-associated fluorescence of DU145 cells treated with rhodamine labelled 
nanoparticles, either U11-targeted, or scram peptide-targeted.  All nanoparticles consisted 
of the platform DODAG/DOPC/chol/mal-PEG2000-DSPE/DOPE-Rho at 20/58/20/1/1, and post-
conjugated with Cys-modified peptides, C-U11 or C-Scram.  Top: Fluorescence microscopy of 
cells after 1 hour incubation with U11-nanoparticles a) and scram peptide-nanoparticles b).  
Left panels show rhodamine fluorescence induced by cellular binding or internalisation of 
nanoparticles, and right panels show bright field images of similarly treated cells.  Bar 
represents 10µm.  Bottom: Flow cytometry of cells after 1 hour incubation with 
nanoparticles.  U11-targeted nanoparticles increased cell-associated fluorescence by up to 
50% compared to that by scram-nanoparticles.  FL2-H represents rhodamine fluorescence 
intensity. 
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Figure 4-17: Luciferase transfection in DU145 cells by nanoparticles targeted with Cys-
modified U11 peptides, attached through covalent conjugation to the distal end of surface-
located PEG2000 chains.  U11-targeted nanoparticles were able to enhance transfection levels 
by up to 30-fold, compared to its non-targeted nanoparticle counterparts.  All nanoparticles 
encapsulated pDNA at a lipid:pDNA ratio of 12:1 w/w.  Transfections were carried out for 4 
hours and cells were further incubated for 48 hours before analysis. 
 
4.6.  Summary of Chapter 4 
 
Decoration of nanoparticle surfaces by the method of post-modification was proven 
achievable, through the conjugation of Cysteine-modified U11 peptides with surface-
associated PEG2000-maleimide groups.  It was found that the inclusion of low mol % 
of PEG2000 chains into liposomal formulations resulted in their organisation to 
mushroom-like configurations.  This resulted in the hindered exposure of the distal 
end of the PEG polymer, onto which the U11 ligands are covalently attached.  
Results suggested the dynamic folding of the conjugated U11 peptides into the 
mushroom-like PEG clouds, a consequence of the low mol % of the PEG-lipids.  
However, this method of ligand presentation was proven to be even more effective at 
enhancing in vitro gene delivery, compared to surface functionalisation by the post-
insertion of short peptide-lipids.  The increase in cell-associated binding and cell-
internalisation is most likely a result of the increased flexibility of the ligand, which is 
conjugated to the nanoparticle surface via a long PEG chain.  To improve the 
exposure of the ligands in this system, the inclusion of higher mol % of PEG-lipids 
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would be required, as this would lead to the transition of the PEG chains into a brush-
like state.  Higher molar percentages of MeO-PEG2000-DSPE are crucial for not only 
surface ligand presentation, but also to provide nanoparticle stability and to maintain 
nanoparticle sizes for in vivo applications.   
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5.  siRNA systems 
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So far, the nucleic acids used for encapsulation have been plasmid DNAs.  The luc-
coded pDNA served as a reporter gene to examine the gene delivery and 
transfection efficiencies of targeted nanoparticles.  However, for use in medical 
applications, encapsulation of therapeutic nucleic acids within the nanoparticles 
would be required.   The use of siRNAs as a therapeutic option for cancer gene 
therapy is becoming a promising area of interest [168].  As a highly potent technique 
of inducing gene silencing, the phenomenon of RNA interference has been exploited 
for its potential as molecular therapy.   Short interference RNAs (siRNA) are short, 
double-stranded RNA sequences of 20-22 nucleotides in length [37].  This special 
type of RNA can repress protein expression by interfering with the translation of 
corresponding mRNA.    On entrance into cellular cytoplasm, siRNAs can bind to the 
RISC (RNA-induced silencing complex) enzyme complex which proceeds to unwind 
the short double-stranded RNA into separated sense and anti-sense strands (Figure 
5-1).  The RISC enzyme complex can then recruit endogenous mRNA strands with 
sequences corresponding to the sense strands of the siRNA.  Upon complementary 
binding, the RISC complex then cleaves the mRNA strand at the areas which are 
bound to the siRNA. This results in the eventual inhibition of expression of the 
corresponding protein, a mechanism useful for knockdown of oncogenic proteins in 
cancer therapy.  Examples of using siRNA for treatment of cancer include the 
knockdown of Tie2 and CD31 gene targets, genes coding for proteins involved in the 
angiogenesis around tumour sites [169].  Particularly for the treatment of hormone-
refractory prostate cancer and breast cancer, the delivery of siRNAs against EZH2 
and p110-α genes (with atelocollagen nanoparticles) have been shown to reduce 
tumor growth in vivo [22].  These genes have been characterised to be 
overexpressed in prostate cancer cells of patients and have been described to be 
involved in cell proliferation [170-171].   
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Figure 5-1: Representation of siRNA action leading to inhibition of mRNA translation.  The 
siRNA attaches to the RISC enzyme complex, which ultimately results in the cleavage of the 
mRNA sequence complementary to the siRNA.   
 
The challenges posed for siRNA-based cancer therapy are similar to those posed for 
DNA-delivery.  As with all drug delivery systems for cancer therapies, the vector 
requires properties that allow their accumulation at tumour sites via the EPR effect.  
The differences in delivery occur after cellular internalisation, where DNA, but not 
siRNA, requires further transportation into the nucleus to allow the effect of gene 
expression.  The efficiencies of both delivery systems are subject to release from 
endosomal compartments after endocytosis, a mechanism which requires the use of 
lipids such as DOPC which can induce phase transition of lipid bilayers to release 
their liposomal content.  Another main difference between siRNA and DNA delivery 
systems is in their formulation, particularly in the step of nucleic acid encapsulation. 
The size and shape of siRNAs differ to that of pDNAs in that siRNAs are short and 
rigid (19- 21 base pair duplexes), whereas pDNA is much larger, with molecular 
weights of approximately 4 x106 Da, and can condense into smaller structures in the 
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presence of cationic charges [51].  As with DNA, siRNA also needs to be 
encapsulated within a nanoparticle system to facilitate intracellular uptake and 
protect it from enzymatic degradation on in vivo delivery [172-174].  Following the 
optimisation of a low-charged liposomal formulation for targeted DNA delivery, we 
continued in the optimisation of nanoparticles for the delivery of siRNA, in particular 
for applications in vivo, as siRNA can show therapeutic potential in cancer.  Before 
considering the decoration of targeting ligands, it is important to formulate a 
nanoparticle platform that is suitable for in vivo siRNA delivery.  
 
5.1.  Preparation of siRNA nanoparticles- Varying the charge ratio to 
decrease surface charge 
 
Previously described is the encapsulation of pDNA through its condensation by the 
electrostatic interactions between the negative charges of the phosphate backbone 
within the nucleic acid with the cationic charges of the liposome.  Using the optimised 
low-charged nanoparticle platform consisting of 20 mol% DODAG, the siRNA was 
loaded using the same method as for pDNA loading: 
 
lipid Molar % of total lipids 
DODAG 20 
DOPC 59 
Cholesterol 20 
MeO-PEG2000-DSPE 1 
 
One advantage of using siRNA as the nucleic acid instead of pDNA is that the charge 
ratio of the nanoparticles can be altered more easily.  Each molecule of siRNA 
carries a maximum of 42 minus charges, a much smaller number than the 
approximately 13000 minus charges per pDNA molecule (for calculations, see 
Methods of Chapter 5).  Addition of increasing amount of siRNAs to liposome 
formulations is another method of fine tuning the overall zetapotential of the 
nanoparticle.  The charge ratios are essentially the relative number of cationic 
charges from the lipids within the formulation [47], and the anionic charges from the 
phosphates of the nucleic acids (2 per base pair).  Previously it was found that non-
specific electrostatic interactions between nanoparticles and cell membranes can be 
minimised by reducing the overall cationic charge of the nanoparticle.  This has been 
demonstrated earlier to be important in maximising the effect of the targeting ligand 
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for receptor-specific binding. So far, the reduction in nanoparticle zetapotential has 
been successful through decreasing the amount of cationic lipid within the 
formulation.  In a siRNA system, the zetapotential of a nanoparticle can also be 
manipulated by varying its charge ratio, or its N to P ratio (N= protonated amines 
from cationic lipids, and P= negatively charged phosphate ion).  This was performed 
by keeping constant the amount of lipids within the empty nanoparticle formulation 
followed by the encapsulation of increasing amounts of siRNA.  
 
It was anticipated that the lower the lipid:siRNA ratios, in other words the lower the 
charge ratio, the lower the zetapotentials of the formulated nanoparticles.  The 
nanoparticle characteristics that vary according to change in charge ratio were 
examined for the formulation of an optimal siRNA-encapsulated nanoparticle for 
cancer delivery.   
 
Using dynamic light scattering, it was found that the diameters of the loaded 
nanoparticles increased from 96nm to 126nm as the charge ratio decreased from 16 
to 1.5 (Figure 5-2).  This increase in size was attributed to the fact that nanoparticles 
of lower charge ratios are packed with greater amounts of siRNA which occupy more 
space within the nanoparticle.  As the ultimate application of the developed 
nanoparticle is for in vivo systemic delivery, the sizes of nanoparticles remain an 
important factor to consider.  Diameters above 100nm limit the delivery process by 
reducing the nanoparticles’ ability to bypass the fenestration within the tumour 
vasculature.  Low-charge ratio nanoparticles, of charge ratios of 2 and 1.5 exhibited 
diameters larger than 100nm, a consequence of their increased amounts of 
encapsulated siRNA, and are therefore less advantageous for the purpose of siRNA 
delivery.   
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Figure 5-2: Change in nanoparticle size as charge ratio is decreased.  Nanoparticles consisted 
of optimised low-charge lipid formulation (20% DODAG), which were used to encapsulate 
increasing amounts of anti-GAPDH siRNA.  Diameters were measured by dynamic light 
scattering.   
 
The zetapotentials of the nanoparticles ultimately varied depending on the charge 
ratio (Figure 5-3).  As expected, nanoparticles of lower charge ratios, encapsulating 
larger amounts of siRNA exhibited lower zetapotentials, a result of increased charge 
neutralisation.  However, the decrease in zetapotential plateaus at the charge ratio of 
2, after which the zetapotential increases on the addition of further siRNA.  It is 
suspected that the charge ratio of 2 is the minimum ratio between the lipid and siRNA 
that can be achieved.  At charge ratios of 1.5, the zetapotential of the nanoparticles 
increase to values higher than that of charge ratio 2, which is suggesting dissociation 
of the siRNA from the nanoparticle on achieving maximum encapsulation. 
 
This change in zetapotentials indicates a change in lipid:siRNA association on 
varying the charge ratio.  Between charge ratios of 16 and 2, the zetapotential 
decreased steadily due to increase in siRNA to lipid ratio, suggesting the full 
association of siRNA with the nanoparticle.  The amount of encapsulated siRNA was 
consequently measured by fluorescence-based encapsulation assays. 
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Figure 5-3: Zetapotentials of nanoparticles with decreasing charge ratios.  Charge ratios 
reflect the mole ratio between the cationic lipid portions of the liposome formulation with 
that of the amount of encapsulated siRNA.  Liposomal formulations were based on the low-
charge 20 mol% DODAG platform previously optimised. Charge ratios of nanoparticles were 
varied by increasing the amount of siRNA for encapsulation.   
 
Using propidium iodide, a nucleic acid intercalating agent, the amount of un-
encapsulated siRNA in loaded nanoparticles could be monitored by the change in 
fluorescent intensity.  The graph represents the fluorescence intensities of each 
incubation as a percentage of that measured for free siRNA (Figure 5-4). 
 
All charge ratio formulations were shown to encapsulate high percentages of siRNA, 
at >80% in comparison to free siRNA.  However, the encapsulation efficiency was 
found to increase as the ratio of lipid to siRNA increases, as is hypothesised, due to 
the greater amount of lipid present for interaction with the nucleic acids.  
Nanoparticles of charge ratio 4, 8 and 16 were able to encapsulate over 95% of the 
siRNA, compared to 80% and 85% encapsulation by nanoparticles of charge ratio 
1.5 and 2, respectively.  These data again realise one of the drawback of lower 
charge ratios (lower siRNA:lipid ratios),  being reduced siRNA:lipid association, which 
could lead to loss of siRNA during administration of nanoparticles.  
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Fnanoparticle= Fluorescence intensity of PI-intercalated siRNA after encapsulation into 
nanoparticles of varying charge ratios, 
Ffree siRNA= Fluorescence intensity of PI -intercalated free siRNA (non-encapsulated). 
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Figure 5-4: Quantifying amount of siRNA encapsulated into nanoparticles on decreasing 
charge ratio.  Percentage encapsulation was measured using propidium iodide as a nucleic 
acid intercalator that fluoresces on interaction with free, unencapsulated siRNA.  
 
So far it is clear that the charge ratio can affect the physical characteristics of a 
nanoparticle in terms of size, zetapotential and siRNA-encapsulating efficiencies.  
These characteristics in turn determine the biological effect of the nanoparticles.   
 
5.2.  In vitro studies with siRNA-nanoparticles platforms (low-PEG) 
 
Biological studies on the siRNA nanoparticles were commenced by examining their 
cell-uptake efficiencies by flow cytometry on the DU145 cell line.  Nanoparticle 
formulations of 20% DODAG were prepared as before to encapsulate FAM-labelled 
siRNAs at charge ratios of 2, 4, 8 and 16 (Figure 5-5).   The prepared nanoparticles 
were administered to cells and examined for cell-associated fluorescence at time 
points of 2hrs and 4hrs.   Firstly, it was observed that naked, non-encapsulated 
siRNA did not show cell-associated fluorescence, even at longer incubation times.   
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The inability of siRNA to be internalised into cells is due to its reduced attraction to 
the cell membrane, as result of charge repulsion.  Only siRNA that is encapsulated 
within nanoparticles were able to exhibit cell-associated fluorescence, due to the 
cationic and the lipidic nature of the nanoparticles, which aids cell-binding and 
endocytosis.  In terms of encapsulated siRNAs, the nanoparticles of higher charge 
ratios were able to be associated to DU145 cells in higher amounts.  This result can 
be attributed to higher zetapotentials and hence the increased electrostatic attraction 
to cell membranes of nanoparticles with higher charge ratios.  At incubation times of 
2 hours, nanoparticles of charge ratio 2, the lowest charge ratio in the series, did not 
show any association to cells.  Nanoparticles of charge ratio 2 were measured to 
have zetapotentials of +10mV, similar to that of nanoparticles of charge ratio 4.  
However, the difference between the two charge ratios is the maximum amount of 
siRNA encapsulated.  Charge ratios of 4 could encapsulate siRNA to almost 100%, 
whereas the encapsulation efficiencies were lower, in the case of charge ratio 2, 
hence the lower amount of siRNA association to cells.   However, at longer 
incubation times of t= 4hrs, association to cells is then observed by nanoparticles of 
charge ratio 2.  In the case of all nanoparticles, higher percentages of cell-associated 
fluorescence are observed at longer incubation times.   
 
Nanoparticles with higher charge ratios have therefore higher efficiencies for cell-
binding and cell-internalisation, due to their higher zetapotentials for electrostatic 
interactions.  However, as high charge ratios are prepared with high lipid content, 
their use for biological applications requires the introduction of nanoparticles at high 
concentrations.  Disadvantages of administration of either drug, or drug delivery 
vehicle at higher concentrations include higher risks of toxicity, plus the need for 
larger amounts of material.  The nanoparticle itself is still regarded as a foreign agent 
to the body, due to its charge, size and inclusion of synthetic lipids, therefore its 
administration at higher concentrations could potentially be toxic.  For use in vivo, it is 
safer to introduce nanoparticles at concentrations as low as possible.   
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Figure 5-5: Uptake of nanoparticles encapsulating FAM-siRNA at various charge ratios, 
determined by flow cytometry.  After administration of nanoparticles to DU145 cells, cell-
associated fluorescence was examined at t= 2hrs, a) and at t=4hrs.  Naked siRNA did not 
show cell-association, whereas nanoparticle-encapsulated siRNA exhibited cell-associated 
fluorescence dependent on charge ratio and incubation time.   FL1-H represents FAM 
fluorescence intensities 
 
In the quest to optimise a nanoparticle platform, the ability of different charge ratios to 
induce siRNA-knockdown was examined.  Nanoparticles were prepared with the 
charge ratios of 2, 4, 8 and 16, encapsulating siRNA specific for β-galactosidase (β-
gal).  Before administration of the siRNA-nanoparticles, the DU145 cells were pre-
transfected for 24 hours with pDNA encoded to induce transient expression of β-gal 
for siRNA knockdown.  After 4 hours of transfection and further 48 hours incubation, 
it was found that low-charge siRNA-nanoparticles were able to functionally silence 
anti-β-gal expression in cancer cells (Figure 5-6).  Nanoparticles of all four different 
charge ratios were able to inhibit the expression of β-gal protein, although with 
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modest efficiencies.  The low charge ratio of 2 had the lowest knockdown efficiency, 
whereas the higher charge ratios, 4, 8 and 16 reduced protein expression to slighty 
higher extents.  The overall low efficacy of siRNA knockdown by all low-charge 
nanoparticles is a consequence of their low zetapotentials hence low binding affinity 
for cell membranes.   Although nanoparticles with charge ratio 2 were measured to 
express similar zetapotentials to those of charge ratio 4, their especially low efficacy 
for functional delivery is perhaps due to their lower siRNA encapsulation efficiency.   
These in vitro data show the potential of the charge ratio 4.  At this charge ratio, 
nanoparticles have low surface charge, high siRNA encapsulation and can be used 
at lower concentrations to induce siRNA knockdown at levels comparable to that of 
nanoparticles with higher charge ratios.   
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Figure 5-6: Knockdown of transiently expressed β-gal by anti-β-gal siRNA encapsulated in 
nanoparticles (20% DODAG) at varying charge ratios.  After transfection of DU145 cells with 
β-gal encoding pDNA, nanoparticles containing anti-β-gal or control siRNA was administered 
to cells and incubated for 4 hours before cell lysis and analysis for β-gal protein content.  
Protein content was normalised with BCA protein concentration assay. *control= cells 
transfected with β -gal plasmid only, without siRNA treatment. 
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5.3.  Increasing Percentage of PEG within Nanoparticle Formulation 
 
Here, it is proposed the low charge liposome formulation consisting of 20% DODAG, 
in conjunction with encapsulation charge ratios of 4, is an optimal nanoparticle 
platform for introduction of targeting ligands.  For use in vivo, the inclusion of higher 
percentages of PEG lipids into the nanoparticle platform is crucial for providing 
nanoparticle stability [175].  Nanoparticle stability, defined in terms of their anti-
aggregation properties and integrity, must be maintained on systemic administration 
to maximise nanoparticle accumulation at tumour sites.  Long chains of linear PEG 
are intended to create a spherical, steric barrier around the liposomal particle, 
reducing the tendency for particle aggregation, through the generation of steric 
repulsion [176].  The PEG chains can prevent nanoparticle aggregation, and help 
protect the nanoparticles from immune surveillance, avoiding recognition by opsonin 
proteins.   
 
From reports studying the amount of PEG2000 required, it is generally concluded that 
a minimum of 5 mol% is necessary to provide stealth properties to the nanoparticle 
[61-62].  Therefore, 5 mol% of MeO-PEG2000-DSPE was incorporated into the lipid 
formulation, in the attempt of formulating a high-PEG nanoparticle platform.  To 
accommodate higher percentages of PEG lipids within the formulation, the molar 
percentages of DOPC and cholesterol were reduced, whilst maintaining the molar % 
of the cationic lipid at 20%.  The physical and in vitro biological properties of the high 
PEG-nanoparticles were then examined to identify the suitability of the high-PEG 
nanoparticle platform for ligand incorporation.   
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Table 5-1: Lipid compositions and physical characteristics of high-PEG nanoparticle 
formulations optimised for in vivo applications.  In contrast to the low PEG, low charge 
nanoparticles prepared previously, the high PEG nanoparticles included 5 mol% of MeO-
PEG2000-DSPE to induce nanoparticle stability (DODAG, DOPC, cholesterol, MeO-PEG2000-DSPE 
at 20/57/18/5 molar ratio).  Nanoparticles were suspended in 4mM HEPES and encapsulated 
siRNA at the optimal charge ratio of 4.   
 
Lipid Molar % of total lipids 
DODAG 20 
DOPC 57 
Cholesterol 18 
MeO-PEG2000-DSPE 5 
Size (diameter) 81nm 
Zetapotential (mV) 0.3mV 
% siRNA encapsulation 90% 
 
 
Firstly, it was found that introduction of higher molar percentages of PEG lipids 
resulted in lower encapsulation efficiencies (Figure 5-7).  This is most likely due to 
the steric hindrance of the PEG chains, which affect the contact and the attraction 
between the siRNA and the nanoparticles.  Charge ratios of 2 were again a more 
undesirable choice of lipid:siRNA ratio as maximum encapsulation was around 50 
percent.  Higher charge ratios were able to encapsulate siRNA at higher efficiencies, 
close to that of nanoparticles of low PEG content.  However, these higher 
encapsulation efficiencies were only achieved if the siRNA-nanoparticle complexes 
are incubated at slightly elevated temperatures of 37oC for a short period of time.   
 
Chapter 5- siRNA systems 
140 
 
0
20
40
60
80
100
2 4 8 16
Nanoparticle charge ratio
5mins, RT
10mins, RT
30mins, 37C
%
 s
iR
N
A
 e
n
c
a
p
s
u
la
ti
o
n
 
 
Figure 5-7: Quantifying amount of siRNA encapsulated into high-PEG nanoparticles on 
varying the charge ratio.  Percentage encapsulation was measured using propidium iodide as 
a nucleic acid intercalator that fluoresces on interaction with free, unencapsulated siRNA.  
 
Other physical properties of nanoparticles also differed when higher percentages of 
PEG were introduced.  Firstly, compared to low-PEG nanoparticles, the diameters 
were measured to be much smaller (Figure 5-8).  This is likely due to the larger 
space required by the PEG clouds on the exterior of the nanoparticle, constraining 
the liposomal layer to form surfaces of higher curvature [177].  For the optimal charge 
ratio of 4, the zetapotential was much lower on the incorporation of higher 
percentages of PEG.  When 5 mol% of PEG is recruited, the measured zetapotential 
was measured to be near 0mV.  Again, the extra PEG chains act as sterical masks, 
inhibiting the exposure of the cationic charges to the external electrical field.   
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Figure 5-8: Diameters of High-PEG nanoparticles encapsulating siRNA at varying charge 
ratios.  Nanoparticle platform consists of the lipid formulation, DODAG, DOPC, cholesterol, 
MeO-PEG2000-DSPE at 20/57/18/5 molar ratio.  Nanoparticles suspended in HEPES 4mM.  
Sizes were measured by dynamic light scattering and presented as an average of n=3.   
 
High-PEG nanoparticles were also examined for their ability to avoid aggregation in 
buffers of high serum concentrations, a model that mimics the environment in blood 
circulation (Figure 5-9).  The effect of high concentrations of serum were investigated 
by monitoring the change in turbidity of solutions containing nanoparticles, which was 
quantified by measuring UV absorbance at λ=600nm.  High-PEG nanoparticles were 
measured to be around 80nm in diameter, therefore aggregation between the 
colloids would result in a decrease in transmission of light at λ=600nm due to the 
scattering of light by the colloids.  No change in absorbance at 600nm was observed, 
indicating the resistance to aggregation by the High-PEG nanoparticle.  The empty 
nanoparticles themselves appeared to aggregate over time, as concluded from the 
increase in turbidity at λ=600nm, suggesting that the encapsulation of nucleic acid, 
hence reduction in surface charge, is also advantageous for resisting aggregation.  
This highlights the importance of the extra PEG content, which provides the steric 
hindrance required to prevent inter-particle attraction.  The high PEG siRNA 
nanoparticles with charge ratio 4 again appeared to be the optimal formulation for in 
vivo purposes.   
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Figure 5-9:  Nanoparticle stability over time in 80% serum (20% PBS) at 37oC, as measured by 
change in absorbance in turbidity at UV λ=600nm, at concentrations of 10mg lipids/mL, a) 
and 1mg lipids/mL, b).   
 
The dispersity and the structural arrangement of such low-charge, high-PEG siRNA 
nanoparticles were examined by cryo-transmission electron microscopy (cryo-TEM).  
To compare the effect of PEG % in the formulation, nanoparticle platforms containing 
Chapter 5- siRNA systems 
143 
 
higher percentages of PEG, 7 mol% were also examined.  The use of higher PEG 
densities could be advantageous in terms of overcoming systemic barriers during in 
vivo delivery, although the inclusion of higher amounts of PEG lipids could lead to 
deformation of the nanoparticle structure.   
 
a) b)
100nm
 
 
Figure 5-10: Cryo-TEM micrographs of siRNA nanoparticles, prepared from the liposomal 
platform of DODAG, DOPC, cholesterol and MeO-PEG2000-DSPE, consisting of 5mol% or 7 
mol% of PEG2000-lipids.  a)  siRNA-nanoparticles (charge ratio 4) with 5 mol% MeO-PEG2000-
DSPE, b) siRNA-nanoparticles (charge ratio 4) with 7 mol% MeO-PEG2000DSPE.  Black arrows 
indicate spherical micelles and white arrows indicate disc-like micelles.  Bar= 100nm. 
 
After encapsulation of siRNA at charge ratio 4, cryo-TEM studies showed that both 
5mol% and 7 mol% PEG-nanoparticles formed apparently unilamellar structures 
around 100nm in diameter (Figure 5-10).  In both cases, observed were also smaller 
structures, around 10-20nm in diameter, structures which were more abundant in the 
nanoparticles of 7 mol% PEG.   Images of such nanoparticles with higher PEG 
content also indicated the presence of denser, disc-like structures, around 20nm in 
length and 5nm in width.  The formation of spherical or disc-like micellar entities is a 
result of the PEG-lipids de-anchoring from the liposomal surface to form new 
varieties of macrostructures.   The formation of such micellar structures is likely a 
result of the saturation of the nanoparticle surfaces with polymer clouds.  The Flory 
radius of PEG2000 clouds has been described to be around 5.6nm, where PEG 
densities above 5 mol% result in the overlapping of the PEG chains, leading to 
destabilisation into micellar structures (Figure 5-11).   In the sample of 5 mol% PEG, 
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around 20% of the particles observed are small enough to be considered PEG 
micelles.  The other 80% can be attributed to complete PEGylated nanoparticles.  On 
the introduction of 7 mol% PEG, 30% of the observed structures are spherical PEG 
micelles, plus another 30% which are the micellar discs.  These disc-like shapes are 
only observed in formulations with the 7 mol% PEG, and their presence is highly 
indicative of the detrimental effects of high PEG concentrations.  The data suggests 
that the formation of the disc micelles utilises the extra PEG-lipids that were not 
recruited for spherical micelle construction. The disc micelles are likely to contain 
non-PEGylated lipids from the liposomal formulation, which would be required to form 
the varied curvature [66, 178].  The recruitment of PEG- and non-PEG lipids to form 
micellar structures means that the remaining siRNA-liposomes cannot be fully 
protected by the PEG chains.  Exposed liposomal surfaces are easily recognised by 
the RES which ultimately results in their removal from circulation.  The cryo-TEM 
data is essentially highlighting the importance in optimising the amount of PEG lipids, 
as in this case, less can be more.   Other studies utilising high densities of PEG2000 in 
liposomal formulation also report the ‘stripping’ of lipids from the lipid bilayer to form 
mixed micelles with the PEGylated lipids [179]. 
 
Many groups have anticipated the use of higher mol percentages of PEG chains 
within formulations to prevent nanoparticle aggregation, and more importantly to 
diminish adsorption of opsonin proteins on the nanoparticle surfaces.  It is commonly 
accepted that the introduction of PEG2000 at a mol ratio of 5 % within a nanoparticle 
system forces a brush-like conformation on the polymer chains [12].  At this molar 
ratio, all the PEG chains remain within the bulk of the nanoparticle liposomes, 
covering their surfaces by as much as possible.  However on over-loading of the 
PEG component, at mol ratios above 5 mol%, the PEG-lipids start to dissociate from 
the bulk liposomes.  In this scenario, the mol % of remaining PEG-lipids within each 
nanoparticle is unknown, although it can be concluded that there are larger areas of 
nanoparticle surfaces left unprotected.   
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3/5a 
 
Figure 5-11: Representation of interactions between two PEG polymer clouds on the surface 
of a liposomal nanoparticle.  Rf denotes the Flory diameter, which describes the area 
occupied by a polymer chain. For PEG2000, the Rf has been calculated to be around 3.5nm, 
where N= number of monomer units (45 for PEG2000) and a= length of one monomer (3.5Å 
for one unit of ethylene glycol) [180] .  
 
The amount of PEG was kept at 5 mol% and their abilities to induce gene silencing 
were examined.  These nanoparticles with 5 mol% of PEG were able to functionally 
deliver siRNA, although at lower efficiencies than that with lower PEG percentage.  
Carrying siRNA against the GAPDH protein, nanoparticles were able to inhibit protein 
expression in a dose dependent manner in DU145 cells (Figure 5-12).  The GAPDH 
protein, Glyceraldehyde 3-phosphate dehydrogenase, is an enzyme involved in the 
glycolysis process, and is considered a ‘house-keeping’ protein, as it is essential for 
cell survival and expressed uniformly in all cells.  This anti-GAPDH siRNA was 
encapsulated into high-PEG nanoparticles at the charge ratio of 4, and transfected 
with DU145 cells for 4 hours.  The protein knockdown efficiencies were compared 
with that by low-PEG nanoparticles, previously optimised to consist of a low mol %, 1 
mol% of MeO-PEG2000-DSPE.  After a further incubation time of 48 hours, the cells 
were analysed for GAPDH content by the Ambion KD Alert® fluorescence-based 
assay.   Observed were the overall lower protein knockdown abilities by high-PEG 
nanoparticle-encapsulated siRNA, compared to that encapsulated by low-PEG 
nanoparticles.  This is demonstrating the obvious limitations for in vitro biological 
activity on the inclusion of higher molar percentages of PEG lipids.  Higher surface-
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densities of PEG chains reduce the affinity of the nanoparticles for cell membranes, 
due to steric masking of the cationic nature of the nanoparticle surfaces. 
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Figure 5-12: siRNA knockdown of GAPDH protein in DU145 cells, delivered by nanoparticles 
of low and high PEG, carrying anti-GAPDH siRNA.  Nanoparticle platforms consisted of 20% 
DODAG and either 1 or 5 mol% of MeO-PEG2000-DSPE.  siRNA (siCon or siGAPDH) was 
encapsulated at the optimal charge ratio of 4 and incubated with DU145 cells for 48 hours.  
*% GAPDH content was calculated according to manufacturer’s recommendations (see 
material and methods), using non-treated cells as a negative control (100% GAPDH 
expression).  
 
The implications of higher PEG densities are not limited to reduced association of 
nanoparticles to cell membranes.  It has been reported that once endocytosis does 
occur, the high-PEG nanoparticles are challenged in their ability to overcome the 
next obstacle, which is that of endosomal release [113, 242-243].  Attempts at 
overcoming this hurdle have included the engineering of PEG-triggerable 
nanoparticles, where detachment of PEG chains from nanoparticle surfaces is 
triggered by a change in pH [181-183].  Although the highly PEGylated nanoparticles 
are shown to promote siRNA-knockdown at limited efficiencies, it is encouraging to 
observe that this nanoparticle platform remains functional.  It is hypothesised that an 
introduction of receptor-specific ligands are able to re-establish the functional binding 
and delivery abilities of highly PEGylated nanoparticle templates.  
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5.4.  In vivo activity of high-PEG nanoparticles 
 
Preliminary in vivo experiments were conducted to gain insight into the delivery 
abilities of the high-PEG nanoparticles to tumour sites.  siRNA-nanoparticles were 
fluorescently labelled at two sites, FAM-labelling on the siRNA and rhodamine-
labelling on the nanoparticle.  On encapsulation at charge ratios of 4, the complexes 
were administered iv into mice bearing subcutaneous IGROV ovarian cancer 
tumours (Figure 5-13).  24 hours after administration, organs were removed, 
sectioned and examined for fluorescence.  The first observation is the evident 
localisation of the nanoparticles into tumour sites.  Both FAM and rhodamine 
fluorescence are observed in the IGROV tumour 24 hours after injection, indicating 
that the siRNA-nanoparticle complex is still intact.  Although it is clear that tumour 
accumulation is successful, the fluorescence images are not validation of 
internalisation of the nanoparticles into the cancer cells.  It is highly possible that  the 
nanoparticles’ retention is only within the tumour stroma, the extracellular space 
surrounding the tumour.  This phenomenon has been reported for liposomal delivery 
systems, a result of the reduced affinity and internalisation abilities of the highly-
PEGylated surfaces [56, 159].  If this is the case, then the recruitment of surface 
ligands could help overcome this problem.  On the consideration of nanoparticle 
integrity, it is encouraging to find that the siRNA remains encapsulated on arrival at 
the tumour stroma at least.  This means that nucleic acids can be delivered and 
functionality of therapeutic siRNA could be maintained until arrival in the cancer cells.   
 
However, the accumulation into tumours is limited by the uptake of nanoparticles into 
the liver and spleen, likely due to recognition by the organ-resident macrophages.  
Commonly reported is the accumulation of nano-sized colloids into the liver, a fate 
that is a result of macrophage-related clearance from the blood circulation and that of 
the leaky character of the vasculature [184].  Mentioned earlier is the effect of 
nanoparticle opsonisation in circulation, an immune response technique that 
identifies cationically charged foreign objects within the body [185].   Liver-associated 
macrophages, the Kupffer cells, can then recognise nanoparticles by the presence of 
opsonin proteins on their surfaces [61, 67, 186], and proceed by inhibiting their re-
entry into circulation.  Due to the large fenestration of the hepatic blood vessels, 
hardly is a reported case where systemic administration of nanoparticles avoided 
liver localisation [184].  It is probable that the collection of nanoparticles into the liver 
is only prevented if the organ is chemically pre-saturated before administration of 
therapy [248].  To confirm the residency of the nanoparticles within the Kupffer 
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comparments of the liver, tumour histological samples would need to be stained with 
antibodies against the F4/80 glycoprotein, a marker for macrophages.  Contrasting to 
liver-association, almost zero amount of fluorescence was observed in the kidneys.  
Avoidance of the nanoparticle accumulation into kidney cells is encouraging, as it 
indicates the avoidance of clearance from circulation through glomelular filtration.  
This is further suggesting the integrity of the siRNA-nanoparticles in circulation, as 
glomerular filtration only removes species under the size of 5nm for excretion [187-
190].   
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Figure 5-13: H & E-stained and fluorescence microscopy images of sectioned organs (kidney 
top, liver middle, tumour bottom), 24 hours after systemic administration of siRNA-
nanoparticles.  FAM-labelled siRNA was encapsulated into rhodamine-labelled high-PEG 
nanoparticles at a charge ratio of 4.  Minimal fluorescence was observed in kidney cells, as 
the intact nanoparticles were too large to be filtered through the glomelular (top left).  High 
concentrations of rhodamine fluorescence were found in the liver cells (middle right).  
Accumulation of nanoparticles was apparent in tumour sections, shown by the presence of 
FAM-fluorescence (bottom middle) and rhodamine-fluorescence (bottom right).  The 
superimposition of the areas of FAM and rho fluorescence in the tumour sections indicates 
the integrity of the nanoparticles. 
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5.5.  Summary of Chapter 5 
 
Introduced in this chapter is the use of siRNA, plus the development of siRNA-
nanoparticles suitable for in vivo delivery.  The optimal charge ratio for siRNA 
encapsulation was concluded to be at 4, a ratio where the nanoparticle diameter and 
zetapotential were at magnitudes suitable towards in vivo delivery.  On consideration 
of nanoparticle stability in biological fluids, higher molar percentages, specifically 5 
mol%, of MeO-PEG2000-DSPE was included into the liposomal formulation.  High 
PEG nanoparticles encapsulating siRNA at the optimal charge ratio of 4 were found 
to have features advantageous for in vivo applications.  The siRNA-nanoparticles 
were small in diameter, with zetapotentials near 0mV, and were found to be resistant 
to aggregation in high-serum buffers.  In vitro transfection studies demonstrated the 
reduction in cell-association of nanoparticles with higher mol percentages of surface 
PEG.  However, the surface functionalisation with higher densities of PEG chains 
allowed the successful delivery of the siRNA-nanoparticles to tumour sites.  The 
siRNA-nanoparticles were found to be intact on their arrival at the tumours, inferring 
their usability for therapeutic delivery.  The optimised high-PEG nanoparticle 
formulation optimised therefore is suitable as a platform onto which U11 ligands can 
be incorporated for enhancing their in vivo activities.   
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6.  Preparing targeted nanoparticles for in vivo 
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On establishment of a high-PEG nanoparticle suitable for in vivo application, the 
conjugation of U11 peptides on their surfaces was then attempted to render cell-
specificity to the delivery vehicle.   
 
6.1.  Conjugation of U11 peptides onto the surface of High-PEG 
nanoparticles 
 
Highly PEGylated nanoparticles are impaired in their ability to be endocytosed into 
cancer cells, due to the masking of the nanoparticle surface by the PEG polymers.   
Again, it was envisioned that the introduction of receptor-specific ligands could aid 
nanoparticle binding and entry into the cancer cells.  The decoration of such 
nanoparticles with U11 ligands were carried out using the previously described 
method of post-conjugation.  In progression to the low PEG-nanoparticle platform, 1 
mol % of mal-PEG2000-DSPE was included along with 4 mol% of MeO-PEG2000-DSPE 
to make up a total of 5 mol% of PEG2000 content in the liposomal formulation (Table 
6-1).   
 
Table 6-1: Lipid compositions of High-PEG nanoparticle formulations optimised for U11-
functionalisation.  1 mol% of mal-PEG2000-DSPE was included into the formulation to induce 
maleimide functional groups, and 4 mol% of MeO-PEG2000-DSPE was added to make up a 
total of 5 mol% PEG2000.     
 
Lipid Molar % of total lipids 
DODAG 20 
DOPC 57 
Cholesterol 18 
MeO-PEG2000-DSPE 4 
Mal-PEG2000-DSPE 1 
 
 
After the formulation of high PEG, maleimide-functionalised liposomal platforms, Cys-
modified U11 peptides were again added to the liposomal dispersion at a 1:1 mol/mol 
ratio.  The amount of peptide coupling to the nanoparticle surfaces was then 
examined by HPLC and Ellman’s reagent at various time points (Figure 6-1).  Both 
assays showed that maximum coupling of peptides to nanoparticle surfaces to be up 
to 80%, a value twice as high as that of coupling efficiencies onto low-PEG 
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nanoparticles (see Chapter 4, Figure 4-5).  The rate of coupling was also faster, 
where the maximum coupling of 80% was achieved at 15 hours, compared to the 
maximum coupling time of 21 hours, onto to low-PEG nanoparticles.  These results 
give an indication of the difference in organisation of the surface PEG chains in low 
and high PEG nanoparticles.  When PEG2000-lipids were included at low molar 
percentages, the organisations of the surface PEG chains were found to be in 
mushroom-like conformations.  The higher coupling efficiency and faster coupling 
rate onto high PEG nanoparticle surfaces suggests that the surface maleimide-
groups are more exposed, and readily available for reaction with Cys-U11 peptides.  
Here, the increased exposure of the surface-maleimide groups suggests that the 
PEG chains are re-organising into brush-like conformations, when it is recruited in 
higher concentrations (see Chapter 4, Figure 4-6) [191]. 
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Figure 6-1: Maximum coupling of Cys-modified U11 peptides to low and high-PEG 
nanoparticles.  Cys-modified U11 peptides added to nanoparticles at 1:1 mole ratio with 
mal-PEG200-DSPE and incubated for 24 hours at room temperature. a) Monitoring the 
coupling reaction of C-U11 peptides to nanoparticles over time by HPLC. b) Coupling of C-
U11 and U11-C peptides to nanoparticles analysed by Ellman’s reagent after 24 hours 
incubation (averaged as n=2). 
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6.2.  Organisation of peptides on nanoparticle surfaces- Fluorescence 
spectroscopy 
 
To investigate the PEG conformation on the increase of MeO-PEG2000-DSPE lipids 
within a nanoparticle, the change in fluorescent emission properties of the U11-Trp 
residues were probed after surface-conjugation (Figure 6-2).  The emission pattern is 
similar to that observed previously when U11 peptides were conjugated onto low-
PEG nanoparticles.  Both C-U11 and U11-C peptides exhibited a blue shift in Emmax 
on nanoparticle conjugation, indicating movement of the peptides into the PEG 
clouds, which is a more apolar environment.  However, peptide-conjugation onto 
high-PEG nanoparticles differs from that on low-PEG nanoparticles in the emission 
pattern on acrylamide quenching.  Previously, acrylamide quenching revealed the 
microenvironments of conjugated peptides to be less polar than H2O, as observed by 
the lower Emmax= of λ=328nm.  Here, the Emmax of both conjugated peptides, were at 
the same wavelength, before and after acrylamide quenching, eliminating the notion 
that the peptides are arranged in more than one microenvironment of different 
polarity (Figure 6-4).  This indicates that the peptides are homogenously organised, 
exposed from the nanoparticle exterior, through extension via the PEG chains.  This 
organisation is therefore reminiscent of the brush-like conformation, a type of PEG 
configuration that allows full exposure of the peptides into the outer aqueous phase.      
 
 
 
 
Chapter 6- Preparing targeted nanoparticles for in vivo 
156 
 
338
335
0
20
40
60
80
100
300 320 340 360 380 400
nm
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
 e
m
is
s
io
n C-U11 conjugated
U11-C conjugated
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
 e
m
is
s
io
n
a)
 
335
334
0
5
10
15
20
300 320 340 360 380 400
nm
C-U11 conjugated quenched
U11-C conjugated quenched
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
 e
m
is
s
io
n
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
 e
m
is
s
io
n
b)
 
Figure 6-2: Comparing fluorescence emission spectra of acrylamide-quenched Cys-modified 
U11 peptides, C-U11 and U11-C, before conjugation, a), and after conjugation, b), onto 
nanoparticle surfaces containing 1 mol% mal-PEG2000-DSPE and 4 mol% MeO-PEG2000DSPE.  
Peptides were quenched in 600mM acrylamide and excited at λ=279nm.  Emission 
intensities were collected between λ=300nm-400nm.  Values within the spectra depict the 
Emmax of each peptide, and highlight the lower Emmax of the conjugated U11-C peptide, after 
quenching of exposed Trp residues by aqueous-soluble acrylamide.   
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Further evidence pointing towards the brush-like conformation of the PEG was found 
in the sequential quenching of conjugated peptides (Figure 6-3).  The Stern-Volmer 
plots of peptides conjugated to high-PEG nanoparticles gave quenching constants 
much higher than that of peptides conjugated onto low-PEG nanoparticles.   Higher 
quenching constants indicate that the conjugated peptides are more accessible to the 
aqueous exterior; hence their fluorescence is more easily quenched by the 
acrylamide. 
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Figure 6-3: Comparing Stern-Volmer plots of acrylamide-quenched Cys-modified U11 
peptides, C-U11and U11-C, before and after conjugation onto nanoparticle surfaces 
containing 1 mol% mal-PEG2000-mal and 4 mol% MeO-PEG2000.  Peptides were quenched in 
increasing concentrations of acrylamide and excited at λ=279nm.   
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Table 6-2: Quenching constants, KQ of U11 peptides, C-U11 and U11-C before and after 
conjugation onto nanoparticles of high or low % PEG. 
 
 
KQ x100 
C-U11 U11-C 
Free peptide 1.12 0.86 
Conjugated to low-PEG nanoparticle 0.66 0.46 
Conjugated to high-PEG nanoparticle 0.73 0.62 
 
The fluorescence data overall advocate the change in mushroom to brush-like 
conformations of the PEG chains, when the PEG2000 is introduced at higher molar 
percentages of 5 mol% (Table 6-2).  The organisation into a brush state allows the 
distal tips of the PEG chains to be exposed to the aqueous exterior, hence improving 
the rate of peptide-conjugation, and improving the presentation of the conjugated 
peptides.  Although the introduction of higher percentages of PEG generally has a 
negative effect on cell internalisation, it can enhance the exposure of the surface 
ligands, and potentially improve the functional delivery properties of the nanoparticle. 
 
U11-C conjugated peptide C-U11 conjugated peptide
Trp residue
High PEG-nanoparticle platform 
U11 peptide
 
 
Figure 6-4: Representation of C-U11 and U11-C peptides conjugated onto high-PEG 
nanoparticles (1 mol% mal-PEG2000-DSPE plus 4 mol% MeO-PEG2000-DSPE) surfaces.  The 
conjugated U11 peptides were highly exposed to the external aqueous environment, due to 
the brush-like conformation adopted by the PEG chains.   
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6.3.  In Vitro activity of targeted high-PEG nanoparticles 
 
As the post-conjugation of Cys-modified peptides onto high-PEG nanoparticles was 
successful, their ability to transfect siRNA into cancer cells was further examined.  
Firstly the ability of targeted high-PEG nanoparticles to resist aggregation in high 
serum conditions was examined by turbidity experiments. The high-serum 
environment is to model the conditions in circulation, where high concentrations of 
serum proteins are likely to adsorb onto nanoparticle surfaces and cause aggregation. 
After prolonged incubation of nanoparticles, an increase in turbidity was not observed, 
demonstrating the maintenance of colloidal stability (Figure 6-5).  Resistance for 
aggregation is an advantageous characteristic which would encourage the diffusion 
of nanoparticles into tumour sites by the EPR effect. 
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Figure 6-5: Stability of high-PEG, targeted and non-targeted nanoparticles over time in 80% 
serum (20% PBS) at 37oC, as measured by change in absorbance in turbidity at UV λ=600nm, 
at concentrations of 1mg lipids/mL. 
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Cancer cell lines stably-expressing luciferase were then characterised for their level 
of expression of the uPAR receptor.  DU145-luc and MDA-MB-231-luc, a breast 
cancer cell line, were shown by RT-PCR to express high levels of mRNA for uPAR, 
therefore suggesting them to express high levels of surface uPAR receptors (Figure 
6-6).  Protein characterisation techniques such as Western Blotting or 
immunohistochemisty would be required to confirm the content of uPAR protein in 
the cancer cells.  In vitro experiments using anti-luciferase siRNA served as a proof-
of-concept to pre-assess the nanoparticle’s viability for functional delivery in vivo. 
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Figure 6-6: Expression of uPAR mRNA in various cancer cell lines, as quantified by RT-PCR.  
Expression of uPAR mRNA presented as that relative to uPAR mRNA levels in HEK293 cells, a 
human embryonic kidney cell line know to have minimal expression of the receptor.  DU145-
luc and MDA-MB-231-luc were shown to have higher levels uPAR expressions.  uPAR mRNA 
expression in cell lysates were normalised with GAPDH mRNA levels.   
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Table 6-3: Nanoparticles used in in vitro and in vivo luciferase-silencing experiments.  Non-
targeted nanoparticles consisted of 5 mol% of PEG2000 and encapsulated siRNA at charge 
ratios of 4.  Targeted nanoparticles were composed of the same liposomal platform as that 
of the non-targeted nanoparticles, and were decorated with 1 mol% of U11 on the 
nanoparticle surfaces.   
 
 U11-targeted Nanoparticles Non-targeted Nanoparticles 
 
 
Surface  0.8mol% U11 - 
Diameter  100nm 94nm 
Zetapotential  7.0mV 0.3Mv 
 
 
U11-targeted high-PEG nanoparticles encapsulating anti-luciferase or control siRNA 
at a charge ratio of 4 were administered to uPAR overexpressing cells (Table 6-3).  
After transfection, cell lysates were analysed for luciferase expression.  In both 
DU145-luc and MDA-MB-231-luc cell lines, it was observed that the non-targeted 
high-PEG nanoparticles had very low efficiencies in inducing luciferase knockdown 
(Figure 6-7).   These highly PEGylated nanoparticles promoted siRNA knockdown at 
very minimal levels, by only 5%.  Again, this is highlighting the sacrifice of cell 
internalisation for colloidal stability on introduction of high percentages of PEG lipids.  
However, upon decoration with surface ligands, U11-targeted nanoparticles were 
able to knockdown luciferase protein at higher levels, by around 20% in both cell 
lines.  This transfection data emphasises the importance of using surface-associated 
targeting ligands, to recover the loss of function in nanoparticles decorated with 
higher percentages of PEG chains.    
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Figure 6-7: siRNA transfection in luciferase-expressing cell lines, DU145-luc, a) and MDA-MB-
231-luc, b).  Highly PEGylated nanoparticles, U11-targeted (C-U11) or non-targeted, 
encapsulated anti-luciferase and negative siRNA at charge ratio 4 and were administered to 
cells for 4 hours followed by further incubation for 48hours before analysis.  Degrees of 
luciferase knockdown were also compared to that of non-encapsulated naked siRNA, and 
that of the commercial in vitro transfection reagent, Dharmafect.   
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siRNA transfection experiments were also performed in PC3-luc cells, a prostate 
cancer cell line shown to express low levels of uPAR mRNA.  Similar to previous 
transfections on uPAR-overexpressing cell lines, the level of luciferase silencing 
induced by U11-targeted nanoparticles were measured to be around 20%.  However, 
contrasting with previous transfections, the non-targeted nanoparticles were also 
able to induce gene silencing by 20%.  The suspectabilities of lipid-based 
transfections vary across cell lines, as judged by the differing effeciencies of standard 
transfection agents (Dharmafect) to induce luciferase silencing.  PC3-luc cells are 
generally more susceptible to transfection, as highlighted by the almost complete 
depletion of luciferase expression in Dharmafect-delivered transfections.  This could 
explain the reason why the PC3-luc cell lines were able to internalise non-targeted 
nanoparticles at higher levels, compared to the MDA-MB-231-luc and DU145-luc 
cells.  The important realisation here is the comparable protein knockdown 
efficiencies between the targeted and the non-targeted nanoparticles.  In the case of 
PC3-luc cells, the presence of the U11 ligand clearly did not have an advantageous 
effect on functional delivery, as the cells themselves do not overexpress the ligand 
for which the U11 peptide is specific.  However, the use of the U11 ligand also did 
not hinder transfection efficiencies, indicating that the presence of a non-functional 
ligand is not detrimental to the delivery effect of high-PEG nanoparticles. 
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Figure 6-8: siRNA transfection in the luciferase-expressing cell line, PC3-luc, a prostate 
cancer cell line that does not overexpress the uPAR receptor.   Highly PEGylated 
nanoparticles, U11-targeted (C-U11) or non-targeted, encapsulated anti-luciferase and 
control siRNA at charge ratio 4 and were administered to cells for 4 hours followed by 
further incubation for 48hours before analysis.  Knockdown levels were also compared to 
that of non-encapsulated naked siRNA, plus that by the commercial in vitro transfection 
reagent, Dharmafect.   
 
6.4.  In vivo activity of U11-targeted nanoparticles- in uPAR over-expressing 
tumour models 
 
Following the in vitro luciferase-silencing experiments in DU145-luc, MDA-MB-231-
luc and PC3-luc cell lines, in vivo gene silencing studies were carried out in tumour 
xenograft models. DU145-luc and MDA-MB-231-luc cells were implanted 
subcutaneously in nude BALB/C mice and grown for 7 days before treatment.  
Nanoparticles, U11-targeted or non-targeted were prepared to encapsulate anti-
luciferase siRNA or negative siRNA and administered intravenously through the tail 
vein at a dose of 2.5mg/kg (Table 6-3).  A second dose was injected at 48 hours after 
the first dose, and the changes in tumour-associated bioluminescence were 
monitored by the Xenogen IVIS imaging system.   These xenograft experiments were 
performed as preliminary studies, and the data are presented here to give an 
indication of the in vivo activity of the U11-nanoparticles. 
Chapter 6- Preparing targeted nanoparticles for in vivo 
165 
 
In the breast cancer MDA-MB-231-luc model, tumours treated with U11-
nanoparticles encapsulating anti-luciferase siRNA were shown to reduce luciferase 
activity to over 65% (relative to day 0, Figure 6-9).  Compared to the activity of the 
U11-targeted nanoparticles, treating tumours with non-targeted nanoparticles did not 
result in overall luciferase knockdown.  The accumulation of the nanoparticles should 
not be dependent on the presence of a ligand, as predicted by the EPR effect [192].  
Therefore, the higher protein knockdown efficiencies induced by the U11-
nanoparticles are most likely due to the enhanced binding and cell uptake by the 
cancer cells.   Although the non-targeted nanoparticles were not able to dimish 
luciferase expression overall (i.e. relative to luciferase expression on day 0), a 
relative reduction in tumour-associated bioluminescence was observed after the 2nd 
dose of administration.  If this is a true indication of gene suppresion, it is likely that 
for the clear effect of protein silencing, tumours require the accumulation of higher 
concentrations of non-targeted nanoparticles.  Other important observations from this 
experiment is that demonstrated by the effect of control nanoparticles carrying 
negative siRNA.  The non-targeted-neg siRNA nanoparticles were unable to induce 
reduction in luciferase expression, an effect that is prolonged until day 3 (24 hours 
after 2nd injection), after which the tumour-associated bioluminescence appears to 
reduce.  Many other studies have also described the off-target effect of control 
nanoparticles, and have attributed this observation to the induction of an interferon 
(IFN) response by liposomal siRNA systems [193-196].  Ma et al have shown the 
enhanced activation of the IFN response-related STAT1 proteins in the lung and the 
spleen, which are organs that are subjected to maximum nanoparticle-uptake [193].  
In vitro studies by Kariko et al also suggest that the induction of IFN response is due 
to recognition by the Toll-like receptors, receptors generally associated with RNA-
related anti-viral mechanisms [196].  Sensitisation of mice in IFN response with such 
liposomal delivery systems can ultimately affect the growth of tumour xenografts.  
Necrosis within the low-oxygen areas of the xenograft tumours can also lead to 
spontaneous reduction of luciferase expression due to tumour cell death.  On the 
other hand, U11-targeted-neg siRNA nanoparticles did not produce similar luciferase-
expression patterns as that of non-targeted-neg nanoparticles.  What is observed is 
in fact a steady, and a much slower rate of expression increase.  This is suggesting 
that the presence of the U11 peptide as part of the nanoparticle system can affect 
tumour growth.  The uPAR-uPA interaction is a process highly involved in tumour 
progression, and it is possible that the U11 peptides are competitively binding with 
uPA to the uPAR receptors [133, 197].  Considering that the U11 peptide is derived 
from the binding region of uPA, inhibition of uPAR-recognition by uPA can therefore 
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decrease the rate of tumour growth.  Incubation of competitively uPAR-binding 
peptides to cancer cells has shown reduction in tumour intravasation, a result which 
could explain our slower tumour growth rates [198-199].  Naked siRNA was not 
considered as a control as its systemic administration has been consistently reported 
to result in excretion through the kidney and bladder, due to glomelular filtration [200].   
 
If the observed reductions in bioluminescence are a real suggestion of gene silencing, 
the time points at which they are apparent prove interesting.  With both U11- and 
non-targeted nanoparticles, tumours continued to increase in luciferase expression 
24 hours after the first injection (Figure 6-9, top).  It is only after 48 hours that 
reduction in bioluminescence becomes apparent in tumours treated with U11-
targeted nanoparticles.  Many studies on tumour-associated luciferase also observe 
first signs of luciferase silencing 48 hours after the first administration of siRNA-
nanoparticles [263-264].  It is likely that this time-period is a sum of the kinetics 
involved in tumour accumulation, cell-internalisation, and of the RNAi pathway.  From 
the previous chapter, the in vitro data demonstrates that the silencing effect can be 
promoted and maintained 48 hours after transfection, suggesting that the arrival of 
nanoparticles at the tumour site is achieved before that time point.  The presence of 
nanoparticles is very likely to be persisting in the tumour cells 48 hours post- 
administration, as luciferase expression is further lowered after a 2nd dose of siRNA-
nanoparticles.  Although again, the effect of the 2nd dose of nanoparticles is not 
apparent until 48 hours after administration.   
 
It should be emphasised that the delivery of luciferase siRNA is not a model for 
therapeutic cancer treatment, as the silencing of luciferase does not inhibit the 
growth of the cancer.  In a therapeutic situation, where the siRNA delivered is 
specific for oncogenic mRNAs, the successful delivery would result in the reduction in 
tumour size, or the decrease in tumour growth.   
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Figure 6-9: Change in tumour-associated bioluminescence in MDA-MB-231-luc tumour 
xenograft model on treatment with siRNA-nanoparticles.  Formulations of non-targeted and 
U11-targeted nanoparticles encapsulating anti-luciferase siRNA or control (negative) siRNA 
were administered to tumour-bearing mice by iv injection at a dose of 2.5mg/kg.  
Nanoparticles were injected on day 0 and on day 2.  Tumour-associated bioluminescence 
(flux, photons/sec) was examined on ip injection of luciferin.  Red arrows indicate 
administration of nanoparticles.  Number of tumours per group were n=2. 
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Preliminary xenograft experiments were also conducted with the DU145-luc cells, a 
cell line that also over-expresses uPAR mRNA, although to a lesser extent than that 
by MDA-MB-231-luc.  Like the previous study, the number of tumours used within the 
experiment was low, hence variation/change within the tumour-associated luciferase 
should be interepreted with caution.  Here, 3 out of 4 mice treated with targeted-luc 
nanoparticles were able to reduce tumour-associated bioluminescence to levels 
lower than that of day 0.  On the first administration of targeted nanoparticles, the 
rate of luciferase increase is much slower compared to tumours treated with non-
targeted-luc nanoparticles.  The same observation was demonstrated in the MDA-
MB-231 model, where the effect was attributed to both the enhanced uptake of 
nanoparticles, plus the competitive binding of U11 peptides with uPA.  The effect of 
luciferase reduction is not observed until after 48 hours, and the pattern of yoyo-type 
luciferase expression is repeated after the 2nd injection dose.  In relation to the 
targeted nanoparticles, the non-targeted nanoparticles were again, unable to reduce 
luciferase expression to levels lower than at day 0. However, a modest effect was 
observed 48 hours after both the 1st and the 2nd injection, a silencing pattern that 
mimics what is previously observed by targeted nanoparticles.  It is likely that these 
tumour xenografts were higher in vascularisation than the MDA-MB-231 model 
(although lower in uPAR-expression), which allowed enhanced accumulation of non-
targeted nanoparticles into the tumour site.  However, to understand the associated 
angiogenesis patterns, tumours would have had to been collected, sectioned and 
stained with anti-CD31 antibodies for immunohistochemical analysis.  Although an 
indication of luciferase silencing is apparent by treatment with both targeted and non-
targeted nanoparticles, these experiments are still in preliminary stages.  Larger 
numbers of animals and tumours, plus appropriate negative controls would be 
required to demonstrate significant statistical differences between the treatments. 
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Figure 6-10: Change in tumour-associated bioluminescence in DU145-luc tumour xenograft 
model, after treatment with siRNA-nanoparticles  Formulations of non-targeted and U11-
targeted nanoparticles encapsulating anti-luciferase siRNA were administered to tumour-
bearing mice by iv injection at a dose of 2.5mg/kg.  Nanoparticles were injected on day 0 and 
on day 2.  Luciferase activity within the xenograft tumours was examined after ip injection of 
luciferin. Red arrows indicate administration of nanoparticles.  Number of tumours, n=4 per 
group. 
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Figure 6-11:  In vitro uptake of fluorescently-labelled high PEG, low-charged nanoparticles (1 
mol% of NBD-PC) in DU145-luc cells, as determined by flow cytometry.  After administration 
of nanoparticles to DU145 cells, cell-associated fluorescence was examined at t=20mins, 
40mins, 60mins and 80mins.  Binding of nanoparticles to cells was not apparent until 40mins 
after incubation, as indicated by the red arrow in the top row.  It is only after 60mins that 
differentiation in cell-associated fluorescence is apparent between cells treated with 
targeted and non-targeted nanoparticles, as indicated by the red arrow in the bottom row. 
 
The MDA-MB-231 and DU145 cells both over-express the uPAR receptor, and when 
prepared as xenografts, both models showed similar luciferase expression, after 
treatment with siRNA-nanoparticles.  Using the DU145-luc cell lines, the in vitro 
luciferase silencing was found to be apparent at 24 hours, with further persistence up 
to 72 hours after administration.  This is to suggest that the cellular silencing of the 
luciferase protein can occur from as early as 24 hours, although the effect can only 
be observed if a sufficient concentration of siRNA is internalised into the cells.  In a 
tumour model, it is likely that the presence of surface ligands aids the internalisation 
of nanoparticles into the cells, hence creating more room within the extracellular 
space in the tumour stroma for the entry of further nanoparticles.  Davis et al have 
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demonstrated that the tumour environment acts like a ‘sink’ into which nanoparticles 
accumulate [201].  The sink-effect is primarily a result of nanoparticle diffusion via the 
EPR effect, although sequential and hence enhanced accumulation of nanoparticles 
only occurs when the sink is ‘de-clogged’ through transport of the nanoparticles into 
the intracellular space.  The accumulation of nanoparticles therefore also depends on 
their rate of internalisation into tumour cells. In vitro binding and internalisation of 
nanoparticles has been reported to be of a first order kinetic reaction, where the rate 
is dependent on the surface characterisations of the nanoparticles [83].  Using 
DU145-luc cells, our studies have demonstrated that high PEG and low-charged 
nanoparticle platforms, whether ligand targeted or not, are not internalised until 40 
mins after administration to cells (Figure 6-11). It is after 60 mins that there is a 
difference in internalisation between targeted and non-targeted nanoparticles.  
Furthermore, in vitro studies have shown that the effect of luciferase is also 
concentration dependent.  Lower concentrations of Dharmafect-siRNA complexes 
resulted in lower knockdown of luciferase expression, an observation that could also 
be extrapolated to in vivo situations.  Although it is likely that the receptor-specific 
ligands increase the internalisation of nanoparticles, it is also important to remember 
that targeting ligands can also function as an aid to endosomal escape [136].  The 
presence of targeting molecules could possibly be aiding the function of 
nanoparticles by acidifying endosomal compartments, hence enhancing release of 
siRNA into the cytosol for gene silencing.  Regardless of their mechanism for 
improving delivery, it is apparent that the use of targeting ligands is crucial for 
treating smaller tumours with lower densities of vasculature.  In this type of tumour 
anatomy, the concentration of tumour-accumulated nanoparticles can be low, due to 
the limitations in the route of transport.  However, the use of ligands can compensate 
for this disadvantage through aiding cellular internalisation and intracellular release of 
siRNA-nanoparticles.   
 
6.5.  In vivo activity of U11-targeted nanoparticles- in uPAR low-expressing 
PC3M-luc bone metastatic tumour models 
 
In contrast to the previous two cancer models, the PC3-luc in vivo model differed in 
three major ways.  Firstly, the PC3-luc cell line, another prostate cancer cell line, was 
characterized by RT-PCR to be low in uPAR mRNA expression (Figure 6-6).  
Secondly, the implantation of the PC3M-luc cells was into the tibia of the mice, to 
mimic the common metastatic progression to bone cancer from prostate cancer.  The 
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final main difference was the tumour size of the implanted PC3M-luc tumours, which 
were much larger and speculated to be higher in vascularisation than the previous 
models.  As before, to confirm this assumption, immunohistochemitry studies using 
angiogenesis markers such as anti-CD31 antibodies on tumour sections would be 
required.  With the higher densities of blood vessels, it is most likely that higher 
concentrations of accumulated nanoparticles can diffuse into the tumour sites.    
 
As the PC3-luc tumours do not over-express the uPAR receptor, the decoration of 
nanoparticle surfaces with U11 peptides should not be advantageous to functional 
delivery.  Like before, the number of animals used in this study was limited, hence 
the large variation in luciferase expression rendered it difficult to for data 
interpretation.   However, the patterns of change in biolouminescence were similar in 
the majority of tumours treated with the same treatment, on which the approximate 
explanations presented here are based.  After treatment with nanoparticles, targeted 
or non-trageted, luciferase expressions within the tumours were observed to change 
in a similar manner (Figure 6-12).  Same as the previous models, maximum 
reduction in tumour-associated luciferase expression was observed 48 hours after 
administration, by both targeted and non-targeted nanoparticles.  Interestingly, the 
control U11-targeted-neg siRNA nanoparticles were able to lower luciferase 
expression to levels exhibited by luc siRNA-nanoparticles.  This is again suggesting 
the anti-tumour effect of the U11 peptide itself, through the possible mechanism of 
competitive binding with uPA. The non-targeted–neg siRNA nanoparticles on the 
other hand, did not suppress luciferase expression, eliminating the possibility of 
nanoparticle-induced IFN response.  
 
As the number of tumours available for analysis was low, these data can only be 
considered as preliminary. To confirm the speculations derived from this data, in 
regards to gene silencing, more tumours (plus protein analysis post-treatment) would 
be required to prove the action of luciferase reduction.  Using this PC3-bone 
metastatic model, Takeshita et al have shown the efficacy of atelocollagen-based 
nanoparticle delivery systems 24 hours post-injection [42, 266].  Atelocollagen is a 
peptide-based delivery system, which could differ to liposomal systems in their 
mechanism of intracellular delivery [202].  In all cases, when luciferase knockdown is 
induced by functional delivery of siRNA-nanoparticles, the levels of gene silencing is 
not maintained for extended periods of time, due to tumour growth, and the non-
functionality of the luciferase protein.   
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Figure 6-12: Change in tumour-associated bioluminescence in PC3-luc bone metastasis 
tumour model.  PC3- luc cells were characterised by RT-PCR to have minimal expression of 
the uPAR receptor.  Different formulations of non-targeted and U11-targeted nanoparticles 
encapsulating anti-luciferase siRNA were administered to tumour-bearing mice by iv 
injection at a dose of 2mg/kg.  Bottom graph is zoomed in version of top graph, showing on 
the luciferase expression of tumours treated with U11-targeted nanoparticles and non-
targeted-luc nanoparticles. Red arrow indicates administration of nanoparticles.  For luc-
siRNA treated tumours, n=4, and for control treatments, n=2. 
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6.6.  In vivo activity of U11-targeted nanoparticles- biodistribution in PC3M-
luc bone metastatic tumours models 
 
Previously, the accumulation of nanoparticles into tumour sites was identified using 
fluorescence microscopy (see Chapter 5, Figure 5-13).  It was found that both the 
nanoparticle shell plus the encapsulated siRNA were intact on arrival in the tumour 
area 24 hours after administration.  Here, the biodistribution of nanoparticles and its 
cargo are quantified using RT-PCR, after the administration of nanoparticles 
encapsulating microRNA16 (miR16).  miR16 has been described to be involved in 
the regulation of bcl-2 protein expression, and hence is down-regulated in a variety of 
tumours.  A few studies have already considered the use of miR16 as a therapeutic 
nucleic acid, for the control of tumour growth [203-204].  In this experiment, miR16 is 
used solely as a marker for nanoparticle distribution into the organs, and the 
therapeutic effect of the miR16 was not examined.  To assess the functionality of mir-
16 delivery, what could have been performed is the quantification of bcl-2 protein 
content in the tumours after delivery. 
 
Like siRNA, microRNAs are non-coding RNAs which regulate gene expression by 
inhibition of mRNA translation.  Mature microRNAs are single-stranded RNA 
molecules consisting of 20-22 nucleotides in length.  Mature microRNAs are 
processed through a sequence of enzyme-dependent reactions before they are 
functional for gene regulation.  Firstly, microRNAs are transcribed as primary 
transcripts (pri-miRNA), which are then transformed into shorter chains of 70 
nucleotides called pre-mRNAs through interaction with an enzyme complex called 
the microprocessor complex.  On further modification with the endonuclease DICER, 
the pre-microRNAs are cleaved into short sequences of 20-22 nucleotides, which are 
complementary to one or a family of mRNA strands.   
 
miR16 was encapsulated in the same manner as the siRNA at the charge ration of 4.  
Encapsulation studies and dynamic light scattering showed the miRNA-nanoparticles 
to be of similar characteristics as that when encapsulating siRNA.  The PC3-luc bone 
metastatic model was used in this experiment to identify the difference in 
biodistribution of U11-targeted and non-targeted nanoparticles to a tumour model 
that the ligand is not specific for. After preparation, miRNA-nanoparticles were 
administered by tail vein at the same doses of the siRNA.  24 hours later, organs 
were analysed for miR16 content which was normalised against liver material not 
subjected to miR16 delivery.   
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Examination of the miR16 concentrations within the organs allowed the allocation of 
nanoparticle distribution within the body, 24 hours after administration (Figure 6-13).  
The amount of accumulation within the tumour sites was found to be low by both 
U11-targeted and non-targeted delivery.  However, the biodistribution into tumour 
sites reflect that of the luciferase silencing in PC3-luc tumours, where there is no 
difference in the effect of targeted or non-targeted nanoparticle delivery.  The excised 
tumours were homogenised whole, therefore the measured miR16 content indicated 
successful internalisation of nanoparticles into tumour cells 24 hours after 
administration.  This means that ligand-targeted nanoparticles and non-targeted 
nanoparticles accumulate and internalise at equal efficiencies into tumour cells to 
which the ligand is not specific.  From the luciferase silencing experiment in the same 
model, it was suggested that the effect of luciferase knockdown can be apparent 24 
hours after administration of siRNA-nanoparticles.   
 
In fact, differences in miR16 content between organs treated with U11-targeted or 
non-targeted nanoparticles were all found to be minimal, except in the case of the 
liver and the spleen. In these organs, the accumulation of U11-targeted nanoparticles 
were higher, almost by 2-fold, compared to that of non-targeted nanoparticles. 
Accumulation into such organs is most likely a result of the recognition and 
consequent clearance by organ-specific macrophages.  The possibility for this could 
be attributed to a variety of reasons relating to the surface characteristics of the 
nanoparticles.  Firstly, the zetapotentials of the U11-targeted nanoparticles were 
measured to be slightly higher than that of non-targeted nanoparticles, by around 
7mV.  The slightly higher cationic surface charge, and hence the increased 
similarities to alien bodies of the U11-nanoparticles could contribute to its enhanced 
recognition by such macrophages [247, 270-272].  Other examples of ligand-targeted 
delivery describe the common observation that the rate of plasma clearance 
correlates with the rate of liver/spleen uptake [138, 146, 149].  This occurrence is 
likely to be a result of increased adsorption of plasma proteins, particularly opsonin 
proteins, which leads to greater recognition by the RES [89, 186, 205-207].  Another 
likely factor that could have led to the increased accumulation of U11-nanoparticles 
into the spleen and liver cells is the recognition of the U11 peptide by receptors such 
as the epidermal growth factor receptor (EGFR) [208-209].  The U11 peptide is 
derived from the ‘growth factor domain’ of the uPA ligand, called so due to its 
structural similarity with the epidermal growth factor, a natural ligand for the EGFR.  
Regardless of the mechanism, it is the presence of the targeting peptide which 
induces enhanced uptake into the liver and the spleen.  It is likely that this effect is 
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more pronounced when the ligand is highly exposed on the nanoparticle surface, as 
they are in this case.  Earlier it was demonstrated that the conjugation of U11 
peptides onto a brush-PEG platform resulted in the higher quenching constants by 
acrylamide, reflecting the extended presentation of the ligands.  Although enhanced 
exposure of targeting ligands can aid their recognition by cell-surface receptors, such 
an organisation can also lead to greater adsorption of plasma proteins.  Presence of 
miR16 was also found in the kidneys, which could be a result of nanoparticle 
disintegration, leading to glomerular filtration of small RNA molecules. 
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Figure 6-13: Biodistribution of nanoparticles in animals bearing PC3-luc bone metastatic 
tumours.  Nanoparticles were used to encapsulate miR16 microRNAs, and were 
administered by tail vein injection at a dose of 2.5mg/kg.  After 24 hours, organs were 
homogenised and analysed by RT-PCR for the amount of miR16.  n=6.  miR16 levels were 
normalised with miR24 content. 
 
In vivo studies on the PC3-luc model indicated that the use of non-specific ligands on 
the surface of delivery nanoparticles is not disadvantageous to its ability for tumour-
delivery.  The biodistribution experiment showed that the concentrations of 
nanoparticles accumulated in the tumours were similar, and not dependent on the 
presence of non-specific surface-ligands. The internalisation and further gene 
silencing activity of the nanoparticles were also independent of the U11-ligand, as 
demonstrated by the siRNA-induced luciferase knockdown.  The only difference in 
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the activities of non-targeted and U11-targeted nanoparticles is in their accumulation 
into liver and spleen cells.  The greater removal of targeted nanoparticle from 
circulation and into the liver/spleen appears to not affect their silencing ability in 
tumours.  However, recognition by the RES can lead to a decrease in the 
concentration of nanoparticles left to accumulate into tumour tissues.  Suggestions to 
overcome this issue, and to maximise the potential of targeted nanoparticle systems, 
have included the masking of surface ligands during circulation.  Ligands can be 
temporarily buried within longer PEG chains, and be revealed on arrival at tumour 
sites, through the triggerable release of the PEG mask [210].     
 
6.7.  Summary of Chapter 6 
 
In this chapter, the effect of in vivo delivery and luciferase knockdown by targeted 
nanoparticles to xenograft tumours was examined.  Using tumour models that over-
express the uPAR receptor, we were able to identify the enhanced delivery and gene 
silencing efficiencies of U11-nanoparticles over non-targeted nanoparticles.  In 
models bearing DU145-luc and MDA-MB-231-luc tumours, tumour-associated 
luciferase showed apparent knockdown when treated with U11-nanopartilces 
carrying anti-luciferase siRNA.  The effect in luciferase reduction was more enhanced 
in the MDA-MB-231 tumours, which over-expressed the uPAR mRNA at levels higher 
than other cell lines.  The noticeable effect of luciferase suppression was observed 
48 hours after treatment, a time frame that considers the overcoming of both 
systemic and cellular barriers by the nanoparticles.  On the other hand, the effect of 
non-targeted nanoparticles was minimal, and only observed when higher 
concentrations of nanoparticles were administered.  This suggests the advantages of 
targeting ligands, which is likely to increase cellular internalisation through receptor-
mediated endocytosis.  Interestingly, when nanoparticles were delivery to tumours 
with low-uPAR expression, the effect of the targeting ligands was not apparent.  The 
targeted and non-targeted nanoparticles were able to localise at the tumour site at 
similar concentrations, and induced luciferase reduction to similar levels.  
Biodistribuntional studies in such a model further showed that the presence of U11 
ligands increased nanoparticle accumulation in the liver, which could be a result of 
greater recognition by the RES.  Ultimately, we still require more detailed 
experiments in order conclude that the introduction of U11 peptides in an optimal 
manner can increase the drug delivery abilities of nanoparticles. 
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7.  Conclusions and future work 
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7.1.  Conclusions 
 
The ability of U11 peptides to act as a targeting agent was first demonstrated in 
chapter 1, where high-charge nanoparticle platforms were decorated with U11-
peptide-lipids.  Encapsulation of pDNA within the U11 targeted nanoparticles were 
able to enhance transfection efficiencies in cancer cells by 4-fold.  The specificity of 
the U11 peptide was also established on comparison with nanoparticles decorated 
with a scrambled peptide sequence.  These control nanoparticles were unable to 
increase in vitro transfection efficiencies, plus they did not enhance binding to uPAR-
overexpressing cells, due to the non-specificity of the targeting sequence.  However, 
it was concluded that the cationic character of the nanoparticle platform was limiting 
the full targeting potential of the U11 peptide. 
 
By reducing the cationic lipid content within the liposomal formulation, a new lower-
charged nanoparticle platform was formulated.  In chapter 2, the formulation process 
was described using a new cationic lipid, DODAG, combined with cholesterol and 
DOPC lipids.  It was shown that lowering the zetapotential of the nanoparticle 
platform reduced the background electrostatic attraction between the nanoparticle 
and the cell membrane.   Functional gene delivery by U11-targeted low-charge 
nanoparticles increased transgene expression to levels significantly higher than that 
found by targeted high-charge nanoparticles.  The nanoparticle platform was 
optimised for targeted delivery, but the exposure of the U11 peptide from the 
nanoparticle surface could be improved further by optimising the peptide presentation.  
 
Using the method of post-conjugation, U11 peptides were able to be conjugated onto 
the nanoparticle surfaces via a long PEG2000 chain.  This was able to extend the 
ligand from the nanoparticle surfaces, which increased their in vitro gene delivery 
properties to even further levels.  The inclusion of a low molar percentage of PEG2000, 
from which the ligand stems, results in the collapse of the PEG chains into a 
mushroom-type conformation, folding the ligand into the PEG cloud.  The mushroom 
conformation can only transition to the brush conformation when the PEG2000 chains 
are included at higher concentrations.   
 
The introduction of higher percentages of PEG2000 is in fact important for increasing 
circulation half-life for in vivo purposes, but also to force the brush conformation of 
the PEG chains on the nanoparticle surfaces to enhance the exposure of the surface 
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ligands.  In chapter 5, a high-PEG nanoparticle platform containing 5 mol% of MeO-
PEG2000-DSPE was formulated to give small and monodisperse nanoparticle 
platforms.  In this chapter, the focus of delivery was turned to the potential of siRNA 
as a genetic therapy for cancer treatment.  The high-PEG formulation was therefore 
shown to be able to encapsulate siRNA at varying charge ratios, the optimal being 
charge ratio of 4, which rendered siRNA-nanoparticles of low charge and high 
stability in high serum solutions.  Furthermore, the ability to render protein 
knockdown in vitro was conferred by the silencing of GAPDH by nanoparticles 
carrying anti-GAPDH siRNA to cancer cells.  In an IGROV tumour model, the 
distribution of the nanoparticles was shown to accumulate successfully in 
subcutaneous tumours, a result of their diffusion through the leaky vasculature 
provided by tumour angiogenesis.  However, a high concentration of nanoparticles 
still appeared within the liver, likely due to their recognition by the macrophages of 
the RES.  The fact that these siRNA-nanoparticles were able to home to the tumour 
in an intact state proves the ability of this platform as a delivery vehicle for cancer 
drugs, an ability which could be enhanced on the introduction of the U11 peptide for 
tumour targeting. 
 
In chapter 6, the high-PEG siRNA nanoparticles were used as a platform onto which 
the U11 peptides were again introduced.  The coupling kinetics and fluorescence 
spectroscopy proved that the presence of extra PEG enhances the presentation of 
the U11 ligand.  The data point to the reorganisation of the PEG chains into a brush 
conformation, when PEG2000 is incorporated at percentages of 5 mol%.  The 
anchored PEG chains force the U11 peptides away from the surface of the 
nanoparticles, increasing their ability for receptor-recognition.  Using luciferase-
expressing cancer cell lines, the gene silencing abilities of the U11 targeted 
nanoparticles were again shown to be higher than that by the non-targeted 
nanoparticles.  It is important to note that the use of high percentages of PEG leads 
to an overall decrease in transfection efficiencies, which can only be recovered if 
receptor-specific ligands are recruited onto the nanoparticle surfaces.  By doing so, 
luciferase silencing abilities were up to 30-fold-higher that non-targeted nanoparticles, 
in uPAR-overexpressing cells.  Agreeably, the use of the U11 peptides as a surface 
ligand did not hinder the transfection effect in control cells, those which do not over-
express the receptor for targeting.   
 
In tumour models bearing uPAR-positive xenografts, only nanoparticles 
functionalised with U11 ligands were able to indicate reductions in luciferase 
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expression.  On the other hand, non-targeted nanoparticles had a very minimal effect 
appeared to have very little effect. 
 
 
 
 
Figure 7-1: Development of targeted nanoparticle gene delivery systems.  Each stage 
represents a further modification of either the nanoparticle platform or the ligand 
presentation, which leads to sequential improvement in targeting, and delivery of nucleic 
acids to cancer cells. 
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7.2.  Future work 
 
Indicated in this report is the ability of receptor-targeted nanoparticles to enhance 
gene delivery to cancer cells.  It is suggested that for the effect of the targeting 
ligands to be apparent, a series of considerations need to be optimised: 
 
1) The targeting ligand requires affinity for a tumour-related receptor which 
induces receptor-mediated endocytosis on binding. 
2) The nanoparticle platform needs to be optimised in terms of low cationic 
charge and sufficient PEGylation. 
3) The targeting ligand should be presented from the nanoparticle surface 
through a long PEG spacer, which extends its distance and hence increases 
its ability for receptor targeting. 
4) The amount of PEGylation requires fine tuning to a brush-state in order to 
both provide enough steric protection of the nanoparticle platform and also to 
extend the conjugated ligand from the PEG cloud. 
5) The ligand density needs to be high enough to increase the probability for 
receptor binding, but low enough to prevent inter-ligand aggregation. 
 
If the above criteria can be achieved, a ligand-targeted nanoparticle can have greater 
potential for delivery through enhanced internalisation into cancer cells. 
 
From the in vivo results, we hypothesise that the recruitment of receptor-specific 
ligands is particularly important for nanoparticle delivery to tumours of lower vascular 
densities.  This could be especially useful for drug delivery to smaller or metastatic 
tumours, which have not yet developed concise angiogenic networks.  In this report, 
the use of luciferase-based tumour systems was used as a reporter model for gene 
silencing by siRNA delivery.  However, the knockdown of the reporter luciferase 
protein is not a true therapeutic model, and only provides a method of straightforward 
detection.  Silencing of luciferase proteins does not lead to apoptosis or reduction in 
tumour growth, as would the delivery of therapeutic siRNA against oncogenic 
proteins.  Using siRNAs against targets such as survivin, bcl-2, or HER-2 would 
result in the death of cancer cells, hence an overall decrease in tumour size.  It is 
likely that the systemic delivery of drugs to tumours can only reach the outer 
epithelial layer of the cancer cells.  Hence, the successful destruction of whole 
tumours is achievable only through the succession of obliteration of tumour layers.  
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This effect can only be observed if the siRNA leads to apoptosis to reveal the next 
layer of cancer cells to be treated.   
 
Further biodistribution experiments are also crucial for determining time points for 
maximum localisation into tumour sites and other organs.  This knowledge of 
nanoparticle pharmacokinetics would allow the identification of optimal doses and 
time periods for administration of therapy.  Biodistribution studies could be achieved 
by tagging the nanoparticles with optical labels, contrast agents or radiolabels that 
would permit the detection of nanoparticle concentration within organs as a function 
of time.   
 
Presently, one major hurdle in the design of nanoparticles for cancer drug delivery is 
their propensity for liver and spleen accumulation.  This is generally a result of 
recognition and retention by the Kupffer macrophages within the liver and the 
sinusoidal macrophages of the spleen.  The nanoparticles presented in this report 
also suffer the same ordeal, where high concentrations of localisation are found in 
such organs.  This phenomenon is possibly only prevented by designing 
nanoparticles that can avoid interaction with opsonin proteins, which on adsorption 
onto nanoparticle surfaces acts as a recognition tag for the macrophages.  It is 
known that higher densities of PEG polymers in conjunction with longer PEG chains 
can provide greater protection of nanoparticle surfaces from protein adsorption.  
However, there is a maximum concentration of which the PEG polymers can be 
loaded before they dissociate from the liposomes to form micellar structures.  What 
could be investigated is the effect of using different combinations of PEG polymers of 
different lengths.  Shorter PEG chains would have smaller radii of gyration, which 
could allow better packing efficiencies in conjunction with longer PEG chains.   
Furthermore, the architecture of the liver vasculature could also lead to nanoparticle 
entry.  Diffusion of nanoparticles through the leaky vessels can perhaps be prevented 
if the liver is pre-saturated with non-toxic species before the administration of 
therapeutic nanoparticles.    
 
Our in vivo biodistribution studies also showed high accumulation of U11-
nanoparticles to the liver and the spleen, compared to non-targeted nanoparticles.  
This could be related to the affinity of the peptide for receptors expressed on the 
macrophages, as indicated by the increase in binding of the U11 peptide to U937 
cells that are induced to exhibit macrophage-like properties [112].  To identify the 
viability of this hypothesis, the binding of U11 peptides and U11-targeted 
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nanoparticles to isolated Kupffer cells could be compared to their binding to 
hepatocytes.  However, whether or not the U11 peptide has affinity for macrophages, 
techniques that protect the targeting ligand from the systemic environment are ideal 
to prevent the degradation or aggregation of the surface ligands.  Such a technique 
would involve the preparation of a triggerable polymer surface that can expose the 
targeting ligand on interaction with tumour-associate enzymes [109]. 
 
For a drug delivery system to successfully arrive at and deliver to tumour cells, it is 
clear that a wide range of factors need to be considered.   This report complies a few 
of those considerations that can enhance the delivery abilities of such a nanoparticle 
system.  What we have learnt is that all the components of a nanoparticle delivery 
system require fine optimisation.  Ultimately, the assembly of all the optimised 
components results in an accumulation of beneficial characteristics, which can lead 
to enhanced drug delivery to cancer cells.   
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Chemical: 1,2-dioleoyl-3-sn-phosphatidylethanolamine (DOPE), 1,2-Dioleoyl-sn-
Glycero-3-Phosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl) (DOPE-Rho) 
and N-[methoxy(polyethyleneglycol-2000)]-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (MeO-PEG2000-DSPE) were purchased from Avanti Polar 
Lipids (Alabaster, AL).  N-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine 
(CDAN), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), NDB-DOPE and 
cholesterol lipids were obtained from Sigma and Aldrich (UK).  4-(4-Formyl-3-
methoxy phenoxy)butyryl AM (FMPB AM) resin, Gly-modified Wang resin and 
Cys(Trt)-modified Wang resin, O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
(HBTU), hydroxybenzotriazole (HOBt) and all N-protected Fluorenyl 
methyloxycarbonyl (Fmoc)-amino acids were purchased from Novabiochem 
(Nottingham, UK).  N,N-diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), 
triisopropylsilane (TIPS) and piperidine were obtained from Sigma-Aldrich (Poole, 
UK).  Dimethylformamide (DMF) and acetonitrile were purchased from Rathburn 
(Walker-Burn, Scotland).  Centrifugal filter device was obtained from Millipore UK.  
Agarose gel, etidium bromide, DNA ladder, acrylamide, DNTB (Ellma's reagent).  
Other solvents (chloroform, isopropanyl, ethanol, and methanol) and all buffer 
reagents (HEPES, Tris, sodium acetate, sodium hydroxide) were purchased from 
VWR.    
 
Biological: DU145 and HEK293 cell lines were obtained from the ECACC 
(European Collection of Cell Culture, Wiltshire, UK). DU145-luc were (DU145 cells 
stably transfected with luciferase gene) were kindly supplied by Dr Orestis Agyros 
and Dr Richard Harbottle.  MDA-MB-231-luc, PC3-luc and 143B-luc cells were kindly 
supplied by Dr Takahiro Ochiya and Dr Osaki.  Dulbecco’s Modified Eagle Media 
(DMEM), RPMI, Optimem®, fetal calf serum (FCS), penicillin and streptomycin, 
phosphate-buffered saline (PBS) and trypsin-EDTA were purchased from Gibco 
(Invitrogen, Netherlands).  Luciferase reporter gene assay kit, β-gal reporter gene 
assay and reporter lysis buffer 5x were obtained from Promega (Southampton, UK) 
and BCA total protein content assay was purchased from Pierce.  Urokinase 
plasminogen activator (uPA) was obtained from American Diagnostica (CT, USA).  
All plastic-ware, including falcon tubes and tissue culture flasks were obtained from 
Falcon (Becton Dickinson, UK). GAPDH siRNA (anti-GAPDH and negative siRNA), 
KD Alert GAPDH assay kit were purchased from Ambion. Anti-luciferase siRNA for in 
vivo studies were obtained from Qiagen. 4’,6’-diamidino-2-phenyindole, dilactate 
(DAPI) nuclear staining was purchased from Sigma-Aldrich (Poole, UK).  Taqman 
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probes for miR16, miR24 and uPAR were purchased from Applied Biosystems and 
Trizol, plus all PCR reagents (cDNA synthase kit and PCR kit) were from Invitrogen. 
 
8.1.  General Methods 
 
Characterisation of nanoparticles 
 
Nanoparticle sizes were measured by photon light scattering on a Coulter Delta N4 
PCS plus 440SX photon correlation spectrometer (PCS).  After assembly, all 
nanoparticles were diluted to 0.1mgmL-1 in ddH2O, or HEPES 4mM (pH 7), a 
concentration allowing the count rate to stabilise between 4-6x104 counts per second.  
The calculated unimodal distribution was used as the determinant for average 
diameter size.  For aggregation studies, the nanoparticles were diluted in the same 
volume of Optimem® used in preparation of transfection cocktail.  The diluted 
nanoparticles were then incubated at 37°C and average particle diameter analysed at 
the time-points of 0, 30, 60, 90 and 120 mins post-formulation.  For aggregation 
studies in serum, nanoparticle solutions were diluted in fetal calf serum instead of 
Optimem®.  The diameter errors were taken as the standard deviations calculated by 
dynamic light scattering. 
 
Growth and maintenance of cells 
 
DU145 and HEK293 cells were maintained in DMEM supplemented with 10% FCS 
(v/v) and 1% penicillin and streptomycin (DMEM +/+) in T-25 tissue culture flasks.  
On confluency, media was removed by aspiration and washed with 5mL PBS.  Cells 
were then detached from the flask by addition of 1.5mL of trypsin-EDTA and 
incubated for 10mins at 37°C and 10% CO2.  After detachment, cells were diluted 
with 5mL DMEM+/+ and centrifuged to removed trypsin solution.  Cells were re-
suspended in 5mL DMEM+/+, diluted 1:10 with more DMEM+/+, of which 5mL of 
diluted cells were placed in a new T-25 culture flask.  DU145 cells were used up to a 
passage number of 30, after which they were discarded and a new batch defrosted.   
MDA-MB-231-luc, PC3-luc and 143B-luc cells were maintained as above, in RPMI 
supplemented with 10% FCS and 1% zeocin (RPMI +/+).  Cells cultured in RPMI +/+ 
media were grown in 5cm3 or 10cm3 (diameter) round culture dishes. 
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8.2.  Methods of Chapter 2 
 
Synthesis of U11 peptide-lipids 
 
FMPB AM resin (250mg, 0.74mmol/g loading) was combined with hexadecylamine 
(447mg, 1.85mmol, 10 eq) and dissolved in DMF (50mL).  Acetic acid (105μL, 
1.85mmol, 10 equiv) was then added to the flask followed by NaCNBH3 (116mg, 
1.85mmol, 10 equiv), and the reaction was stirred at 80°C for 3 h under reflux.  The 
resin was then transferred into a filtered reaction vessel and washed with CH2Cl2, 
MeOH, CH2Cl2, DMF and CH2Cl2 three times in the respective order.  Using a few 
beads from the reaction, the presence of a secondary amine was confirmed by the 
chloranil test (26).   The U11 peptide sequence was extended by standard Fmoc-
coupling strategy.  All Fmoc-amino acids were activated with HOBt and HBTU (3 eq) 
for 45 mins per coupling and the Fmoc group removed at each step using 20% 
piperidine in DMF.  The terminal amine was capped with Ac2O and DIPEA (3eq) for 
45mins before cleavage off the resin using 10mL of 95:2.5:2.5 TFA/TIS/H2O cocktail 
for 5 h.  The solution was filtered and the TFA mixture was precipitated in cold ether.  
The precipitate was collected by filtration followed by re-solvation in H2O and 
lyophilised overnight.  Purification of peptide-lipids was carried out on a Gilson semi-
preparative HPLC system (Merck Hitachi Labchrom, equipped with L7455 dioarray 
and PL-ELS1000 light scattering detectors) at a flow rate of 10mL/min, using a Vydac 
C4 protein column, with a gradient of 10% to 90% Acetonitrile (20mins).  ES mass 
spectroscopy of purified peptide-lipids was [M+H]+, 1774. 
 
Formulations of nanoparticles  
 
Lipids Molar percentage 
CDAN  50  
DOPE 50-x-y 
MeO-PEG2000-DSPE 
U11 peptide-lipid 
x 
y 
 
The following lipids CDAN, DOPE, and MeO-PEG2000-DSPE were dissolved in 
chloroform at 5mgmL-1, 5mgmL-1, and 1mgmL-1 respectively.  Appropriate aliquots 
were combined in a round-bottom flask (5 mL) and the solvent evaporated to dryness 
in vacuo to form a thin-lipid film on the walls of the flask. For non-stealth, core 
nanoparticles, CDAN and DOPE lipids were combined in a 1:1 (mol/mol) ratio.  For 
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PEGylated nanoparticles, CDAN, DOPE and MeO-PEG2000-DSPE lipids were 
combined in a 50:50-x:x, mol/mol/mol ratio (where x was between 0.5 and 5 as 
required).  The flask was further purged with argon gas to remove final traces of 
organic solvent, then hydrated with double distilled H2O (ddH2O) to give a lipid 
dispersion, which was then subjected to sonication for 30mins at 40°C (final total lipid 
concentration, 1mgmL-1).  After sonication, resulting cationic liposome solutions were 
further diluted to 0.5mgmL-1 and pDNA (0.1mgmL-1 in ddH2O) was then added slowly 
by pipette under heavy vortex mixing conditions (final lipid:pDNA ratio, 12:1 w/w).  To 
prepare targeted nanoparticles (ABCD), U11 peptide-lipid (or scrambled peptide-lipid) 
was dissolved (1mgmL-1 in 20% EtOH in H2O) and an appropriate aliquot (containing 
1-5 mol% of peptide-lipid as required) was added to formulations of PEGylated, (ABC) 
or non-PEGylated, (AB) nanoparticle suspension (with different mol% of MeO-
PEG2000-DSPE) and the mixture was then incubated for 1 h at 37°C. Excess peptide-
lipids left un-inserted into nanoparticles were removed by a centrifugal filtration 
(MWCO= 30KDa) and centrifuged at 8000g for 6 mins before the re-dilution of the 
filtrate (containing nanoparticles) with ddH2O and the supernatant was analysed.  
The amount of un-inserted peptide-lipid in the supernatant was determined by 
measuring the intrinsic amino acid fluorescence (excitation wavelength: Iex 298 nm; 
emission maximum: Imax 349nm) and extrapolated against a concentration-dependent 
calibration curve. Components of all purified nanoparticles were characterised by the 
following methods:  Analytical HPLC ((Merck Hitachi Labchrom, equipped with L7455 
dioarray and PL-ELS1000 light scattering detectors, 0% to 100% Acetonitrile in 
20mins, flow rate 1mL/min) was used to determine the amount of CDAN lipids within 
the purified formulation, the Stewart assay for the determination of the amount of 
DOPE lipids (27) and UV-visible spectroscopy for the analysis of encapsulated DNA, 
using an A0.1260 value of 30. 
 
Organisation of U11 peptides on surface of nanoparticles- circular dichroism 
 
Circular dichroism experiments were conducted using the Jasco J-715 
spectropolarimeter equipped with Jasco PCT-348WI thermostat device.  Targeted 
nanoparticles were prepared as before, by incubation of either 1 or 5 mol % U11 
peptide-lipids with naked nanoparticles formulated with 0.5 mol % of MeO-PEG2000-
DSPE, at a lipid concentration of 1mg/ml.  A 0.1mm path length cell was used to 
record spectra, values of ∆A were collected from 250 nm to 190 nm at an elevated 
temperature of 37°C.  A scan rate of 10nm/min and a step resolution of 0.2nm were 
used throughout. 
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Aggregation of nanoparticles over time 
 
Lipid 
Molar percentage in formulation, % 
U11-targeted Non-targeted 
CDAN 50 50 
DOPE 48.5 or 44.5 49.5 
MeO-PEG2000-DSPE 0.5 0.5 
U11 peptide-lipid 1 or 5 0 
 
U11-targeted (1 or 5 mol% U11 peptide-lipid) and non-targeted nanoparticles were 
prepared according to the liposomal formulations stated above, encapsulating pDNA 
at a 12:1 lipid/pDNA w/w ratio, at a concentration of 1mgmL-1 lipids in H2O.  
Nanoparticles were then diluted in either Optimem or FCS to give final nanoparticle 
concentrations of 0.01mgmL-1 lipid.  Diluted nanoparticles were incubated at 37oC 
and measured by dynamic light scattering at 30 minute intervals for up to 2 hours. 
 
Characterisation of nanoparticles- diameters and zetapotentials 
 
Nanoparticle sizes were measured by photon light scattering on a Coulter Delta N4 
PCS plus 440SX photon correlation spectrometer (PCS).  After assembly, all 
nanoparticles were diluted to 0.1mgmL-1 in ddH2O, a concentration allowing the count 
rate to stabilise between 4-6x104 counts per second.  The calculated unimodal 
distribution was used as the determinant for average diameter size.  For zetapotential 
measurements, samples were prepared as before and electrophoretic mobilities were 
measured on a Malvern Zetasizer-Nano instrument equipped with a 4 mW He−Ne 
laser (633 nm) and avalanche photodiode detector.  Zetapotentials were then derived 
using the Smoluchowski equation. 
 
In vitro Transfections 
 
uPAR-overexpressing human prostate cancer cell line (DU145) was cultured with 
DMEM +/+ at 37°C and 5% CO2.  Cells were seeded at 4x10
4 cells/well in 24 well 
plates (0.5mL volume per well) and incubated for 80h (70% confluency) before 
experiments.  For transfections, growth medium was removed from wells by 
aspiration and replaced with 0.5mL of Optimem® containing delivery systems that 
allowed 1μg pDNA per well.  Transfections were carried out for 3h before transfection 
media was removed by aspiration and replaced with DMEM+/+ for further cell growth. 
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After further incubation at 37°C for 48hrs, cells were lysed with 80μL of 1x reporter 
lysis buffer per well.  1 cycle of freeze-thaw was carried out before cells were 
scraped from wells and centrifuged at 8000g for 2 mins to separate cellular debris.  
Supernatants were analysed for luciferase transgene expression and normalised with 
the BCA total protein content kit. 
 
 
 
Representation of luciferase-encoding plasmid used to assess transfection 
efficiencies of nanoparticles in vitro 
 
Fluorescence Imaging 
 
6-well plates were loaded with pre-sterilised circular coverslips (thickness 1mm) and 
cells seeded on top at a density of 6x104 cells/well.  After incubation at 37°C and 5% 
CO2 for 80 hours (70% confluency), growth media was removed from wells and 
replaced with an aliquot of nanoparticles (50μg) in Optimem®.  Nanoparticles were 
incubated with cells for 1 or 2 h, before removal by aspiration, thereafter coverslips 
were washed twice with PBS.  Coverslips were then treated with paraformaldehyde 
per well (1mL, 4%v/v) and incubated at 37°C for 20mins, followed by another PBS 
wash (x2) and further incubation with 1 mL glycine solution (20mgmL-1).  Cells were 
stained with 1mL DAPI solution (100nM) for 5 mins at 37°C, and after one last PBS 
wash, mounted face-down onto a microscopy slide with 1 drop of PBS:Glycerol (1:1, 
v/v).  Images were taken on an Olympus 251 scope. 
 
Competitive binding of targeted nanoparticles in the presence of uPA  
 
DU145 cells were seeded in 6-well plates and incubated for 80 hours before 70% 
confluency was achieved.  Cells were washed twice with cold PBS followed by 
incubation at 4°C with glycine/NaCl (0.05M/0.1M, pH3) for 5 mins.   After incubation, 
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HEPES/NaCl (0.5M/0.1M, pH7.5) was added to the wells before removal of all 
solution and washing with PBS.  Optimem® containing 0 or 40nM uPA was applied to 
the cells and incubated at 4°C for 30min.  Rhodamine-labelled pDNA-encapsulated 
nanoparticles (ABCD; with U11- or scramble peptide) were then spiked into the cell 
medium to form concentrations of 25μg lipids/well.  The cells were then incubated for 
a further 30mins at 4°C before removal of media and washing with PBS twice.  After 
final washing, 1mL of PBS (2% FCS) was added to each well and the cells were 
detached from the wells. The cell-associated fluorescence per well was then 
analysed by flow cytometry (channel FL-2) using a Becton Dickinson FACS 4 Colour 
Caliber. 
 
8.3.  Methods of Chapter 3 
 
Synthesis of U11 peptide-lipids 
 
FMPB AM resin (250mg, 0.74mmol/g loading) was combined with hexadecylamine 
(447mg, 1.85mmol, 10 eq) and dissolved in DMF (50mL).  Acetic acid (105μL, 
1.85mmol, 10 equiv) was then added to the flask followed by NaCNBH3 (116mg, 
1.85mmol, 10 equiv), and the reaction was stirred at 80°C for 3 h under reflux.  The 
resin was then transferred into a filtered reaction vessel and washed with CH2Cl2, 
MeOH, CH2Cl2, DMF and CH2Cl2 three times in the respective order.  Using a few 
beads from the reaction, the presence of a secondary amine was confirmed by the 
chloranil test (26).   The U11 peptide sequence was extended by standard Fmoc-
coupling strategy.  All Fmoc-amino acids were activated with HOBt and HBTU (3 eq) 
for 45 mins per coupling and the Fmoc group removed at each step using 20% 
piperidine in DMF.  The terminal amine was capped with Ac2O and DIPEA (3eq) for 
45mins before cleavage off the resin using 10mL of 95:2.5:2.5 TFA/TIS/H2O cocktail 
for 5 h.  The solution was filtered and the TFA mixture was precipitated in cold ether.  
The precipitate was collected by filtration followed by re-solvation in H2O and 
lyophilised overnight.  Purification of peptide-lipids was carried out on a Gilson semi-
preparative HPLC system at a flow rate of 10mL/min, using a Vydac C4 protein 
column, with a gradient of 10% to 90% acetonitrile 
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Formulations of nanoparticles 
 
Chloroform solutions of the lipids DODAG, DOPC, Cholesterol and MeO-PEG2000-
DSPE were mixed in varying volumes in a round bottomed flask and dried in vacuo. 
The lipid film was then hydrated in HEPES 4mM (pH 7) and sonicated for 30 mins at 
room temperature.  pDNA was encapsulated by addition of pDNA (1mgml-1 in H2O) to 
empty liposome solution under heavy vortex at ratio of 12:1 w/w.   
 
To identify the lowest amount of cationic lipid, DODAG, that could be used within the 
nanoparticle, a series of formulations based on the following was assembled.  After 
encapsulation of pDNA, nanoparticles were measured by dynamic light scattering for 
their diameters. 
 
Lipid Molar percentage of total lipids, % 
DODAG x 
DOPC (99.5-x)/2 
Cholesterol (99.5-x)/2 
MeO-PEG2000-DSPE 0.5 
 
To optimise the amount of DOPC and Cholesterol within a formulation containing 20 
mol% DODAG, another series of nanoparticles were prepared based on the following.  
After encapsulation of pDNA, nanoparticles were measured by dynamic light 
scattering for their diameters. 
 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC x 
Cholesterol 79.5-x 
MeO-PEG2000-DSPE 0.5 
 
 
Characterisation of nanoparticles- diameters and zetapotentials 
 
Nanoparticle sizes were measured by photon light scattering on a Coulter Delta N4 
PCS plus 440SX photon correlation spectrometer (PCS).  After assembly, all 
nanoparticles were diluted to 0.1mgmL-1 in HEPES 4mM (pH 7), a concentration 
allowing the count rate to stabilise between 4-6x104 counts per second.  The 
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calculated unimodal distribution was used as the determinant for average diameter 
size.  The calculated unimodal distribution was used as the determinant for average 
diameter size.  For zeta potential measurements, samples were prepared as before 
and electrophoretic mobilities were measured on a Malvern Zetasizer-Nano 
instrument equipped with a 4 mW He−Ne laser (633 nm) and avalanche photodiode 
detector.  Zetapotentials were then derived using the Smoluchowski equation. 
 
% pDNA encapsulation: Propidium iodide intercalation assay and gel electrophoresis 
 
The amount of encapsulated pDNA within the targeted and non-targeted 
nanoparticles was determined by a PI-based intercalation assay, and gel 
electrophoresis.  Optimised nanoparticles were prepared at 1mgml-1 lipid 
concentration in 4mM HEPES, according to the following lipid ratios: 
 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 59.5 
Cholesterol 20 
MeO-PEG2000-DSPE 0.5 
 
pDNA (1μg, 1mgml-1 in H2O) was encapsulated then by nanoparticles (12μg, 1mgml
-1) 
by vortexing.  For targeted systems, 1mol% of U11 peptide-lipid was incubated with 
liposomal nanoparticles according to methods described in Chapter 2.  
 
For the PI-based assay, after complexation and post-insertion, the nanoparticles 
were diluted with 249μL H2O before addition of 250μL propidium iodide solution (PI, 
2.5μM in H2O).  The solutions were further mixed by vortex and incubated at room 
temperature for 10mins before analysis of fluorescence emission.  The samples were 
excited at λ= 535nm and the emissions intensities were collected at λ=617nm.  % 
encapsulation was calculated by : 
%  pDNA encapsulation = 100100 






pDNA free
lenanopartic
F
F
,  
where Fnanoparticle and FpDNA represent the measured fluorescence intensities of 
propidium iodide solutions incubated with nanoparticle-encapsulated pDNA and free 
pDNA, respectively.  The fluorescence intensities of PI solution incubated with 
nanoparticles only (no pDNA, targeted and non-targeted) were used as background 
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measurements. Fluorescence data was collected using a RF-5301PC fluorescence 
spectroflourimeter. 
 
Gel electrophoresis was used to visualize the encapsulation efficiencies of the 
nanoparticles.  After pDNA-complexation and post-insertion of U11 peptide-lipids, 
aliquots of each formulation containing 0.5µg pDNA were then loaded into wells of a 
0.8% agarose gel stained with ethidium bromide, Electrophoresis was performed at 
60mV for 60 mins and the intact pDNA was visualized under UV light.    
In vitro transfections 
 
Optimised low-charge nanoparticles, U11 targeted or non-targeted, were formulated 
as before, according to the lipid formulation below, numbers in brackets indicate the 
molar percentages of lipids used to formulated non-targeted controls. 
 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 58.5 (or 59.5) 
Cholesterol 20 
MeO-PEG2000-DSPE 0.5 
U11 peptide-lipid 1 (or 0) 
 
DU145 were seeded at 4x104 cells/well in 24 well plates (0.5mL volume per well) and 
incubated for 80h (70% confluency) before experiments.  Growth media was 
removed from wells by aspiration and replaced with 0.5mL of Optimem® containing 
delivery systems that allowed 1μg pDNA per well.  Transfections were carried out for 
3h before transfection media was removed by aspiration and replaced with DMEM+/+ 
for further cell growth. After further incubation at 37°C for 48hrs, cells were lysed with 
80μL of 1x reporter lysis buffer per well.  1 cycle of freeze-thaw was carried out 
before cells were scraped from wells and centrifuged at 8000g for 2 mins to separate 
cellular debris.  Supernatants were analysed for luciferase transgene expression and 
normalised with the BCA total protein content kit. 
 
In vitro uptake studies- Fluorescence imaging 
 
Fluorescently-labelled, low-charge nanoparticles, U11 targeted or non-targeted, were 
formulated as before, according to the lipid formulation below: 
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Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 57.5 (or 58.5) 
Cholesterol 20 
MeO-PEG2000-DSPE 0.5 
DOPE-Rhodamine 1 
U11 peptide-lipid 1 (or 0) 
 
6-well plates were loaded with pre-sterilised circular coverslips (thickness 1mm) and 
DU145 cells seeded on top at a density of 6x104 cells/well.  After incubation at 37°C 
and 5% CO2 for 80 hours (70% confluency), growth media was removed from wells 
and replaced with an aliquot of nanoparticles (50μg) in Optimem®.  Nanoparticles 
were incubated with cells for 1 or 2 h, before removal by aspiration, thereafter 
coverslips were washed twice with PBS.  Coverslips were then treated with 
paraformaldehyde per well (1mL, 4%v/v) and incubated at 37°C for 20mins, followed 
by another PBS wash (x2) and further incubation with 1 mL glycine solution 
(20mgmL-1).  Cells were stained with 1mL DAPI solution (100nM) for 5 mins at 37°C, 
and after one last PBS wash, mounted face-down onto a microscopy slide with 1 
drop of PBS:Glycerol (1:1, v/v).  Images were taken on an Olympus 251 scope. 
 
In Vitro uptake studies- Flow cytometry 
 
Fluorescently-labelled nanoparticles were prepared according to the formulations in 
the table above, encapsulating pDNA at 12:1 w/w (lipid/pDNA) ratio.  Nanoparticles 
were then diluted in Optimem to 2µg pDNA/mL (24µg lipid/mL).  DU145 cells were 
seeded at 4x104 cells/well in 24 well plates (0.5mL volume per well) and incubated 
for 80h (70% confluency) before experiments.  Growth medium was removed from 
wells by aspiration and replaced with 0.5mL of Optimem® containing nanoparticles to 
give 1μg pDNA (12μg lipids) per well.  Nanoparticles were incubated with cells for 
time points of 10, 20, 30, 40 and 60mins, after which cells were washed with PBS 
(2x), and dislodged from wells by incubation with trypsin (100μL per well) for 5 mins 
at 37˚C.  Detached cells were then diluted with 500μL DMEM+/+ and transferred to 
eppendorf tubes for centrifugation at 15rpm for 5 mins.  Trypsin-containing 
supernatant was removed by aspiration to leave a cell pellet that was resuspended in 
500mL cold (4˚C) PBS containing 2% FCS to render a cell concentration of 
approximately 2x105 cells/mL.  Cells were then analysed for rhodamine content using 
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the FL2 channel on a Becton Dickinson FACS 4 Colour Caliber.  Data was analysed 
using WinMDI software. 
 
Circular Dichroism 
 
Circular dichroism experiments were conducted using the Jasco J-715 
spectropolarimeter.  Targeted nanoparticles were prepared as before, at a lipid 
concentration of 1mg/ml.  Peptide-lipids were incubated with nanoparticles at 15µM 
targeting ligands, a 0.5mm path length cell was used to record spectra; values of ∆A 
were collected from 250 nm to 190 nm at room temperature.  Spectra of peptide-
lipids only were recorded at concentrations of 1.5µM, 3µM, 7.5µM, 12µM and 23µM 
in H2O.  A scan rate of 5nm/min and a step resolution of 0.2nm were used throughout.  
CD signals from non-targeted liposomes were used as background measurement 
and deducted from final CD spectra of targeted nanoparticles. 
 
Fluorescence quenching 
 
Nanoparticle solutions (1mgml-I) were pipetted into U-bottomed black well plates and 
to it was added solutions of acrylamide solutions of 0mM, 100mM, 200mM, 300mM 
or 400mM (in H2O).  Quenched solutions were incubated at room temperature for 
10mins before excitation at λ= 289nm.  Excitation data was again collected between 
λ=300nm and 400nm.  Volmer-Stern graphs were plotted according to the equation, 
[ ]Q K1
F
F
Q
0
+= , where F0 and F are the fluorescence intensities in the absence 
and presence of quencher Q, respectively.  KQ therefore represents the quenching 
constant.  Fluorescence data was collected using Varioskan (thermo scientific) 
microplate reader. 
 
8.4.  Methods of Chapter 4 
 
Synthesis of Cys-modified U11 and control peptides 
 
Standard Fmoc solid phase peptide procedures were used for the synthesis of all 
peptides. The solid support was Wang resin-based, functionalised with pre-loaded 
amino acids.  All Fmoc-amino acids were activated with HOBt and HBTU (3 equiv) 
Materials and methods 
198 
 
for 45 mins per coupling and the Fmoc group removed at each step using 20% 
piperidine in DMF. Each step during the coupling and de-protection procedures was 
confirmed by the Kaiser test. Cleavage off the resin was performed with 10mL of a 
95:2.5:2.5 TFA/TIS/H2O cocktail for 5 hr.  The solution was then filtered and the TFA 
mixture was precipitated in cold ether.  The precipitate was collected by filtration 
followed by re-solvation in H2O and lyophilised overnight.  Purification of peptide-
lipids was carried out on a Gilson semi-preparative HPLC system at a flow rate of 
10mL/min, using a Vydac C4 protein column, with a gradient of 10% to 90% 
Acetonitrile (20mins).  ES mass spectroscopy of purified peptide-lipids was [M+H]+, 
1539. 
 
Conjugation of Cys-peptides to mal-PEG2000-DSPE 
 
Cys-peptides (C-U11 or U11-C, 57μmol, 1.678mg) and mal-PEG2000-DSPE (57μmol, 
0.865mg) were dissolved in 1mL HEPES 4mM (pH 6.8 or 7) and stirred under N2 at 
room temperature.  Samples of 100μL were removed at various time points to 
analyse by HPLC and Ellman's test (see following for analysis methods). 
 
Analysis of peptide-PEG-lipid conjugation- Ellman’s Test and HPLC 
 
Reaction kinetics were monitored by the Ellman's test and by HPLC.  For the 
Ellman’s test, 40µL of reaction solution (45μM of Cys-peptide and 45μM of mal-
PEG2000-DSPE ) was removed at various time points and added to 60µL of TRIS 
buffer (1M, pH8), followed by addition of 120µL of DNTB solution (2mM, and sodium 
acetate 50mM).  Assay incubated at room temperature for 10 mins and the UV 
absorbance at 413nm was measured.  
 
 For HPLC analysis, 100µL of reaction solution was removed at various time points 
and analysed on a Vydac C4 column (equipped with L7455 dioarray and PL-ELS1000 
light scattering detectors), using the following solvent gradients, at a flow rate of 
1mL/min: 
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Time/mins % Acetonitrile % H2O %MeOH/CHCl3 %MeOH 
0.00 0 100 0 0 
15.0 100 0 0 0 
15.1 0 0 100 0 
35.0 0 0 100 0 
35.1 0 0 0 100 
45.0 0 0 0 100 
45.1 0 100 0 0 
55.0 0 100 0 0 
 
HPLC traces were detected using light scattering and UV (216nm) detection units. 
 
 
Conjugation of Cys-peptides onto nanoparticle surfaces 
 
Liposomal platforms were prepared as previously, at the lipid composition of: 
 
Lipids Molar percentage of total lipids, % 
DODAG 20 
DOPC 59 
Cholesterol 20 
Mal-PEG2000-DSPE  
(or MeO-PEG2000-DSPE) 
1 
Cys-peptide 1 
 
Lipid films were hydrated with HEPES 4mM (pH 7) at a lipid concentration of 45μM 
and sonicated for 30mins at room temperature.  Cys-modified U11 peptides (C-U11, 
U11-C or C-scram) were dissolved at 1mgml-1 in H2O and added to the liposomal 
solution at a 1:1 molar ratio to the maleimide content within the formulation (1 mol%, 
4.5μM).  The reaction flask was purged with N2 and stirred for various periods of 
time (21 hours for complete reaction).  Samples were removed from the reaction 
mixture at various intervals for analysis of conjugation content. After conjugation, 
pDNA was encapsulated at the ratio of 12:1 lipid:pDNA w/w by addition of pDNA 
(1mgmL-1) to lipid suspension under heavy vortexing.   
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Analysis of conjugation reactions: Ellman’s test and HPLC 
 
For the Ellman’s test, 40µL of reaction solution (4.5μM of Cys-peptide and 4.5μM of 
mal-PEG2000-DSPE, or 45μM total lipid concentration) was removed at various time 
points and transferred to a clear-bottomed UV 96-well plate wells.  To each well was 
added 60µL of TRIS buffer (pH8), followed by 120µL of DNTB solution (2mM, and 
acetate 50mM).  Assay was incubated at room temperature for 10 mins and the UV 
absorbance at 413nm was measured.   
 
For HPLC analysis, 100µL of nanoparticle conjugation reaction was removed from 
the reaction flask at various time points.  Analytical Preparative HPLC was performed 
on a C18 column (equipped with L7455 dioarray and PL-ELS1000 light scattering 
detectors), at a flow rate of 1ml/min, with the following solvent conditions of: 0mins- 
0% Acetonitrile (0.1% TFA) and 100% H2O (0.1% TFA). Gradient increased until 
20mins- 100% Acetonitrile (0.1% TFA) and 0% H2O (0.1% TFA). 20mins-30mins, 
Chloroform 100%, 30mins-50mins MeOH.  
 
Time/mins % Acetonitrile % H2O %MeOH 
0.00 0 100 0 
20.0 100 0 0 
25.0 100 0 0 
25.1 0 0 100 
45.0 0 0 100 
45.1 0 100 0 
55.0 0 100 0 
 
Retention times of various lipids and peptides are listed below: 
 
Molecule Retention time/mins 
Cys-peptide (C-U11 or U11-C) 14-14. 
DODAG 27.1 
DOPC 30.6 
Cholesterol 26.9 
PEG2000-DSPE (MeO or mal or U11) 36-43 
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Characterisation of nanoparticles- diameters and zetapotentials 
 
Nanoparticle sizes were measured by photon light scattering on a Coulter Delta N4 
PCS plus 440SX photon correlation spectrometer (PCS).  After assembly, all 
nanoparticles were diluted to 0.1mgmL-1 (of lipids) in 4mM HEPES, a concentration 
allowing the count rate to stabilise between 4-6x104 counts per second.  Nanoparticle 
sizes were measured pre and post-peptide conjugation. The calculated unimodal 
distribution was used as the determinant for average diameter size.  The calculated 
unimodal distribution was used as the determinant for average diameter size.  For 
zeta potential measurements, samples were prepared as before and electrophoretic 
mobilities were measured on a Malvern Zetasizer-Nano instrument equipped with a 4 
mW He−Ne laser (633 nm) and avalanche photodiode detector.  Zetapotentials were 
then derived using the Smoluchowski equation. 
 
% pDNA encapsulation: Propidium iodide intercalation assay and gel electrophoresis 
 
The amount of encapsulated pDNA within the targeted and non-targeted 
nanoparticles was determined by a PI-based intercalation assay, and gel 
electrophoresis.   
 
For the PI-based assay, after post-conjugation and pDNA-encapsulation, the 
nanoparticles were diluted with 249μL H2O before addition of 250μL propidium iodide 
solution (PI, 2.5μM in H2O).  The solutions were further mixed by vortex and 
incubated at room temperature for 10mins before analysis of fluorescence emission.  
The samples were excited at λ= 535nm and the emissions intensities were collected 
at λ=617nm.  % encapsulation was calculated by : 
%  pDNA encapsulation = 100100 






pDNA free
lenanopartic
F
F
,  
where Fnanoparticle and FpDNA represent the measured fluorescence intensities of 
propidium iodide solutions incubated with nanoparticle-encapsulated pDNA and free 
pDNA, respectively.  The fluorescence intensities of PI solution incubated with 
nanoparticles only (no pDNA, targeted and non-targeted) were used as background 
measurements.  Fluorescence data was collected using a RF-5301PC fluorescence 
spectroflourimeter. 
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Gel electrophoresis was used to visualize the encapsulation efficiencies of the 
nanoparticles.  After post-conjugation of Cys-peptides and pDNA-complexation, 
aliquots of each formulation containing 0.5µg pDNA were then loaded into wells of a 
0.8% agarose gel stained with ethidium bromide, Electrophoresis was performed at 
60mV for 60 mins and the intact pDNA was visualized under UV light. 
 
Fluorescence Spectroscopy 
 
All Trp fluorescence spectroscopic data was collected on a Varioskan plate reader, 
using black U-bottomed 96-well plates.  100uL of nanoparticles, targeted or non-
targeted (45μM total lipid concentration, 4.5μM of Cys-peptides and 4.5μM of mal-
PEG2000-DSPE) were pipetted into plates and diluted with 100μL of H2O.  Samples 
were mixed by pipetting (final concentration of 22.5μM total lipid and 2.25μM Cys-
peptide) and analysed by scanning static spectroscopy.  All samples were excited at 
λ=279nm and emission data collected between λ=300nm and 400nm, at bandwidths 
of 5.  Emission spectra for HEPES 4mM alone and non-targeted nanoparticles were 
also collected to act as controls.  After collection of data, emission spectra of controls 
(HEPES and non-targeted nanoparticles) were subtracted from peptide-containing 
samples accordingly. 
 
Fluorescence quenching 
 
100uL of nanoparticles, targeted or non-targeted (45μM total lipid concentration, 
4.5μM of Cys-peptides and 4.5μM of mal-PEG2000-DSPE) were pipetted into plates 
and diluted with 100μL of acrylamide solutions of 0mM, 100mM, 200mM, 300mM, 
400mM, 600mM, 800mM or 1200mM.  Samples were mixed by pipetting (final 
concentration of 22.5μM total lipid and 2.25μM Cys-peptide) and incubated at room 
temperature for 10mins before excitation at λ= 279nm.  Excitation data was again 
collected between λ=300nm and 400nm.  Quenched emission spectra for HEPES 
4mM alone and non-targeted nanoparticles were also collected to act as controls.  
After collection of data, emission spectra of controls (HEPES and non-targeted 
nanoparticles) were subtracted from peptide-containing samples accordingly.  Data 
collected using a Varioskan (thermo scientific) microplate reader. 
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8.5.  Methods of Chapter 5 
 
Formulation of nanoparticles 
 
Low-PEG nanoparticles were prepared with the following lipid compositions, in 4mM 
HEPES (pH 7), at lipid concentrations of 1mgml-1 
 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 59 
Cholesterol 20 
MeO-PEG2000-DSPE 1 
 
Following lipid film hydration and sonication for 30mins, the liposomal platforms were 
used to encapsulate siRNA at different charge ratios.  In formulation optimisation, the 
amount of siRNA was kept constant at 20pmol per formulation, and the amount of 
lipid was varied as follows: 
 
Charge ratio siRNA/pmol DODAG/nmol Lipid/µg 
1.5 20 0.71 5.29 
2 20 0.94 7.06 
4 20 1.88 14.12 
8 20 3.76 28.24 
16 20 7.53 56.47 
 
siRNA (anti-GAPDH or anti-βgal, 50µM) was added to liposomal solutions and mixed 
by gentle pipetting.  The complexes were incubated at 37oC for 10 mins before 
characterisation or biological analysis.  For in vitro experiments, the above ratios 
were scaled up accordingly.  
 
High-PEG nanoparticles were formulated according to previous methods and 
consisted of the following lipid compositions: 
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Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 55 
Cholesterol 20 
MeO-PEG2000-DSPE 5 
 
Lipid films were hydrated with HEPES 4mM (at 1mgml-1, unless otherwise stated) and 
sonicated for 30mins. siRNA (either anti-GAPDH, anti-βgal or FAM-siRNA) was 
added to the liposomal solutions at different concentrations to produce varying 
charge ratios and mixed by pipetting.  siRNA-complexes were then incubated at 37oC 
for 10 mins before use. 
 
FACS studies on siRNA-nanoparticle uptake 
 
Using the low-PEG nanoparticle platform described above, FAM-siRNA (anti-GAPDH) 
was added at increasing concentrations, under vortex, to form siRNA-nanoparticles 
of varying charge ratios.  After encapsulation of FAM-siRNA, nanoparticles were 
suspended in Optimem.  DU145 cells were seeded at 4x104 cells/well and grown for 
72 hours, after which the growth media was removed and replaced by nanoparticles 
in Optimem.  After incubations of 2 or 4 hours, nanoparticles solutions were removed 
by aspiration and cells washed with PBS.  Cells were dislodged by trypsin and 
centrifuged with growth media.  Trypsin-containing supernatant was removed and the 
cell pellet was re-suspended in PBS containing 2% of FBS at 1x106 cells/mL.  Cell 
suspensions were analysed by flow cytometry for fluorescence in the FL-1 channel. 
 
In vitro siRNA knockdown of transient Beta-gal (βgal) expression 
 
DU145 cells were seeded into 24-well plates at a density of 1x104 cells/well.  After 72 
hours of incubation and 70% confluency. Cells were transfected with pcmv-βgal 
pDNA (complexed in Trogene according to previous methods, x1µg per well) for 3.5 
hours at 37oC in Optimem.  After incubation, pDNA/Trogene solutions were removed 
by aspiration and replaced with siRNA-nanoparticles, prepared as follows.  Anti-βgal 
siRNA (0.1mgml-1) was complexed with low-PEG nanoparticles (20/59/20/1, 
DODAG/DOPC/Chol/PEG2000, 1mgml
-1) at charge ratios of 1.5, 2, 4 and 8, by pipette 
mixing.  Complexes were incubated at 37oC for 10mins before dilution in Optimem to 
concentrations of 76nM (38 pmol siRNA per 500mL/well, or 0.5µg siRNA per 
500mL/well).  After incubation of 3.5 hours, siRNA-nanoparticles solution removed by 
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aspiration and replaced by growth media.  Cells were cultured for a further 48 hours 
before lysis and analysis for βgal content. 
 
βgal assay: 
 
After 48 hours incubation, growth media removed from wells and washed with PBS 
x2.  Cells lysed with 100µL reporter lysis buffer for 30 mins at room temperature.  
Cell lysates scraped from wells and transferred into microtubes and centrifuged to 
separate supernatant.  30µL of supernatant transferred into 96-well plates and further 
diluted with 20µL of RLB (final volume 50µL of lysate).  50µL of βgal assay solution 
(Promega) added to each well and reaction incubated at 37oC for 30mins.  Reaction 
then quenched with 150µL of sodium bicarbonate solution and the UV absorbance at 
λ=405nm of each well measured.  The amount of remaining βgal content, post-
treatment, was quantified by extrapolating from a previously obtained βgal-standard 
curce.  Protein content per variable was normalised using the BCA protein kit 
(Promega). 
 
Stability of nanoparticles in high-serum: Turbidity studies 
 
Nanoparticles, high PEG, were prepared (1mgml-1 in 4mM HEPES pH 7) to 
encapsulate siRNA at charge ratios of 2, 4 and 8.  siRNA solutions were prepared at 
50µM concentrations and kept constant at either 22.5pmol or 225pmol per 
formulation before dilution to 300µL with FCS to make final siRNA concentrations of 
75nM and 750nM.  The following amounts of lipids were used to formulate varying 
charge ratios: 
 
Charge ratio 75nM 750nM 
mol DODAG mass lipid mol DODAG mass lipid 
2 1.07 nmol 40 µg 10.7 nmol 400 µg 
4 2.14 nmol 80 µg 21.4 nmol 800 µg 
8 4.28 nmol 160 µg 42.8 nmol 160 µg 
 
After encapsulation of siRNA according to the charge ratios stated above, 
nanoparticles were diluted to 300µL in FCS and incubated in cell-bottomed 96-well 
plates at 37oC for up to 2 hours.  UV absorbance at λ=600nm was measured every 
10mins. 
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Cryo-transmission electron spectroscopy of nanoparticles 
 
Nanoparticles of high PEG content, either 5mol% or 7 mol% MeO-PEG2000-DSPE, 
were prepared at 5mgml-1 lipid concentration.  Nanoparticle lipid content consisted of: 
 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 56 
Cholesterol 18 
MeO-PEG2000-DSPE 5 
DOPE-Rhodamine 1 
 
Or 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 26 
Cholesterol 16 
MeO-PEG2000-DSPE 5 
DOPE-Rhodamine 1 
DSA-DOTA-Gd 30 
 
Liposomal platforms were then used to encapsulate siRNA (anti-GAPDH) at charge 
ratio of 4.  The DSA-DOTA-Gd, a Gadolinium-containing contrast agent lipid was 
employed to render additional MRI-imaging properties to the nanoparticle Liposomal 
dispersions were dropped onto the surface of copper grids in an environment 
chamber with a relative humidity of 100% at 297K.  Nanoparticles were then cryo-
fixed by plunging into liquid ethane cooled in liquid nitrogen. Images were examined 
using a Philips CM200 microscope operating at 200 kV. 
 
 
 
DSA-DOTA-Gd (synthesised by Nazila Kamaly, Imperial College London) 
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In vitro GAPDH silencing with anti-GAPDH siRNA 
 
DU145 cells were seeded into 96 well plates at the density of 1000 cells/well and left 
to grow for 72 hours before 70% confluency was achieved.  High-PEG nanoparticles 
(5mol% MeO-PEG2000-DSPE) were prepared to encapsulate anti-GAPDH (or 
negative) siRNA at the charge ratios of 2, 4 and 8 and administered to cells in DMEM 
at 10µM, 20μM or 33μM siRNA concentrations (250μL total volume per well).  After 4 
hours of incubation, nanoparticle solutions were removed by aspiration and replaced 
with DMEM+/+.   Cells were further incubated for 48 hours.  Cells were then treated 
according to the Promega KD Alert protocol.  Briefly, cells were lysed with KD alert 
lysis buffer and cell lysis solutions were added to assays solutions and fluorescence 
at λ= was measured at t=0mins and t=4mins after mixing with assay solutions.  
GAPDH protein content was calculated according to correlation with the linear 
GAPDH calibration curve. 
 
%  GAPDH knockdown = 100100 






siRNA negative
siRNA GAPDH
 Fluor
 Fluor
 
 
FluorGAPDH siRNA and Fluornegative siRNA corresponds to the fluorescence readings of post-
assay cells lysates of cells treated with anti-GAPDH siRNA and negative siRNA, 
respectively.  
 
In vivo biodistribution of high-PEG nanoparticles 
 
Subcutaneous tumour xenografts were prepared by implantation of IGROV-1 cells, 5 
× 106, into the flanks of 6–8 week old Balb/c nude mice.  After 2 weeks (estimated 
tumour weights 40–50 mg), fluorescently-labelled nanoparticles were injected into the 
tail vein at concentrations of 28 nmol siRNA/kg mouse (or 390µg siRNA/kg). 24 hours 
post-injection, animals were sacrificed and tumours excised, frozen in liquid nitrogen, 
embedded in OCT (VWR) embedding fluid, and 10 μm thick sections cut, mounted 
on slides, and studied by fluorescence microscopy.  High-PEG nanoparticles were 
prepared at 9mgml-1 lipid concentrations in 4mM HEPES, according to the 
formulation as follows: 
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Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 26 
Cholesterol 16 
MeO-PEG2000-DSPE 7 
DOPE-Rhodamine 1 
DSA-DOTA-Gd 30 
 
Liposomal platforms (188nmol DODAG, 909 µg total lipid) were then used to 
encapsulate FAM-labelled siRNA (anti-GAPDH, 2 nmol, 50µM) at charge ratio of 4.  
The DSA-DOTA-Gd, a Gadolinium-containing contrast agent lipid was employed to 
render additional MRI-imaging properties to the nanoparticle.   
 
8.6.  Methods of Chapter 6 
 
Formulation of U11-targeted nanoparticles (high-PEG) 
 
High-PEG liposomal platforms were prepared as previously, at lipid compositions as 
follows (numbers in brackets indicate the molar percentages of lipids used to 
formulated non-targeted controls): 
 
Lipid Molar percentage of total lipids, % 
DODAG 20 
DOPC 55 
Cholesterol 20 
MeO-PEG2000-DSPE 4 (or 5) 
Mal-PEG3000-DSPE 1 (or 0) 
 
Lipid films were hydrated with HEPES 4mM and sonicated for 30mins.  Cys-modified 
U11 peptides were dissolved at 1mgml-1 in H2O and added to the liposomal solution 
under N2 for 21 hours for complete reaction.  For in vitro experiments, maleimide-
functionalised nanoparticles were prepared as above, followed by the addition of 
Cys-peptides at 1:0.8 mol ratio (mal-DSPE-PEG2000 /Cys-peptide).  The conjugation 
reaction was allowed to proceed for 10 hours over night at room temperature, under 
inert gas.   
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Analysis of conjugation reactions: Ellman’s test and HPLC 
 
Conjugation reactions between Cys-peptides and mal-PEG2000-DSPE or Cys-
peptides and maleimide-functionalised nanoparticles were prepared in HEPES 4mM 
(1:1 equiv of 45µM Cys-peptide and mal-PEG2000-DSPE).  For the Ellman’s test, 40µL 
of reaction solution was removed at various time points and transferred to a clear-
bottomed UV 96-well plate wells.  To each well was added 60µL of TRIS buffer (pH8), 
followed by 120µL of DNTB solution (2mM, and acetate 50mM).  Assay was 
incubated at room temperature for 10 mins and the UV absorbance at 413nm was 
measured.   
 
For HPLC analysis, 100µL of nanoparticle conjugation reaction was removed from 
the reaction flask at various time points.  Analytical Preparative HPLC was performed 
on a C18 column, at a flow rate of 1ml/min, with the following solvent conditions of:  
 
Time/mins % Acetonitrile % H2O %MeOH 
0.00 0 100 0 
20.0 100 0 0 
25.0 100 0 0 
25.1 0 0 100 
45.0 0 0 100 
45.1 0 100 0 
55.0 0 100 0 
 
For retention times of various lipids and peptides see Material and methods section 
of Chapter 4. 
 
Fluorescence Spectroscopy 
 
All Trp fluorescence spectroscopic data was collected on a Varioskan plate reader, 
using black U-bottomed 96-well plates.  200uL of nanoparticles, targeted or non-
targeted (0.5mgml-1 lipid mass) were pipetted into plates and analysed by scanning 
static spectroscopy.  All samples were excited at λ=279nm and emission data 
collected between λ=300nm and 400nm, at bandwidths of 5.   
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Fluorescence quenching 
 
Nanoparticle solutions (1mgml-I) were pipetted into black well plates and to it was 
added solutions of acrylamide solutions of 0mM, 100mM, 200mM, 300mM or 400mM 
(in H2O).  Quenched solutions were incubated at room temperature for 10mins before 
excitation at λ= 279nm.  Excitation data was again collected between λ=300nm and 
400nm.   
 
Nanoparticle aggregation in high serum solutions- turbidity assays 
 
In clear-bottomed 96-well plates, nanoparticles platforms (77.2µg, 1mgml-1 in 4mM 
HEPES) were complexed with anti-GAPDH siRNA (18.9nmol, 50µM in H2O) by 
gentle pipette mixing.  Following incubation at 37oC for 10 mins, nanoparticles were 
diluted with 100µL FBS and incubated at 37oC for up to 720mins.  Change in turbidity 
of FBS solutions were examined by measuring the change in UV absorbance at 
λ=600nm.   
 
uPAR mRNA expression in cancer cell lines analysed by RT-PCR 
 
DU145, DU145-luc, MDA-MB-231-luc, PC3-luc, HEK293, MCF7 and 143B-luc cell 
lines were seeded and grown to 70% confluency in a 25mm3 flask.  Cellular RNA was 
isolated first by lysing cells with 1mL Trizol. Cell lysates were vortexed with 0.2mL 
chloroform and centrifuged for 15mins at 4oC.  The top aqueous layer was removed 
and precipitated with 0.5mL isopropanyl and incubated at room temperature for 
20mins.   The solution was centrifuged again for 15 mins at 4 oC and the white RNA 
pellet was isolated by removal of the supernatant.  The pellet was air-dried to 70% 
completion and washed with 1mL of 75% EtOH (in DEPC-treated water). The pellet 
was then allowed to dry completely before dissolving it in 200µL of RNA-free H2O.   
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cDNA was synthesised by the preparing the following solution in an eppendorf tube: 
 
10.0 μl heat denatured RNA 
3.0 μl 10 x PCR buffer 
2.5 μl 10mM dNTPs 
6.0 μl 25mM MgCl
2
 
1.0 μl random primers (1.8 mg/ml) 
0.5 μl SuperScript II reverse transcriptase 
17.0 μl Water 
 
Samples were then heated at the temperature cycle: 25°C for 10 minutes, 42°C for 1 
hour, 95°C for 5 mins and then placed on ice.  
 
PCR reaction was carried out by preparing the following primer solution in a 0.5mL 
PCR tube: 
 
6.0 μl cDNA product 
1.5 μl 10 x PCR buffer 
0.2 μl Taq polymerase 
0.5 μl Taqman uPAR (or GAPDH) probe (1.0 mg/ml) 
10.3 μl water 
 
All RT-PCR reactions were carried out using mRNA levels of GAPDH to normalise 
mRNA content.  
 
40 cycles of PCR was performed on AB770: 95°C for 30 seconds, 60°C for 45 
seconds, and then 72°C for 60 seconds.   
 
In vitro luciferase silencing by anti-luciferase siRNA 
 
DU145-luc, PC3-luc or MDA-MB-231-luc cells were seeded into 24 well plates at the 
density of 4x104 cell/well and left to grow for 72 hours before 70% confluency was 
achieved.  Nanoparticles were prepared to encapsulate anti-luciferase (or negative) 
siRNA at the charge ratios of 4 and administered to cells in DMEM at 50µM siRNA 
concentrations.  After 4 hours of incubation, 10% of FBS was added to the wells and 
cells were continued to be incubated for a further 48 hours.  Cells were lysed and 
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analysed for luciferase activity by addition of luciferin to the cell lysates.  % luciferase 
silencing was calculated by: 
%  luciferase knockdown = 100100 






siRNA negative
siRNA Luciferase
 Luciferase
 Luciferase
 
 
Subcutaneous inoculation of luciferase-expressing tumours and luciferase imaging 
 
DU145-luc or MDA-MB-231-luc cells (1 x 106) in 50 µL PBS were inoculated s.c. into 
the backs of male or female (respectively) 5-week-old nude BALB/C mice.  Mice were 
anaesthetised with isoflurane and tumour growth was monitored every 24 hours for 7 
days until stable tumours were formed as identified by luciferase imaging (Xenogen 
50).  On day 0, nanoparticles encapsulating anti-luciferase siRNA (or control siRNA) 
were administered by tail vein iv injection at the dose of 2.5mg siRNA/kg, in 200μL 
volume per injection.  Luciferase expression was then analysed, and every 24 hours 
after, by ip injection of luciferin, at 0.1mg/g, followed by non-invasive imaging using 
the in vivo imaging system, IVIS.  48 hours after the first dose (day 2), a second dose 
of siRNA-nanoparticles at 2.5mg siRNA/kg was administered by tail vein injection.  
After further imaging every 24 hours for 3 days, the experiments were terminated 
according to UK Home Office regulations.  Luciferase expression in the tumours was  
expressed as photons/sec and analysed using the Living Image® software by 
Xenogen.  Data were normalised to luciferase expression measure on Day 0 or on 
Day 1.    
 
FACS studies on siRNA-nanoparticle in vitro uptake 
 
DU145-luc, PC3-luc or MDA-MB-231-luc cells were seeded into 24 well plates at the 
density of 4x104 cell/well and left to grow for 72 hours before 70% confluency was 
achieved.  High-PEG, targeted, fluorescence nanoparticles were prepared by the 
addition of 1 mol% of DOPE-Rho into the pre-modification formulation stated above.  
For targeted nanoparticles, the lipid platform consisted of, DODAG, DOPC, Chol, 
mal-PEG2000-DSPE, MeO-PEG2000-DSPE and DOPE-Rho, at ratios of 20:54:20:1:4:1.  
Non-targeted nanoparticles contained the lipids, DODAG, DOPC, Chol, MeO-
PEG2000-DSPE and DOPE-Rho, at ratios of 20:54:20:5:1.   After post-conjugation of 
Cys-U11 peptides, nanoparticles were used to encapsulate siRNA at charge ratios of 
4.  siRNA-nanoparticles were then diluted in Optimem to concentrations of 50µM 
siRNA and distributed to wells (500µL each well).  After incubations of 20, 40, 60 or 
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80mins, nanoparticle solutions were removed by aspiration and cells washed with 
PBS.  Cells were dislodged by trypsin and centrifuged with growth media.  Trypsin-
containing supernatant was removed and the cell pellet was re-suspended in PBS 
containing 2% of FBS at 1x106 cells/mL.  Cell suspensions were analysed by flow 
cytometry for fluorescence in the FL-2 channel. 
 
PC3-luc bone metastasis model- luciferase knockdown 
 
PC3-luc cells (1 x 106) in 50 µL PBS were inoculated into both tibias of male 5-week-
old nude BALB/C mice.  Tumour growth was continued for 14 days until stable 
tumours were formed as identified by luciferase imaging (Xenogen 50), after 
anaesthetising mice with isoflurane.  On day 0, nanoparticles encapsulating anti-
luciferase siRNA (or control siRNA) were administered by tail vein iv injection at the 
dose of 2.5mg siRNA/kg, in 200μL volume per injection.  Luciferase expression was 
then analysed, and every 24 hours after, by ip injection of luciferin, at 0.1mg/kg, 
followed by non-invasive imaging using the in vivo imaging system, IVIS.  Luciferase 
expression in the tumours was analysed and quantified using the Living Image® 
software by Xenogen.  Data was normalised to luciferase expression measure on 
Day 0. 
 
PC3-luc bone metastasis model- biodistribution studies 
 
After stable formation of PC3-luc bone metastatic tumours, nanoparticles 
encapsulating mir16 at charge ratio of 4 were administered by iv tail vein injection at 
the dose of 2.5mg siRNA/kg.  After 24 hours, organs were harvested, weighed and 
immediately frozen in liquid N2.  RNA from each organ was isolated by homogenising 
samples in 1mL Trizol using a shaker and homogenising beads. cDNA was then 
synthesised and PCR was carried out according to method described in ‘uPAR 
mRNA expression in cancer cell lines analysed by RT-PCR’ using taqman probes 
against miR16.  Taqman probes of miR22 and miR24 were used as controls. 
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Targeting specific receptors is attracting growing interest in the fields of drug delivery and gene therapy for
cancer treatment. The urokinase plasminogen activator receptor (uPAR) is overexpressed on many tumors,
particularly that of prostate and breast cancers. The aim of this study is to design, prepare, and characterize a
synthetic self-assembled nanoparticle that presents targeting ligands at a certain conformation and molar ratio on
the surface of the particles. Here, we describe the synthesis of a novel uPAR targeting ligand consisting of an
11-amino-acid sequence named U11 peptide modified with an alkyl chain to form an U11 peptide-lipid amphiphile.
This peptide-lipid is inserted into the outer layer of a parent stealth liposome by post-modification to derive a
U11 peptide-targeted nanoparticle. We demonstrate that the peptide moieties become separated into more singular
conformations as they are inserted into a liposome membrane, rendering them to be sufficiently biologically
active to observe specific receptor-mediated endocytosis (RME) and delivery of plasmid DNA to uPAR positive
cells (DU145 cells). The U11 peptide targeted nanoparticle transfection of DU145 cells is essentially 10-fold
higher compared to transfection achieved by nanoparticles having a scrambled peptide sequence on their surface.
U11 peptide targeted nanoparticles also proved to be uPAR-specific, as they did not improve transfection levels
on the uPAR-negative cell line, HEK293.
INTRODUCTION
The urokinase plasminogen activator receptor (uPAR) is
overexpressed on a variety of cancer cells, such as those of the
prostate and the breast (1-3). As it is the receptor’s natural
ligand, the urokinase plasminogen activator (uPA) interacts with
the cognate receptor, uPAR, to form a uPAR-uPA conjugate
that enters cells by clathrin-coated, receptor-mediated endocy-
tosis (4). The uPAR-uPA conjugate is subsequently involved
in stimulating various cellular activities such as extracellular
matrix invasion (5, 6), plasminogen activation (7), cell adhesion,
and metastasis (8, 9). The uPA ligand is known to be a
composite structure of three independent regions: an amino-
terminal growth factor domain (termed ATF or GFD; growth
factor domain), a kringle domain, and a carboxy-terminal
domain, the region in which uPA exhibits catalytic proper-
ties (10, 11). Crystallographic studies of the uPAR-uPA
conjugate have revealed that the binding region of uPA for
uPAR is localized at the tip of a -hairpin loop within the GFD
(12), representing amino acid residues 12-32 (10, 13). Within
this tip are two looped structures, one comprising seven amino
acid residues (U7) and one of eleven amino acid residues (U11)
(Table 1). The second loop, U11, appears to be the primary
uPAR binding motif within the uPA binding tip (14, 15).
Previous studies from our laboratory have determined that the
interaction of U11 peptide with uPAR is characterized by an
equilibrium dissociation constant, Kd, of 1.3-1.4 µM (16).
Considering the binding affinity along with and the RME
properties of the uPAR-uPA complex, our expectation has been
that the uPAR-uPA receptor-ligand system could hold potential
for the targeting of synthetic nanoparticles, bearing therapeutic
nucleic acids to either prostate or breast cancer.
Previously, uPAR-targeting has been used in gene delivery
experiments making use of whole GDF fragments (17). In
comparison with the use of antibodies, proteins, or protein
fragments as receptor-targeting moieties, peptide-based ligands
hold several advantages for receptor-mediated targeting such
as increased organizational control plus the opportunity to
exclude undesirable natural biological activities (18). A number
of peptide-based ligands for targeted delivery are already
described in the literature, the most prominent examples being
the use of Rv3/5 integrin receptor-targeting RGD family
peptides (19, 20). Other examples include R91 integrin receptor-
targeting peptide sequences (21) and the ApoE peptide that
targets the LDL receptor (22). uPAR-specific peptides have also
been used for viral vector retargeting and site-specific molecular
imaging (23, 24).
Here, we describe the synthesis of a simple U11 peptide-lipid
amphiphile and the formulation of that peptide-lipid into
nanoparticles using our laboratory’s nomenclature and coding
of each functional component. The “ABCD nanoparticle”
* To whom correspondence should be addressed. E-mail: maya.thanou@
imperial.ac.uk; ming.wang05@imperial.ac.uk. Phone: +44 207 5943156.
Fax: +44 207 594 5803.
† Imperial College London.
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Table 1. Amino Acid Sequences of Binding Epitopes within uPA
with Specificity for uPARa
peptide sequence
residue 11-32 in EGF domain CDCLNGGTC-VSNKYFSNIHWCNC
U7 DCLNGGT
U11 VSNKYFSNIHW
scrambled ISKSVYNFWNH
a U7 and U11 indicate specific fragments within the binding region
that exhibit high receptor affinity as synthetic peptides (15).
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paradigm has been used to define multicomponent nanoparticles
designed to substantially mediate nucleic acid delivery (Figure
1) (25). ABCD nanoparticles comprise a therapeutic nucleic acid
such as pDNA (A-component) condensed into AB core particles
by means of cationic and fusogenic lipids (B-component), which
are then coated by post-modification or postcoupling procedures
with variable amounts of a stealth polymer (such as poly-
(ethylene glycol), lipid-PEG amphiphiles) (C-component) to
provide stability in biological fluids. Ligands (D-component)
may be similarly introduced sequentially for receptor targeting.
Here, we prepare a number of nanoparticles based on ABCD
systems, to identify and promote the targeting potential of such
nanoparticles when decorated with U11 peptide-lipid am-
phiphile. The molar ratio of peptide-lipid in the nanoparticle
is investigated with respect to their size and transfection
efficiency. Nanoparticles are tested on uPAR overexpressing
DU145 prostate cancer cells and on negative uPAR HEK293
(embryonic kidney) cell line as control.
MATERIAL AND METHODS
Chemical.1,2-Dioleoyl-3-sn-phosphatidylethanolamine(DOPE),
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(Lissamine
Rhodamine B sulfonyl) (DOPE-Rho) and N-[methoxy(poly-
(ethylene glycol)-2000)]-1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine (MeO-PEG2000-DSPE), and N-cholesteryloxycar-
bonyl-3,7-diazanonane-1,9-diamine (CDAN) were purchased
from Avanti Polar Lipids (Alabaster, AL). 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), and cholesterol lipids were
obtained from Sigma and Aldrich (UK). 4-(4-Formyl-3-meth-
oxyphenoxy)butyryl AM (FMPB AM) resin, O-(benzotriazol-
1-yl)-N,N,N’,N’-tetramethyluronium (HBTU), hydroxybenzot-
riazole (HOBt), and all N-protected fluorenyl methyloxycarbonyl
(Fmoc)-amino acids were purchased from Novabiochem (Not-
tingham, UK). N,N-Diisopropylethylamine (DIPEA), trifluoro-
acetic acid (TFA), triisopropylsilane (TIPS), and piperidine were
obtained from Sigma-Aldrich (Poole, UK). Dimethylformamide
(DMF) and acetonitrile were purchased from Rathburn (Walker-
Burn, Scotland). Centrifugal filter device was obtained from
Millipore UK.
Biological. DU145 and HEK293 cell lines were obtained from
the ECACC (European Collection of Cell Culture, Wiltshire,
UK). Dulbecco’s Modified Eagle Media (DMEM), Optimem,
fetal calf serum (FCS), penicillin and streptomycin, phosphate-
buffered saline (PBS) and trypsin-EDTA were purchased from
Gibco (Invitrogen, Netherlands). Luciferase reporter gene assay
kit and reporter lysis buffer 5× were obtained from Promega
(Southampton, UK), and BCA total protein content assay was
purchased from Pierce (Rockford, USA). Urokinase plasmino-
gen activator (uPA) was obtained from American Diagnostica
(CT, USA). All plasticware, including falcon tubes and tissue
culture flasks, was obtained from Falcon (Becton Dickinson,
UK). 4′,6′-Diamidino-2-phenyindole, dilactate (DAPI) nuclear
staining was purchased from Sigma-Aldrich (Poole, UK).
Synthesis of U11 Peptide-Lipids. FMPB AM resin (250 mg,
0.74 mmol/g loading) was combined with hexadecylamine (447
mg, 1.85 mmol, 10 equiv) and dissolved in DMF (50 mL).
Acetic acid (105 µL, 1.85 mmol, 10 equiv) was then added to
the flask followed by NaCNBH3 (116 mg, 1.85 mmol, 10 equiv),
and the reaction was stirred at 80 °C for 3 h under reflux. The
resin was then transferred into a filtered reaction vessel and
washed with CH2Cl2, MeOH, CH2Cl2, DMF, and CH2Cl2 three
times in the respective order. Using a few beads from the
reaction, the presence of a secondary amine was confirmed by
the chloranil test (26). The U11 peptide sequence was extended
by standard Fmoc-coupling strategy. All Fmoc-amino acids were
activated with HOBt and HBTU (3 equiv) for 45 min per
coupling and the Fmoc group removed at each step using 20%
piperidine in DMF. The terminal amine was capped with Ac2O
and DIPEA (3 equiv) for 45 min before cleavage off the resin
using 10 mL of 95:2.5:2.5 TFA/TIS/H2O cocktail for 5 h. The
solution was filtered, and the TFA mixture was precipitated in
cold ether. The precipitate was collected by filtration, followed
by resolvation in H2O, and lyophilized overnight. Purification
of peptide-lipids was carried out on a Gilson semipreparative
HPLC system at a flow rate of 10 mL/min, using a Vydac C4
protein column, with a gradient of 10% to 90% acetonitrile (20
min). ES mass spectroscopy of purified peptide-lipids was [M
+ H]+, 1774.
Formulations of Nanoparticles. The following lipids CDAN,
DOPE, and MeO-PEG2000-DSPE were dissolved in chloroform
at 5 mg mL-1, 5 mg mL-1, and 1 mg mL-1, respectively.
Appropriate aliquots were combined in a round-bottom flask
(5 mL) and the solvent evaporated to dryness in vacuo to form
a thin lipid film on the walls of the flask. For nonstealth, core
AB nanoparticles, CDAN and DOPE lipids were combined in
a 1:1 (m/m) ratio. For PEGylated nanoparticles (ABC), CDAN,
DOPE, and MeO-PEG2000-DSPE lipids were combined in a
(50 - x/50 - x/2x m/m/m ratio where x was between 0.25 and
2.5, as required). The flask was further purged with argon gas
to remove final traces of organic solvent, then hydrated with
double-distilled H2O (ddH2O) to give a lipid dispersion, which
was then subjected to sonication for 30 min at 40 °C (final total
lipid concentration, 1 mg mL-1). After sonication, resulting
cationic liposome solutions were further diluted to 0.5 mg mL-1
and pDNA (0.1 mg mL-1 in ddH2O) was then added slowly by
pipet under heavy vortex mixing conditions (final lipid/pDNA
ratio, 12:1 w/w). To prepare targeted nanoparticles (ABCD),
U11 peptide-lipid (or scrambled peptide-lipid) was dissolved
(1 mg mL-1 in 20% EtOH in H2O) and an appropriate aliquot
(containing 1-5 mol % of peptide-lipid as required) was added
to formulations of PEGylated (ABC) or non-PEGylated (AB)
nanoparticle suspension (with different mol % of MeO-PEG2000-
DSPE), and the mixture was then incubated for 1 h at 37 °C.
Excess peptide-lipids left uninserted into nanoparticles were
removed by a centrifugal filtration (MWCO ) 30 kDa) and
centrifuged at 8000 g for 6 min before the redilution of the
filtrate (containing nanoparticles) with ddH2O, and the super-
natant was analyzed. The amount of uninserted peptide-lipid
Figure 1. Structure of the synthetic self-assembly ABCD-type nano-
particle paradigm for nonviral vector mediated nucleic acid delivery.
(Left) ABCD nanoparticles are assembled from tool kits of purpose-
designed chemical components. They comprise the following concentric
layers: A, nucleic acids (siRNA, miRNA, pDNA); B, lipid envelope
layer; C, stealth/biocompatibility polymer layer; and D, biological
recognition ligand layer. (Right) Representation of the actual pDNA-
ABCD nanoparticle system formulated as part of the reported investiga-
tions here.
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in the supernatant was determined by measuring the intrinsic
amino acid fluorescence (excitation wavelength: Iex 298 nm;
emission maximum: Imax 349nm) and extrapolated against a
concentration-dependent calibration curve. Components of all
purified nanoparticles were characterized by the following
methods: Analytical HPLC (0% to 100% acetonitrile in 20 mins,
flow rate 1 mL/min) was used to determine the amount of
CDAN lipids within the purified formulation, the Stewart assay
for the determination of the amount of DOPE lipids (27) and
UV-visible spectroscopy for the analysis of encapsulated DNA,
using an A0.1260 value of 30.
Growth and Maintenance of Cells. DU145 and HEK293 cells
were maintained in DMEM supplemented with 10% FCS (v/v)
and 1% penicillin and streptomycin (DMEM +/+) in T-25 tissue
culture flasks. On confluency, media was removed by aspiration
and washed with 5 mL PBS. Cells were then detached from
the flask by addition of 1.5 mL of trypsin-EDTA and incubated
for 10 min at 37 °C and 10% CO2. After detachment, cells were
diluted with 5 mL DMEM +/+ and centrifuged to removed
trypsin solution. Cells were resuspended in 5 mL DMEM +/+,
diluted 1:10 with more DMEM +/+, of which 5 mL of diluted
cells were placed in a new T-25 culture flask. DU145 cells were
used up to a passage number of 30, after which they were
discarded and a new batch defrosted.
In Vitro Transfections. uPAR-overexpressing human prostate
cancer cell line (DU145) was cultured with DMEM +/+ at 37
°C and 5% CO2. Cells were seeded at 4 × 104 cells/well in 24
well plates (0.5 mL volume per well) and incubated for 80 h
(70% confluency) before experiments. For transfections, growth
media was removed from wells by aspiration and replaced with
0.5 mL of Optimem-containing delivery systems that allowed
1 µg pDNA per well. Transfections were carried out for 3 h
before transfection media was removed by aspiration and
replaced with DMEM +/+ for further cell growth. After further
incubation at 37 °C for 48 h, cells were lysed with 80 µL of
1× reporter lysis buffer per well. One cycle of freeze-thaw
was carried out before cells were scraped from wells and
centrifuged at 8000 g for 2 min to separate cellular debris.
Supernatants were analyzed for luciferase transgene expression
and normalized with the BCA total protein content kit.
Characterization of Nanoparticles. Nanoparticle sizes were
measured by photon light scattering on a Coulter Delta N4 PCS
plus 440SX photon correlation spectrometer (PCS). After
assembly, all nanoparticles were diluted to 0.1 mg mL-1 in
ddH2O, a concentration allowing the count rate to stabilize
between 4 and 6 × 104 counts per second. The calculated
unimodal distribution was used as the determinant for average
diameter size. For aggregation studies, the nanoparticles were
diluted in the same volume of Optimem used in preparation of
transfection cocktail. The diluted nanoparticles were then
incubated at 37 °C and average particle diameter analyzed at
the time points of 0, 30, 60, 90, and 120 min post-formulation.
For aggregation studies in serum, nanoparticle solutions were
diluted in fetal calf serum instead of Optimem. The diameter
errors were taken as the standard deviations calculated by
dynamic light scattering.
Secondary Structure Determination. Circular dichroism ex-
periments were conducted using the Jasco J-715 spectropola-
rimeter equipped with Jasco PCT-348WI thermostat device.
Targeted nanoparticles were prepared as before, by incubation
of either 1 or 5 mol % U11 peptide-lipids with naked
nanoparticles formulated with 0.5 mol % of MeO-PEG2000-
DSPE, at a lipid concentration of 1 mg/mL. A 0.1 mm path
length cell was used to record spectra, values of ∆A were
collected from 250 to 190 nm at an elevated temperature of 37
°C. A scan rate of 10 nm/min and a step resolution of 0.2 nm
were used throughout.
Fluorescence Imaging. Six-well plates were loaded with
presterilized circular coverslips (thickness 1 mm) and cells
seeded on top at a density of 6× 104 cells/well. After incubation
at 37 °C and 5% CO2 for 80 h (70% confluency), growth media
was removed from wells and replaced with an aliquot of
nanoparticles (50 µg) in Optimem. Nanoparticles were incubated
with cells for 1 or 2 h, before removal by aspiration; thereafter,
coverslips were washed twice with PBS. Coverslips were then
treated with paraformaldehyde per well (1 mL, 4%v/v) and
incubated at 37 °C for 20 min, followed by another PBS wash
(×2) and further incubation with 1 mL glycine solution (20 mg
mL-1). Cells were stained with 1 mL DAPI solution (100 nM)
for 5 min at 37 °C, and after one last PBS wash, mounted face-
down onto a microscopy slide with 1 drop of PBS/glycerol (1:
1, v/v). Images were taken on an Olympus 251 scope.
CompetitiVe Binding of Targeted Nanoparticles in the
Presence of uPA. DU145 cells were seeded in 6-well plates
and incubated for 80 h before 70% confluency was achieved.
Cells were washed twice with cold PBS followed by incubation
at 4 °C with glycine/NaCl (0.05 M/0.1 M, pH 3) for 5 min.
After incubation, HEPES/NaCl (0.5 M/0.1 M, pH 7.5) was
added to the wells before removal of all solution and washing
with PBS. Optimem-containing 0 or 40 nM uPA was applied
to the cells and incubated at 4 °C for 30 min. Rhodamine-labeled
pDNA-encapsulated nanoparticles (ABCD; with U11- or scramble
peptide) were then spiked into the cell medium to form
concentrations of 25 µg lipids/well. The cells were then
incubated for a further 30 min at 4 °C before removal of media
and washing with PBS twice. After final washing, 1 mL of PBS
(2% FCS) was added to each well, and the cells were detached
from the wells. The cell-associated fluorescence per well was
then analyzed by flow cytometry using a Becton Dickinson
FACS 4 Color Caliber.
RESULTS
Synthesis of U11 and Control Peptide-Lipids. After
synthesis on solid phase, the crude U11 peptide-lipid was then
purified to homogeneity (>95%) by high-performance liquid
chromatography (HPLC). The identity of the U11 peptide-lipid
(Scheme 2, Table 1) was confirmed by electrospray mass
spectrometry ([M + H]+, 1774.0). The scrambled (control, Table
1) peptide-lipid was prepared in an equivalent manner, retaining
the U11 amino acid residue composition, but with a reordered
sequence.
Scheme 1. Structures of Main Lipids Used in Formulation:
Cationic Lipid CDAN, Fusogenic Lipid DOPE, and Targeting
Lipid U11 Peptide-Lipid
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Formulation of Nanoparticles. Nontargeted and targeted
nanoparticles were prepared using the pDNA construct pEGFP-
Luc (SV40 promoter) expressing the luciferase gene (luc).
Cationic lipid (CDAN), neutral fusogenic lipid (DOPE), MeO-
PEG2000-DSPE, and synthetic U11 peptide-lipid (or control
peptide-lipid) were added.
The CDAN/DOPE (1:1, m/m) cationic liposomes (Scheme
1) were chosen for their capacity to mediate high levels of
transfections without cellular toxicity (28). Targeted, non-
PEGylated nanoparticles were prepared by the method of post-
modification, involving the incubation (at 37 °C, 1 h) of standard
nanoparticles with an appropriate mol % (typically 1 or 5 mol
%) of synthetic U11 peptide-lipid (or scrambled peptide-lipid
as required). This procedure allowed the insertion of the lipid
moieties of peptide-lipids into the outer leaflet membrane of
the AB core nanoparticles in order to create targeted nanopar-
ticles (29). Removal of excess, noninserted peptide-lipids was
carried out by centrifugal filtration (MWCO ) 30 kDa,
Microcon Millipore), and gratifyingly, a very high level of
peptide-lipid insertion (>90%) was observed using fluorescence
analysis of the filtrate. Accordingly, no further nanoparticle
purification steps were considered necessary. These purified
particles were characterized by HPLC and Stewart assay to
verify that CDAN and DOPE compositions, respectively, were
unaltered (comparable to initial molar ratios) by the centrifuga-
tion process. Peptide-lipid content was confirmed by fluores-
cence spectroscopy (excitation wavelength, Iex 298 nm; emission
maximum, Imax 349 nm) and pDNA content was quantified by
UV-visible spectroscopy (using A0.1260 value of 30).
PEGylated nanoparticles (ABC) were formulated along
similar lines by the addition of pDNA to CDAN/DOPE/MeO-
PEG2000-DSPE (50 - x/50 - x/2x, m/m/m; x is 0.25 to 2.5)
cationic liposomes (prepared as before) with rapid vortex mixing
(final lipid/pDNA ratio 12:1, w/w, final pDNA concentration
0.1 mg mL-1). Selected stealth nanoparticle systems were then
incubated (at 37 °C, 1 h) with the appropriate mol % (typically
1 or 5 mol %) of synthetic U11 peptide-lipid (or scramble
control peptide-lipid as required). Once again, this procedure
allowed for the post-modification of these nanoparticle systems
with peptide-lipids and the formation of ABCD-type nano-
particles (25, 29). Excess peptide-lipid was removed once again
by centrifugal filtration and the composition of purified nano-
particles confirmed as described above.
Secondary Structure of U11 in Nanoparticles. Circular
dichroism (CD) spectroscopy has been used widely to character-
ize protein or peptide secondary structures and their conforma-
tional changes (30). Ligand conformation on the surface of the
nanoparticle is important as this affects the binding interactions.
Using CD spectroscopy, we report the change in organization
of U11 peptide-lipids as they are inserted into CDAN/DOPE/
MeO-PEG2000-DSPE (49.75/49.75/0.5, m/m/m) PEGylated
cationic liposomes (Figure 2a,b). CD spectra of the U11
peptide-lipids (1 or 5 mol %) were recorded before and
immediately after incubation with nanoparticles (without pDNA)
and compared with that recorded for U11 peptide-lipids
incubated in H2O only. Incubation of 1 and 5 mol %
peptide-lipids in H2O alone gave rise to spectra with significant
negative maxima at ∆A216, indicating the formation of -sheet
aggregates between the peptide bonds of the peptide-lipid
molecules. The same spectral pattern was observed on the
insertion of 5 mol % peptide-lipids into liposomal solutions,
suggesting that incorporation of high concentrations of peptide-
lipids into liposomes still results in -sheet aggregation, this
time most likely on the liposome surface (Figure 2a). Insertion
of U11 peptide-lipid at a lower percentage, however, generated
a spectrum with fewer characteristics of -sheet formation,
indicating the disruption of the -sheet aggregates as the
peptide-lipids are inserted into the liposomal layer (Figure 2b).
Scheme 2. - Synthesis of U11 Peptide-Lipid on Solid Phasea
a (i) C16H33-NH2, HOAc, NaCNBH3, 80 °C, 3 h. (ii) (a) Extension of peptide chain using standard Fmoc-protocol with 3 equiv Fmoc-amino
acid, HBTU (3 equiv), HOBt (3 equiv) in DMF, 1 h RT per coupling. (iii) Ac2O, DiPEA in DMF, 1 h. (iv) 95/2.5/2.5 TFA/TIS/H2O, 5 h RT.
Figure 2. Circular dichroism spectra of U11 peptide-lipids alone and
when incorporated on the surface of optimized nanoparticles (CDAN/
DOPE/MeO-PEG2000-DSPE 49.75:49.75:0.5, m/m/m) (BC system). (a)
Peptide-lipids incorporated at 5 mol % on nanoparticles (2) and in
H2O at equivalent concentration (grayscale 9); the spectra of liposomes
without peptide-lipids are shown for comparison (O). (b) Peptide-lipids
incorporated at 1 mol % on nanoparticles (9) and in H2O at equivalent
concentrations ((). Negative maximum at ∆A216 indicates the presence
of -sheet aggregates.
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The reduction of -sheet character on liposomal insertion could
indicate the reorganization of the peptide-lipid aggregates into
more separated chains when incorporated into the surface of
the targeted nanoparticles.
Optimizing Mol % of U11 Peptide-Lipid. Core AB
nanoparticles (non-PEGylated) and two targeted nanoparticle
systems (comprising 1 or 5 mol % of U11 peptide-lipid) were
incubated in transfection media or in 50% fetal calf serum (to
mimic in vivo circulation conditions), and particle size was
observed as a function of time. Nanoparticles with surface-
inserted peptide-lipids were clearly less resistant to aggregation,
although higher mole percentages of peptide-lipids lead to
greater tendencies toward aggregation (Figure 3a,b). These data
are consistent with a mechanism of aggregation promoted by
hydrophobic and -sheet-forming interactions between surface
peptide ligands of U11-decorated nanoparticles. It appeared that
colloidal stability of such systems was also poor for transfection
and uPAR-mediated targeting studies. Using a plasmid-based
reporter gene assay, transfection studies were performed with
targeted nanoparticles, where U11-decorated nanoparticle trans-
fections were found to be much less effective than corresponding
lipid/pDNA nanoparticle transfections, thereby linking the
detrimental effects of nanoparticle overaggregation with poor
transfection efficiency (data not shown). Accordingly, we
decided that non-PEGylated nanoparticles were not suitable for
further transfection and that only stable nanoparticles should
be used for uPAR-mediated targeting studies.
Optimizing Mol % of MeO-PEG2000-DSPE in ABCD
Nanoparticles. A general method for alleviating propensity
toward aggregation of nanoparticles is by introducing poly(eth-
ylene glycol) (PEG) units onto the surface of such nanoparticles.
Nanoparticles were prepared with 1 mol % of U11 peptide-lipid
in each case, plus 1-5 mol % of MeO-PEG2000-DSPE. By
increasing the percentage of MeO-PEG2000-DSPE from 1 mol
% to 5 mol %, nanoparticle stability was indeed observed in
transfection media over time. However, transfection experiments
on the DU145 cell (uPAR positive cell line) indicated no
substantial difference in transfection levels achieved by PEGy-
lated-targeted nanoparticles and corresponding nontargeted
nanoparticles (data not shown). The inclusion of even only 1
mol % of MeO-PEG2000-DSPE appeared to render nonfunction-
ality of targeted nanoparticles, presumably due to steric blocking
of surface-attached U11 peptide-lipids by neighboring PEG
chains. Nanoparticles stabilized with 0.5 mol % of MeO-
PEG2000-DSPE (ABCD), however, were shown to resist ag-
gregation in transfection media (Figure 4), and their transfections
were clearly enhanced over corresponding nontargeted nano-
particle-mediated transfections (Figure 5a) on DU145 cells.
U11 Peptide Enhanced Transfection. U11 decorated ABCD
nanoparticles were formulated with 0.5 mol % of MeO-PEG2000-
DSPE and either 1 or 5 mol % of peptide-lipid (U11 sequence
or scrambled control). uPAR is a common trait found in all
cancers, where levels of its expression depend on the cell type
(31). Transfections were performed in two cell lines, namely,
uPAR positive cells (DU145) and uPAR negative cells (non-
cancerous HEK293 human embryonic kidney cell line) (32).
Figure 3. Effect of insertion of 0%, 1%, or 5% U11 peptide-lipid on
the sizes of non-PEGylated nanoparticles (comprising CDAN/DOPE
1:1, m/m, and pDNA, lipid/pDNA ratio 12:1, w/w) incubated in (a)
Optimem and in (b) 50% FCS over 120 min at 37 °C, as measured by
PCS. Non-PEGylated nanoparticles with indicated mol % of U11
peptide-lipid have greater inclination for aggregation in transfection
media, especially systems with high peptide-lipid loading. Diameter
errors are plotted as the standard deviation calculated by PCS.
Figure 4. Effect of inclusion of U11 peptide-lipid (mol % as indicated)
on PEGylated nanoparticle size with time. PEGylated, nontargeted
nanoparticle (comprising CDAN/DOPE 1:1, m/m, and pDNA, lipid/
pDNA ratio 12:1, w/w, MeO-PEG2000-DSPE, 0.5 mol %; ABC) or
targeted nanoparticles (1 or 5 mol % U11 peptide-lipid, ABCD).
Nanoparticles were incubated in Optimem over 120 min at 37 °C, as
measured by PCS. Both nontargeted and targeted (with 1 mol % U11
peptide-lipid) nanoparticles were both stable in transfection media,
where the diameter was maintained under 250 nm throughout incubation
time. However, higher loading with 5 mol % peptide-lipid was still
prone to aggregation. Diameter errors are plotted as the standard
deviation calculated by PCS.
Figure 5. Luciferase transfection on uPAR-positive DU145 (a) and
uPAR-negative HEK293 cell lines (b) with nanoparticles (nontargeted,
comprising CDAN/DOPE 1:1, m/m, and pDNA, lipid/pDNA ratio 12:
1, w/w, MeO-PEG2000-DSPE, 0.5 mol %; ABC) or targeted nanopar-
ticles (with 1 or 5 mol % of U11 peptide-lipid or nonspecific scrambled
peptide-lipid; ABCD). Transfection data normalized on the value of
nontargeted nanoparticle transfections. Transfection times for cells were
3 h in Optimem after which cells were incubated for 48 h before lysis
and analysis for luciferase activity.
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ABCD nanoparticles presenting 1 mol % U11 peptide ligand
mediated the highest levels of DU145 transfection, nearly 3.5-
fold higher than that by nontargeted nanoparticles (Figure 5a).
Nanoparticles presenting 5 mol % U11 peptide-ligand mediated
approximately half the levels of DU145 transfection compared
to 1 mol % nanoparticles. In comparison, the highest level of
HEK293 cell transfection was mediated by nontargeted nano-
particles. On these uPAR-negative cells, ABCD targeted nano-
particles presenting 1 mol % U11 peptide ligand mediated
transfection levels that were about 50% of the control nano-
particle transfection level, while targeted nanoparticles present-
ing 5 mol % of U11 peptide-ligand mediated very poor
transfection (Figure 5b). On uPAR-negative cell lines, the U11
peptide sequence becomes nonspecific for membrane receptors,
hence functioning instead as a steric shield of the surface positive
charges. In addition, as with the use of PEGylated lipids,
inclusion of nonspecific polymer chains into the surface of
nanoparticles results in their impaired cell uptake and transfec-
tion efficiency (33). There is a clear impression with reference
to the nontargeted nanoparticle transfections that DU145 trans-
fection mediated by nanoparticles presenting 1 mol % of U11
scrambled peptide is on par with HEK293 transfection mediated
by nanoparticles presenting 1 mol % of U11 peptide ligand.
Therefore, there appears to be a clear U11 peptide ligand
mediated enhancement of approximately one log in ABCD-type
nanoparticle transfection of uPAR positive cells (DU145)
compared with key controls, namely, the transfection of uPAR
positive cells by nanoparticles presenting 1 mol % of U11
scramble peptide, and the transfection of uPAR negative cells
(HEK293) using nanoparticles presenting 1 mol % of U11
ligand.
For fluorescence microscopy, 1 mol % of the fluorescent
probe lipid DOPE-Rhodamine (DOPE-Rho) was included into
the optimized targeted and nontargeted nanoparticles. After
introduction to DU145 cells, cell-associated rhodamine fluo-
rescence was examined at 1 and 2 h post-administration (Figure
6). We observed that fluorescence intensity was much greater
in cells treated with ABCD targeted nanoparticles as compared
with control ABC nanoparticles, again another indication of
receptor-targeted delivery by uPAR-U11 recognition. Although
the images obtained do not allow us to attribute the increased
fluorescence intensity solely to cell internalization, we can
confidently conclude that the targeted ABCD nanoparticles are
nevertheless binding more efficiently to the cell membrane than
the nontargeted nanoparticles.
Competitive Binding of Targeted Nanoparticles in the
Presence of uPA. Following analysis by fluorescence micros-
copy, flow cytometery was used to assess the uptake of
rhodamine-labeled targeted nanoparticles by DU145 cells
(Figure 6e). Cell-associated fluorescence generated by binding
of scramble peptide-nanoparticles was 15% lower than that of
U11-nanoparticles, indicating a decreased amount of binding
due to the nonspecificity of the scrambled peptide sequence.
The binding of such targeted nanoparticles was challenged by
preincubation of the DU145 cells with a high concentration of
uPA, to competitively block the uPAR receptors before admin-
istration of the nanoparticles. The binding study was performed
at 4 °C to minimize receptor-mediated endocytosis. Using free
uPA to block uPAR, the receptor to which U11 peptides are
specific, binding of U11-nanoparticles was inhibited by 15%,
whereas the binding by scramble peptide-nanoparticles was
not affected. These data again emphasize the selectivity of U11-
nanoparticles for uPAR, but also indicate the high level of
background or nonspecific interactions between the nanoparticles
and cell membranes.
DISCUSSION
The main objective of this study was to identify the potential
of U11 grafting on the surface of nanoparticles for optimum
uPAR binding and cell targeting. Here, the method of post-
modification was chosen for the incorporation of peptide-lipids
onto the surfaces of nanoparticles (29, 34). In order to implement
this strategy, a U11 peptide-lipid was prepared using an
aldehyde-modified resin (FMPB resin) for the attachment of a
hexadecylamine chain to the U11 peptide moiety by a reductive
amination procedure (Scheme 2) (35, 36). Initially, 1 or 5 mol
% of the U11 peptide-lipid was inserted into nanoparticles
lacking a stealth/biocompatibility polymer. The most striking
aspect of the physicochemical behavior of these nanoparticles
was their propensity to aggregate through nonspecific peptide-
peptide interactions. (Figure 3a,b). Nanoparticles without PE-
Gylation exhibited immediate aggregation in transfection media,
where diameters of over >500 nm were recorded after 30-60
min incubation at 37 °C, a more than adequate demonstration
of the need for a stealth polymer such as PEG. However, the
overloading of such a sterically hindering polymer-lipid can
have deleterious effects on the targeting ability of the nanopar-
ticle, caused by shielding of the targeting peptides by the
Figure 6. Uptake and binding of rhodamine-labeled optimized nano-
particles. For fluorescence microscopy, DU145 cells were incubated
with nontargeted, ABC (a,b) and targeted ABCD nanoparticles (1 mol
% U11) for 1 h (a,c) and 2 h (b,d) before fixing and visualizing. Images
were overlaid with DAPI-nuclear staining. At 1 h, the cell-associated
fluorescence appears similar in cells treated with targeted (c) and
nontargeted nanoparticles (a). The difference in fluorescence is more
apparent at 2 h, where cells treated with uPAR-targeted nanoparticles
(d) show increased internal rhodamine intensity, compared to corre-
sponding control nontargeted nanoparticles (b), an indication of either
increased membrane binding or cellular internalization. Competitive
binding of rhodamine-labeled nanoparticles with free uPA, assessed
by flow cytometry (e), shows the lower cell binding by scramble peptide
decorated nanoparticles, and demonstrates U11 specificity for uPAR
by reduced cell binding of U11 nanoparticles after blocking of uPAR
receptors with 40uM uPA.
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polymer chains. The difficulty therefore lies within striking a
balance between the molar percentages of the stealth lipid and
the targeting peptide-lipid.
In this study, we also investigated the properties of the
assembled nanoparticles and the organization of peptide target-
ing ligands on their surface. This poses as the first stage of
development of nanoparticles for uPAR targeting and prostate
cancer drug/gene therapies. For cancer targeting, nanoparticles
require a diameter less than 200 nm to bypass the fenestration
found in leaky tumor vasculature and between the tumor
endothelium (37, 38). Accordingly, in the preparation of ABCD-
type nanoparticles, the amount of stealth/biocompatible polymer
(C-component) attached to the surface of AB core particles
should be sufficient to prevent particle aggregation in all relevant
biological fluids, but not so overburdening as to obscure the
benefits of including a biological targeting ligand. Long chains
of linear PEG units are intended to create a spherical, steric
barrier around pDNA/lipid core nanoparticles, reducing the
tendency for particle aggregation through the generation of steric
repulsion (39). The steric effect provided by PEGylation also
masks the lipophilic nature of the core AB nanoparticle and
provides stealth properties against immune surveillance and
serum aggregation, essential for in vivo applications. However,
PEG at higher surface densities (>1 mol %) may interfere with
the presentation of the ligand, reducing molecular recognition
by the cognate receptor. This is in agreement with our
transfection results using ABCD nanoparticles formulated with
increasing percentages of MeO-PEG2000-DSPE (data not shown).
Much of our nanoparticle study described here was designed
to find the most appropriate balance between incorporated
components for the optimization of both stability and functional
delivery of nucleic acids. In this event, this was achieved by
including 0.5 mol % of MeO-PEG2000-DSPE and 1 mol % of
U11 peptide-lipid (Figures 4 and 5).
Nanoparticle integrity also depends on the balance of surface
ligands. Similarly, as we observed, the inclusion of biological
targeting ligands at higher surface densities (>1 mol %) can
induce nanoparticle aggregation and interligand -sheet ag-
gregation (Figure 2a), without furnishing any benefits for
transfection (Figure 3). Indeed, other reported studies on ligand
loading have shown that lower loading rates of RGD peptide-
lipid (<1 mol %) on DSPC vesicles did not reduce the binding
effects of the ligand, nor was there reduction in the ability of
RGD moieties to induce cell adhesions on HUVEC (human
umbilicord endothelial) cells (40). Concurring with our data, it
is believed that the physicochemical properties of the peptide
(size, hydrophilicity) lead to particle aggregation on excessive
loading.
The incorporation of peptide-lipids into lipid membranes for
presentation of peptide ligands has been used widely in the
literature (41-45), although few studies consider the effect of
the anchoring procedure on the secondary structure of the
ligand (36, 46). In our case, we investigated the effect of
introducing peptide-lipids at high and lower molar percentages
into the outer leaflet membrane of PEGylated cationic liposomes
(Figure 2). The CD data clearly indicate that -sheet, secondary
structures are forming when the peptide-lipids are dissolved
in aqueous solution (47, 48). However, when they are inserted
at low concentrations (1 mol %), the same peptide-lipids appear
to rearrange into more separated structures, as indicated by the
reduction in ∆A216 in the CD spectrum. A targeted nanoparticle
with surface ligands that are more separated into individual
strands is more favorable for receptor binding. This phenomenon
is only observed with peptide-lipids at low molar percentages,
as the introduction of peptide-lipids into liposomes at 5 mol
% showed -sheet aggregation to the same extent as that
observed in aqueous solution alone. This again highlights the
advantages of incorporation of peptide-lipids at lower concen-
trations, where interparticle and intermolecular aggregation is
prevented. Nanoparticle transfections using this formulation
were clearly superior to all control transfections (including
transfections with nanoparticles prepared from scramble control
peptide-lipid) (Figure 5a), thereby suggesting that the U11
peptide-lipids were adopting appropriately active conformations
to enable functional receptor mediated uptake of nanoparticles
where uPAR were presented. Further evidence for receptor-
mediated uptake in uPAR positive cells DU145 was obtained
by fluorescence microscopy (Figure 6).
Previous work on ABCD nanoparticles in our laboratory had
focused on the development of a R91-integrin-targeting
peptide-lipid for incorporation into nanoparticles in order to
induce receptor-mediated uptake into appropriate cell lines
followed by efficient transfection (21). Inclusion of the
peptide-lipid into nanoparticles did indeed result in one log
increase in nanoparticle-mediated transfection of a R91-
overexpressing cell line (in comparison with nanoparticle
transfection without peptide-lipid). However, this enhanced
transfection was found to be the result of nonspecific enhanced
cellular uptake processes, as inclusion of the same ABCD
nanoparticles gave the same increase in transfection of a cell
line without R91-integrin expression (in comparison with
nontargeted nanoparticle transfection). Gratifyingly, the studies
with U11-nanoparticle-mediated transfection and fluorescence
microscopy data (Figures 5 and 6) do indicate the active
involvement of receptor-mediated cell uptake processes and U11
ligand specificity for uPAR receptor. Uptake studies in DU145
cells further demonstrate the receptor specificity of the U11
peptide, where the binding of U11-targeted nanoparticles was
shown to be reduced when the uPAR receptors are preblocked
with high concentrations of free uPA ligand (Figure 6e). Flow
cytometry showed that the binding of nanoparticles decorated
with scramble peptides was 15% lower than that by U11-targeted
nanoparticles, plus its uptake in uPAR-overexpressed cells was
not affected by uPAR blocking. However, the maximum
reduction in U11-nanoparticle binding by uPAR blocking was
15%, indicating the presence of strong nonspecific interactions
that cause the binding of the nanoparticles to the cell membranes.
The challenge of nonspecific cell interactions is also empha-
sized by the relatively low transfection enhancement (3.5-fold)
between transfections mediated by our leading U11-targeted
ABCD nanoparticles and the corresponding control nanoparticles
(Figure 5a). The reason for this may well lie in the high overall
cationic charge of the nanoparticle systems. Zeta potentials were
found to be on the order of +112 mV, a consequence of the
high lipid/pDNA ratio of 12:1 (w/w) that corresponds to an N/P
ratio of 4.25, assuming that each cytofectin CDAN presents a
net charge of +1.7 at neutral pH (49). Cell membranes are
typically anionic, owing in part to negatively charged cell surface
proteoglycans, with which cationic nanoparticles may interact
in a nonspecific manner to trigger cellular uptake by endocytosis
without the requirement for receptor mediation (50). Therefore,
the discrimination between ABCD and ABC-type nanoparticle
mediated transfections should be improved by reducing the
overall cationic charge of both nanoparticles. This could be
feasible by engineering the lipid scaffold of these nanoparticles
using alternative neutral lipids or cytofectins in order to reduce
the lipid/pDNA ratio and overall mol % of cytofectin without
impairing transfection efficiency and nanoparticle stability with
respect to aggregation.
The design of therapeutic nanoparticles must consider both
colloidal stability in biological fluids plus the ability to be tissue-
specific. The targeting of such nanoparticles to tumor cells
involves the use of surface ligands that are recognized and
further internalized by the cancer-related receptors. The primary
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sequence should already have intrinsic selectivity for its targeted
receptor, but also important is the secondary conformation of
the ligand, for maximizing receptor affinity. Here, in this study
we show that, by tuning the mol % of each lipid component
within the nanoparticle system, we can optimize the delivery
efficacy of tumor-targeted nanoparticles.
CONCLUSION
In this study, we present for the first time uPAR-targeted
nanoparticles for prostate cancer cells and we propose the
example of tailormade solutions for different biological chal-
lenges. U11 is a peptide derived from the GFD in domain 1 of
uPA and is responsible for binding to the receptor due to its
epitopal folding. On the basis of this observation, we prepared
U11 peptide-lipids that were inserted on the surface of the
nanoparticles. It was shown that insertion of 0.5 mol % of PEG
lipids induced particle stability and promoted receptor specificity
for improved cell uptake and transfection. The U11-targeting
strategy proved efficient and specific, where the U11 ABCD-
type nanoparticles increased cell uptake and transfection levels
in uPAR-expressing cell lines. It is expected that optimized U11-
nanoparticles for in vivo administration will show the same
specificity to uPAR expressing prostate cancers.
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a b s t r a c t
Nanotechnology applications in medicine, termed as nanomedicine, have introduced a number of
nanoparticles of variable chemistry and architecture for cancer imaging and treatment. Nanotechnology
involves engineering multifunctional devices with dimensions at the nanoscale, similar dimensions as
thoseof largebiological vesiclesormolecules inourbody. Thesedevices typicallyhave features just tens to
hundred nanometers across and they can carry one or two detection signals and/or therapeutic cargo(s).
One unique class of nanoparticles is designed to do both, providing this way the theragnostic nanopar-
ticles (therapy and diagnosis). Being inspired by physiologically existing nanomachines, nanoparticles
are designed to safely reach their target and speciﬁcally release their cargo at the site of the disease,
this way increasing the drug’s tissue bioavailability. Nanoparticles have the advantage of targeting can-
cer by simply being accumulated and entrapped in tumours (passive targeting). The phenomenon is
called the enhanced permeation and retention effect, caused by leaky angiogenetic vessels and poor
lymphatic drainage and has been used to explain why macromolecules and nanoparticles are found at
higher ratios in tumours compared to normal tissues. Although accumulation in tumours is observed cell
uptake and intracellular drug release have been questioned. Polyethyleneglycol (PEG) is used to protect
the nanoparticles from the Reticulo-Endothelial System (RES), however, it prevents cell uptake and the
required intracellular drug release. Grafting biorecognition molecules (ligands) onto the nanoparticles
refers to active targeting and aims to increase speciﬁc cell uptake. Nanoparticles bearing these ligands are
recognised by cell surface receptors and this leads to receptor-mediated endocytosis. Several materials
are suggested for the design of nanoparticles for cancer. Polymers, linear and dendrimers, are associated
with the drug in a covalent or non-covalent way and have been used with or without a targeting ligand.
Stealth liposomes are suggested to carry the drug in the aqueous core, and they are usually decorated by
recognition molecules, being widely studied and applied. Inorganic nanoparticles such as gold and iron
oxide are usually coupled to the drug, PEG and the targeting ligand. It appears that the PEG coating and
ligand decoration are common constituents in most types of nanoparticles for cancer. There are several
examples of successful cancer diagnostic and therapeutic nanoparticles and many of them have rapidly
moved to clinical trials. Nevertheless there is still a room for optimisation in the area of the nanoparticle
kinetics such as improving their plasma circulation and tumour bioavailability and understanding the
effect of targeting ligands on their efﬁciency to treat cancer. The need to develop novel and efﬁcient
ligands has never been greater, and the use of proper conjugation chemistry is mandatory.
© 2010 Elsevier Ltd. All rights reserved.
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. Introduction
Nanomedicine, the application of nanotechnology to medicine,
ims to overcome problems, related to diseases, at the nanoscale
here most of the biological molecules exist and operate. Par-
icularly nanotechnology application to cancer aims to bring
igniﬁcant breakthroughs in diagnosis, treatment and monitor-
ng of cancer. Nanoparticles which are molecular assemblies of
unctional chemistries will be able to overcome biological bar-
iers (bio-barriers), accumulate preferentially in tumours and
peciﬁcally recognise single cancer cells for detection and treat-
ent.
Today, there is a strong focus on nanotechnology application to
ancer. Cancer Nanotechnology is a new ﬁeld of interdisciplinary
esearch cutting across biology, chemistry, engineering and
edicine aiming to lead major advances in cancer detection diag-
osis and treatment [1–4]. The ﬁeld has received strong support
specially in US where several centres for nanotechnology for can-
er have been launched and are operating since 2004. There is no
etter deﬁnition andoverviewof this ﬁeld, other than the one given
n http://nano.cancer.gov/, which is termed as the NCI (National
ancer Institute, US) alliance for nanotechnology for cancer. This
lliance aims to bring several teams together in a surprisingly
ultidisciplinary approach to explore solutions for cancer detec-
ion imaging and diagnosis [5]. In Europe a number of academic
roups focus on research in this ﬁeld. However it is only until
ecently Europe FPVII programs have announced calls for mul-
idisciplinary team projects in nanomedicine for cancer. In the
K the major cancer research organisation (Cancer Research, UK)
ppears hesitant on supporting the ﬁeld, possibly due to potential
isks of non-tested nanomaterials. In a recent report “Roadmaps
n Nanomedicine towards 2020” from Nanomedicine European
echnology platform (http://www.etp-nanomedicine.eu/public)
pecialists foresee that oncology imaging and therapy will be the
ain area of application of various “designer’s” type of Nanopar-
icles. The targeted therapies in oncology are predicted as a 30bn
global market in 2015.
The opportunity lies in the fact that for the ﬁrst time we are able
o tackle cancer management needs and individualise therapies
y developing personalised treatments. Ideally, a clinical lab will
e using nanotechnology based assays and detect tumour mark-
rs of each patient while at the same time scientists from this
ab will formulate the nanoparticles using the same biomarkers
s the ones found in the patient’s tumour, carrying the speciﬁc
enetic drug (i.e. siRNA) designed to knock down the biomarker
rotein related to that tumour. Cancer biomarkers include a variety
f molecules such as mutant genes, RNAs, proteins, lipids, carbohy-
rate and smallmetabolitemolecules. Their alteredpresentation or
xpression is related to a biological change (expressed as neopla-
ia) and a clinical outcome.Molecular proﬁling studies can discover
ancer biomarkers based on the relation between a molecular sig-
ature and cancer behaviour. By deﬁning the interrelationships
mong these cancer biomarkers it could be possible to diagnose
he patient’s cancer molecular proﬁle, leading to personalised and
redictive medicine [3]. A unique molecular proﬁle can be used
o predict the tumour’s invasive characteristics and metastatic
otential. Molecular proﬁling was ﬁrst reported by Golub et al. [6]
ho showed that gene expression patterns could classify tumours,
roviding information on the stage, grade, clinical course and
esponse to treatment. Gene expression can demonstrate that
he molecular signature of each metastatic tumour is a result of
he combined tumoural, stromal, and inﬂammatory factors of the
riginal heterogeneous tumour [7,8]. Further, cancer molecular
roﬁling can combine cDNA microarrays with tissue microar-
ays for biomarker discovery and tissue immunohistochemical
alidation [9].cal Research 62 (2010) 90–99 91
The identiﬁcation of such biomarkers is very important for
individualised therapy and treatment of cancer [10,11]. For exam-
ple Herceptin is a monoclonal antibody targeting ampliﬁed and
over-expressed Erbb2 (HER2) is a tyrosin kinase receptor found in
25–30% of breast cancers. In the process of drug approval, the FDA
required diagnostic tests to detect HER2 over-expression indicat-
ing that individualised therapy for cancer is required to achieve
cancer treatment without the unwanted effects. In vitro diag-
nostics for HER 2 now include an immunohistochemistry assay
and a nucleic acid ﬂuorescence in situ hybridisation (FISH) test
to guide Herceptin treatment decisions. The design of methods
that can detect in vivo the expression of such markers and mon-
itor them during treatment is a real challenge. For the ﬁrst time
nanotechnology can be applied for the design of multifunctional
nanoparticles that will be able to (a) detect, (b) image tumours
and their metastases, (c) treat and (d) monitor treatment pro-
gression. The application and efﬁciency of these nanoparticles
in vivo will help enormously the pre- and post-operative cancer
treatment. The design of such nanoparticles is not trivial as sev-
eral factors have to be taken into consideration. Primarily, the
chemistry of the core and the layers needs to be done with con-
sideration of the structural integrity and stability of the particles
in biological ﬂuids. Further, similar to the process of product drug
development, nanoparticle development needs to consider physic-
ochemical issues related to the properties of the nanoparticles,
biopharmaceutical issues related to the properties of the “bio-
barriers” and pharmacological issues related to the site, time and
duration of nanoparticle’s action. These nanoparticles have to be
considered differently to small and large molecular drugs intro-
ducing novel parameters for their design. FDA states that ADME
(Administration, Distribution, Metabolism and Excretion) studies
need tobe redesigned in thecaseofnanoparticles to takeunder con-
sideration their aggregation and surface chemical characteristics
[12].
Most nanoparticles are expected to accumulate in tumours
due to the enhanced permeation and retention (EPR) effect—a
tumour characteristic that was identiﬁed by Maeda as a means
to target anticancer agents to tumours [13]. Nanoparticle tumour-
accumulation is deemed possible due to the highly permeable
blood vessels of the tumours as a result of rapid anddefected angio-
genesis. In addition tumours are characterised by dysfunctional
lymphatic drainage that helps the retention of nanoparticles in
tumour long enough to allow local nanoparticle disintegration and
release of the drug in the vicinity of tumour cells. The phenomenon
has been used widely to explain the efﬁciency of nanoparticle and
macromolecular drug accumulation in tumours [14].
Our knowledge of nanoparticle biokinetics, metabolism and
clearance is poor as very fewnanoparticle products have been clini-
cally tested.Doxil® andAbraxane® are twonanoparticles for cancer
therapy that have gone through preclinical and clinical evaluation
and FDA approval. Doxil® is a liposomal system for doxorubicin
delivery and treatment of ovarian carcinoma and Abraxane® is
an albumin nanoparticle taxol conjugate for the treatment of
metastatic breast cancer.
2. FDA-approved therapeutic nanoparticles for cancer
The ﬁrst nanoparticles used to deliver cancer chemotherapy
were the liposomes. Liposomes are usually sized at the nanoscale
and consist of a lipid bilayer surrounding a water core hosting
the drug. The ﬁrst studies to report the efﬁciency of liposomes
as nanoparticles focused on the improvement of pharmacokinet-
ics and biodistribution of the anthracycline drug doxorubicin. The
nature of doxorubicin, unfortunately also induces cardiotoxicity
and this can limit the administered dose. To avoid this, doxoru-
bicin was encapsulated in anionic liposomes, after which studies
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howed that liposomal doxorubicin improved accumulation in
umours and had increased antitumour activity while cardiotoxic-
tywas diminished [15,16]. Liposomal doxorubicin has been shown
o be safe and efﬁcient clinically, in ovarian and breast cancer
17,18]. Doxil®, the pegylated liposomal doxorubicin shows high
fﬁciency due to improved pharmacokinetics as it has been shown
o escape the reticulo-endothelial system (RES)—an important
arrier in nanoparticle systemic circulation [19–21]. Polyethye-
eneglycol (PEG) is used with a number of nanoparticles as it
mproves colloidal stability and prevents uptake by the RES. PEG
s usually added on the surface of nanoparticles to create the so-
alled “steric stabilisation” effect where the PEG molecules form
protective hydrophilic layer on the surface of nanoparticles that
revents interaction with each other (aggregation) and with blood
omponents. As a result, grafting of PEG on the surface of nanopar-
icles reduces uptake by the macrophages of the mononuclear
hagocyte system (MPS) and prolongs the blood circulation times
22,23].
The second nanoparticle approved for cancer therapy was an
lbumin Taxol® conjugate. Abraxane ® was designed to overcome
axol® insolubility related issues, through binding of the drug
o 130nm albumin nanoparticles. Also known as nab-paclitaxel,
braxane® was designed to avoid the use of Cremophor EL® sol-
ent (polyethoxylated castor oil) that is used to solubilise Taxol®
24–26] and is the ﬁrst albumin nanoparticle approved for human
se by FDA. Albumin is a natural carrier of endogenous hydropho-
ic molecules which are bound onto it through non-covalent
nteractions, a type of binding interaction that is critical for phar-
acokinetics (protein binding). More importantly, albumin assists
ndothelial trancytosis of protein bound and unbound plasma con-
tituents principally through binding to a cell surface, a 60-kDA
lycoprotein receptor gp60. The receptor then binds to caveolin-
with subsequent formation of trancytotic vesicles (caveolae)
27]. In addition, albumin binds onto osteonectin, secreted pro-
ein acid rich in cystein (SPARC) which is present on breast lung
nd prostate cancer and that way albumin is accumulated in
umours [26,28]. Currently there are more than 50 clinical tri-
ls ongoing using nanoparticles for cancer. The majority of these
anoparticles are nab type (nanoparticle albumin bound) tested
or the treatment of various cancer types (http://clinicaltrials.gov;
earch for nanoparticles and cancer on December 2009). The clin-
cal trials also include a nanoliposomal irrinotecan [29], a SPIO
superparamagnetic iron oxide) to diagnose pre-operative stage of
ancreatic cancer [30] a transferin targeted cyclodextrin polymer
ased nanoparticle for siRNA delivery CALAA-01 [31]. Importantly
he clinical trials include studies of designed nanoparticles such
s the lyso-thermosensitive liposomal doxorubicin (Thermodox®)
s a novel activated therapy using radiofrequency ablation
32,33].
.1. Cancer nanoparticles types, functionalities and modalities
During the last years a number of studies have been presented
hat show smartly designed nanoparticles for tumour targeting,
maging and therapy where reviews have attempted to describe
nd categorise these nanoparticles [34–41].Most of the researchers
gree thatnanocarriers ornanovectors arenanosizedmaterials that
an carry multiple drugs and/or imaging agents [1,34]. Particu-
arly, they consist of a scaffold (polymer or lipids), where drugs
nd contrast agents are attached, a corona of polymeric material
hat improves biokinetics and biodistribution and a ligand that
dds speciﬁcity for cancer biomarker molecular recognition and
ttachment to cancer cells [34–36,42].
Therapeutic nanoparticles with a highly deﬁned lipid scaffold
re mainly the liposomes, discovered 40 years ago by Bangham
43,44]. Liposomes’ size is ranging from a minimal diameter ofcal Research 62 (2010) 90–99
30nm to several microns [45]. Liposomes may vary in size, lipid
composition,methodof preparation andparticularly surface chem-
istry. Liposomes have evolved through the years to a versatile
carrier adaptedeach time tohave adifferent functionality and serve
a certain drug delivery purpose [46,47].
A progressing type of lipid based nanoparticle emerging in
the therapeutic ﬁeld is the Solid Lipid nanoparticles (SLN). Since
their ﬁrst description by Müller et al. [48,49] SLNs have attracted
increasing attention as an efﬁcient and non-toxic alternative to
lipophilic colloidal drug carrier prepared either with physiolog-
ical lipids or lipid molecules used as common pharmaceutical
excipients. Two production techniques have been reported: the
high-pressure homogenisation described by Müller and Lucks and
the microemulsion-based technique by Gasco [49,50]. In contrast
to the preparation method of most polymeric microsphere and
nanoparticle systems, SLN production techniques do not need
to employ potentially toxic organic solvents, which may also
have deleterious effect on protein drugs. Furthermore, under opti-
mised conditions they can be produced to carry lipophilic or
hydrophilic drugs and seem to fulﬁl the requirements for an
optimum particulate carrier system. Their colloidal dimensions
and their controlled release behaviour enable drug protection
through administration by parenteral and non-parenteral routes
thus emphasising the versatility of this nanoparticulate carrier
[51,52].
Dendrimers are the main polymeric architectures that follow in
the category of nanoparticles. They are a unique class of repeat-
edly branched polymeric macromolecules with a nearly perfect
3D geometric pattern. They can be synthesised with either diver-
gent methods (outward from the core) or convergent methods
(inward towards the core). Tomalia was the ﬁrst to synthesise the
3D PAMAM (polyamidoamine) dendrimers using divergent meth-
ods [53]. These dendrimers contain tertiary amines that allow
the binding of a number of molecules. The method of conver-
gent dendrimer synthesis has been established by Frechet [54]
and a dendrimer is characterised by the generation of monomers
(G) added to a main core. The size of these dendrimers varies
between 1.9nm for G1 and 4.4nm for G4, dendrimers, being the
smallest nanocarriers developed which has promoted their sug-
gestion for a number of pharmaceutical applications [55]. They
have been extensively studied in the area of therapeutics and
diagnostics for cancer [56] as well as for photodynamic ther-
apy (activation therapies) [56], boron neutron capture therapy
[57] and hyperthermia therapies using gold nanoparticles [58].
Dendrimers are versatile particles regarding their size and func-
tionality and their chemistry allows for several modiﬁcations for
certain imaging modalities. Gadolinium has been complexed with
dendrimers and it was found that this complex enhanced conven-
tional MR images in a dendrimer molecular weight dependent way
and substantially better, compared with conventional diethylen-
etriaminepentaacetic acid Gd (III) chelates [59]. As drug delivery
agents, dendrimers can carry drugs as complexes or as conju-
gates although one limitation lies in the effort of controlling the
rate of drug release. The encapsulated, complexed, drugs tend to
be released rapidly (before reaching the target site) and in the
dendrimer–drug conjugates, it is the chemical linkage that controls
the drug release. However, dendrimers offer several advantages as
drug carriers targeting cancer. Onemajor advantage is their surface
functionality providing the selective coupling of imaging agents,
targeting ligands and/or other components to increase tumour
speciﬁcity.The abovementioned nanoparticles either based on lipids or on
polymers are generally “soft” and ﬂexible nanoparticles. Their size
ranges from 30nm to slightly more than 100nm. However, they
can penetrate biological membranes due to their ﬂexibility and
biophysical interaction with cellular membrane components.
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The inorganic nanoparticles represent a different class of
anoparticles that are usually much smaller, 5–40nm and they
o not have the ﬂexibility observed in liposomes and polymeric
anoparticles. Inorganic nanoparticles have made their appear-
nce in cancer therapy during the last decades in a number of
pplications [60]. The main type of inorganic nanoparticles—the
ron oxide nanoparticles, has been used for imaging tumours [61].
he main advantage of magnetic nanoparticles is their ability to
e visualised by Magnetic Resonance (MR) imaging. Additionally,
ron oxide nanoparticles can be guided to target sites (i.e. tumour)
sing external magnetic ﬁeld and they can be also heated to
rovide hypethermia for cancer therapy [62]. Yu et al. reported
hermally cross-linked superparamagnetic iron oxide nanoparti-
les that could carry aCy5.5near infra-redprobe (dual imaging) and
oxorubicin for the imaging and treatment of cancer. The nanopar-
icles substantially diminished tumour size and provided the proof
f concept that they can combine several modalities for maximum
ntitumour effect [62]. Magnetic nanoparticles have been used in
he development of dual purpose probes for the in vivo transfec-
ion of siRNA [63,64]. The iron nanoparticles used in that study
elivered siRNA at the same time as imaging their own accumu-
ation in tumour sites. The iron nanoparticles used, were coated
ith dextran on which Cy5.5 and siRNA were chemically coupled
64].
Dextran coated iron oxide nanoparticles are already in clinical
ractice. Ferumoxtran-10® is a commercially available ultrasmall
uperparamagnetic iron oxide particle (USPIO) product [65,66].
fter i.v. injection the particles collect in lymphnodes, liver, spleen,
r brain tissue where they can be seen using MRI. In a lymph node
ith proper architecture and function (healthy) macrophages take
p a substantial amount of Ferumoxtran-10. This uptake results
n a marked reduction in signal intensity and turns the lymph
odes dark when seen by MRI. Inﬁltration of lymph nodes with
alignant cells replaces the macrophages and changes the archi-
ecture of the lymph nodes. In malignant lymph nodes there is
o ferumoxtran-10 macrophage uptake and they can retain the
igh signal intensity or display heterogeneous signal intensity if
icrometastases are involved. This way the grade of tumours and
rognosis can be assessed as micrometastases are important for
his assessment [67].
Gold nanoparticles appear as another type of inorganic metal
article used in targeting tumours. Metal nanoshells are a class of
anoparticles with tunable optical resonances. Metal nanoshells
onsist of a spherical dielectric core nanoparticle, in this case silica,
hich is surrounded by a thin metal shell, such as gold [68]. These
articles possess a highly tunable plasmon resonance, a resonant
henomenon whereby light induces collective oscillations of con-
uctive metal electrons at the nanoshell surface. When studied in
ivo inmice the nanoshellswere “stealthed”with PEG, systemically
njected, and were shown to accumulate preferably at the tumour
ite due to the highly permeable, poorly organized vascular net-
orks common in neo-plastic tumours. Then, NIR (Near Infra-red)
aser treatment of the bulk tissue selectively heats and destroys the
anoshell-laden tumour regions within the tissue, while leaving
urrounding tissue intact [69]. Nanoshells are currently evaluated
n a number of clinical settings after a 5-year period of inten-
ive preclinical development [70]. Such development of nanoshells
ncluded the combination of nanoshells with cancer antibodies.
nti-HER2 antibody was conjugated onto nanoshells providing the
otential of combining antibody therapy with imaging and hyper-
hermia [71].As gold nanoparticles have evolved other gold structures have
lso been suggested. Nanorods, with the appropriate PEG stealth
ayer, are being developed as an improved means of hyperthermia.
fter injection in xenograft bearing mice, aided by computational
tudies, nanorods were shown to eradicate all irradiated tumours.cal Research 62 (2010) 90–99 93
The nanorods were compared to nanoshells for their laser induced
heat. It was found that the PEG-Nanorods solutions exhibited heat
that was generated 6 times faster compared to the heat generated
by nanoshells under the same conditions [72].
Overall, during the last decade nanoparticles for in vivo appli-
cation targeting cancer appeared with different sizes structures
and tuneable properties. However, there are 2 functional compo-
nents that are required for their biological applications for cancer
targeting: The stealth layer and the ligand for cancer receptors.
3. Nanoparticle surface constituents
PEG layers are added onto any nanoparticle that is aimed to
be administered intravenously for accumulation into tumours.
Whether this is a liposome, a dendrimer or an inorganic nanopar-
ticle such a layer (corona or halo) provides long circulation as
it inhibits the accumulation of opsonins and their uptake by the
macrophages.Although, currently therearenoclear rules regarding
the organization and the type of PEG on the surface of nanopar-
ticles, there are some trends, derived from the extensive work on
liposomes for cancer targeting. These trends indicate that the PEG’s
size and density on the nanoparticles are key features thatwill con-
trol the circulation times and accumulation in tumours. Such PEG
layers can interfere with targeting ligands and inhibit them from
interaction with the corresponding receptors. In the following two
sections PEG and cancer targeting ligands will be discussed with
emphasis on liposomes as these nanoparticles have been widely
studied in vivo in tumour animal models.
3.1. Nanoparticle biological stability stealth polymers
Most nanoparticles require colloidal stability in vitro (in buffers
i.e. for storage) and in vivo (biological stability). A protective layer
can therefore be formed by the incorporation of a hydrophilic poly-
mer layer. The FDA-approved PEG polymer is the mostly used
material. PEG is commonly adopted for the stealth function, due
to their enhanced hydrophilicity and ﬂexibility [73]. PEG enhances
the nanoparticle’s lifetime in circulation, by preventing their inter-
action with plasma proteins [74–77]. Particularly for liposomal
nanoparticle systems their protective PEG layer can be achieved
through different methods. The main technique is the inclusion
of PEG-lipid conjugates (Fig. 1) into the lipid ﬁlm of the liposo-
mal formulation. Upon hydration, the liposomes are formed with
PEG polymers exposed on the surfaces [78]. The other techniques
are based on the formation of the liposomal platform before the
addition of PEGpolymers. Themethod of post-conjugation, includes
the covalent attachment of functionalised PEG to the pre-formed
nanoparticles. Post-insertion, on the other hand, is performed by
incubating the pre-formed liposomes with PEG-lipid conjugates in
aqueous solution [79]. The amphiphilic nature of the PEG-lipids
renders them into micellar structures, and their insertion into lipo-
somal surfaces is perceived as amethod of relievingmicellar strain.
However, the method of preparation, the conﬁguration and
the effect of the PEG layer is dependent on the PEG chain length
and their surface densities. The effect of such a layer depends on
its optimisation of the organisation of the PEG chains [80–83].
Although the inclusion of PEG onto liposomal surfaces improves
their efﬁciencies for transport to the tumour sites, it is important
to remember that their presence may hinder their binding to and
uptake by cancer cells.The incorporated PEG-lipid conjugates need to be able to render
steric stability of the nanoparticles and be able to prevent surface
adsorption of opsonin proteins. Higher coverage of liposomal sur-
faces is achieved by introducing higher densities of PEG-lipids in
liposomal systems [84]. However, in the case of liposomes, there is
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eight of approximately 2000Da. PEG units in both lipids are capped at the distal e
maximum molar percentage of the PEG-lipids that can be incor-
orated into the lipid formulation before they become detrimental
o systemic delivery. A liposomal membrane is held together by
on-covalent interactions, therefore the PEG-lipid conjugates are
usceptible to dissociation from the liposomes if the PEG density is
ub-optimal.
When presented on a liposomal surface, individual PEG chains
xhibit a Flory dimension, Rf, which represents the volume that
achﬂexiblePEGcloudoccupies. Longerpolymerchainshave larger
f, although studies have shown that the PEG density on a lipo-
ome surface is more important that the size of the polymer [85].
he Rf of a PEG2000 chain is approximately 5.6nm, and in conjunc-
ion with grafting density, affects the resultant conformation of the
EG chains. Increasing the amount of PEG-lipidswithin a liposomal
ormulation increases the PEG density, which ultimately reduces
he distance, D, between each PEG molecule on the nanoparti-
le surface. When D>Rf, the PEG chains will self-assemble into a
andom-coil like mushroom cloud. When D<Rf, the lateral pres-
ure between the overcrowded PEG mushroom clouds will force
he extension of the PEG chains into a brush conformation (Fig. 2)
86]. The brush regime results from the increased lateral pressure
etween thePEGchains,which forces theextensionof thepolymers
way from the surface, into more linear conformations.
What prolongs a nanoparticle’s retention time in circulation
s its ability to avoid interaction with plasma proteins [87]. The
rrangement of surface PEGs into brush conﬁgurations generates
reater protein repulsion, and generally enhances a liposome’s
ifetime in circulation [88–90]. Another phenomenon related to
rotein adsorption is the recognition of PEGylated liposomes by
ig. 2. Representation of different PEG conformations, formed through their incor-
oration onto surfaces at different densities. When the distance between the
EG-lipids, D, is greater than the Flory diameter of the PEG (D>Rf), the polymer
ill collapse into a mushroom conﬁguration. When D<Rf, the PEG chains will be
xtended from the surface to form a brush-like conformation.s shown are formed with a PEG chain of 45 monomers, correlating to a molecular
th a methoxy group, and conjugated to a DSPE lipid (a), or a DPPE lipid (b).
anti-PEG antibodies [91–93]. This effect has been reported to
occur between 2 and 4 days after the ﬁrst administration of PEG-
liposomes, and leads to the event of accelerated blood clearance
of further PEG-liposomes administered at repeat doses [94–96].
There are yet no data on other pegylated nanoparticles induced
PEG–antibodies and such phenomenon should be critically investi-
gated in the preclinical development of nanoparticles. What is left
is therefore the optimisation of a delivery system with an optimal
amountof PEG-lipids,where too little doesnotprovide enoughcov-
erage to evade protein adsorption, and too much results in removal
of the PEG-lipids.
Inorganic nanoparticles require different methods of coating or
introducing the biocompatibility and colloidal stability layers. Gen-
erally this is performed by the co-precipitation of the particleswith
various typesofpolymersor cross-linkedpolymers [97] a technique
that can improve the particlemonodispersity, an important param-
eter regarding their biological applications. Dextran, albumin and
PEG (Mw 5000) are all types of molecules that have been studies
as coating materials for providing biocompatibility to iron oxide
nanoparticles [98]. PEG with a Mw of 5000 was added as a coating
layer on iron oxide nanoparticles to improve biocompatibility [99].
Gold nanoparticles provide a more suitable surface for PEG-
grafting. Thiol–PEG or bifunctional PEG can be added on the
surface to provide colloidally stable and biocompatible gold
nanoparticles [100]. Sulfydrylated PEG has been added to gold
nanoparticles toprovide38nmnanoparticle that gaveablood–pool
contrast agent for tumour vascular structures [101]. Recently,
PEG bidentate ligands (PEG-thioctic acid and PEG-dihydrolipoic
acid) were introduced onto quantum dots and gold nanoparti-
cles to provide substantially improved stability in biological media
[102].
In contrast to liposome based nanoparticles inorganic nanopar-
ticles form much smaller structures even when coated with a
biocompatibility layer. It is still unknown the effect of the PEG
size and grafting density on all nanoparticle kinetics and accumu-
lation in tumours. For liposomes some studies have indicated the
important role of PEG, however there is minimum work done on
the role of PEG on the kinetics of inorganic nanoparticles. Further
dendrimers and biodegradable polymers’ Pegylation is too variable
to observe trends. On biodegradable polymer nanoparticles PEG is
introduced as part of the copolymer and in most cases a micelle is
formed [103].
3.2. Nanoparticle cancer recognition-targeting ligandsThe addition of a targeting moiety onto the surface of nanopar-
ticles (Fig. 3) aims to increase selective cellular binding and
internalisation through receptor-mediated endocytosis. Without
the incorporation of targeting ligands, nanoparticles rely on non-
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of inducing receptor-mediated endocytosis. Depending on the type
of ligand–receptor interaction, the rate of cellular internalisation
would differ. This is an important factor as rates of internalisa-
tion could affect the accumulation of nanoparticle in tumour sites.
Some ligand species, such as folate, have been shown to haveig. 3. Representation of targeted and non-targeted liposomal nanoparticle system
igands, which can be of an antibody (full or fragment), small molecule, Antibody pe
rugs, such as doxorubicin, or nucleic acids, such as DNA or siRNA.
peciﬁc interactions with cell membranes, which can be low when
overed in a layer of PEG polymers. The targeting effect of the sur-
ace ligands is dependent not only on the nature of the ligand itself,
ut also on a variety of factors that require cooperative optimi-
ation. Discussed in this section are examples of ligand-targeted
anoparticle systemswith emphasis on liposomes. These examples
iffer from each other inmanyways, including liposomal lipid con-
ent, type of ligand, method of ligand loading, degree of PEGylation
nd ligand density. With attention to the physical and biological
ffects of differently prepared nanoparticles, patterns that lead to
nhanced drug delivery to cancers, through the effect of targeting
igands, can be derived.
One challenge of targeting cancers and tumours is that the
efective cells are often very similar in characteristics to its sur-
ounding healthy tissue. To differentiate such cells, the ligands
an be designed to have speciﬁcity for receptors that are over-
xpressed on cancerous cells, but are normally or minimally
xpressed on normal, healthy cells. These molecules should have
igh afﬁnity to their cognate receptors, plus have innate abili-
ies to induce receptor-mediated endocytosis. The targeting layer
oses as the outmost exterior of the nanoparticle delivery sys-
em, where targeting ligands are generally presented on top of the
tealth layer [104]. Structures such as antibodies, antibody frag-
ents, proteins, small molecules, aptamers and peptides have all
emonstrated abilities to induce nanoparticle-targeting to cancer
ells.
Antibodies against the HER-2 receptor, the transferrin receptor
TfR) and the prostate speciﬁc antigen receptor are both com-
on examples of receptor targets, due to their over-expression of
uch receptors on cancer cells [105–108]. These antibodies gen-
rally exhibit strong interactions with corresponding receptors,
ith dissociation constants in the nanomolar range. Antibody frag-
ents, consisting of only the Fab binding regions, have also been
tudied as targeting ligands [109,110]. The advantages of such
tructures is that they are smaller, and do not contain the Fc region
f the antibody which can induce immunogenicity and antigenic-
ty when present on liposome surfaces [111–113]. Like antibodies
nd antibody fragments, the use of whole proteins is also com-
only considered as targeting ligands for their increased afﬁnity
or target receptors. For example, the natural ligand for TfR, trans-
errin, binds to its receptor with a dissociation constant of around
d =40nM. On overcoming systemic barriers to arrive in tumour
icinities, targeted liposomes have greater opportunities for bind-
ng to cancer cells if the ligand has naturally high afﬁnities for the
orresponding receptor. Another protein that has shown potential
or cancer targeting is the urokinase plasminogen activator, uPA,
natural ligand for the urokinase plasminogen activator receptor.
xamples haveusedprotein fragments, containing only thebinding
egion of uPA for targeting the over-expressed receptors on colon
ancers and breast cancers [114].targeted nanoparticles are functionalised with an outer layer of receptor-speciﬁc
r aptamer. The aqueous core of the liposomal nanoparticle can contain hydrophilic
Peptide sequences pose as even shorter and smaller versions of
antibody andprotein fragments. Derived fromphage display assays
and X-ray crystallography studies, short peptide sequences with
receptor-speciﬁcity have also beenused for nanoparticle-targeting.
For uPAR, peptides such as the U11 peptide were identiﬁed from
examination of the binding region of uPA [115,116]. Our work
has focused on promoting this peptide for targeting prostate and
breast cancer cells [117]. Another prominent example of peptide
ligands is the RGD peptide (Fig. 4), identiﬁed through phage dis-
play tohavehigh afﬁnity to53 integrin receptors over-expressed
on angiogenic vasculatures [118–120]. Other types of shorter lig-
ands include small molecules such as anisamide, a ligand for
sigma receptors over-expressed on lung cancer cells [121,122],
and folic acid (Fig. 4), speciﬁc for the folate receptors on ovar-
ian cells [123–125], are more examples of targeting moieties for
nanoparticle-targeting.
Ligands chosen for receptor-targeting should have the functionFig. 4. Structures of ligands commonly used to functionalize nanoparticle surfaces,
for inducing their speciﬁcity and internalisation characteristics to cancer cells. Top,
cyclicRGDpeptide, hasbeenused to targetv3 integrins,whichareover-expressed
on tumour vasculature. Bottom, folic acid, a ligand used to target the folate receptors
on ovarian cancer tissue.
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ast internalisation as well as cell surface recycling rates in can-
er cells [126]. On binding, ovarian cells, characterised to express
–18×106 folate receptors/cell, can internalise 3×105 molecules
f folic acid/h. This inherent property of the ligand–receptor con-
ugate could enhance accumulation of nanoparticles by faster
learance from the tumour interstitium through faster internalisa-
ion of ligand-conjugated nanoparticles. Creating greater diffusion
radientswould encourage faster diffusion of nanoparticle through
he tumour vasculature. The ligands also need to be conjugated
nto nanoparticles in an optimal fashion, as tomaintain their afﬁni-
ies for their corresponding receptors. For example, the measured
issociation constants for optimally conjugated HER-2 antibodies
ere similar to free antibodies, around 12-15nM, depending on
he surface PEG density [112,127]. The targeting layer is presented
s the ultimate exterior of the nanoparticle, the surface that inter-
cts primarily with cell membranes. Irrespective of their nature,
he ligand must have the right conformation, high afﬁnities for
orresponding receptors, and be able to exhibit high rates of cel-
ular internalisation. Furthermore, the loading and presentation of
he ligand on nanoparticle surfaces must be cooperative with the
tealth layer.
It is important to incorporate PEG chains at densities that
llow optimal coverage, which means inducing brush conforma-
ions on nanoparticle surfaces, as discussed earlier. As the brush
onformation allows the extension of the PEG chains away from
he nanoparticle surface, presenting targeting ligands on such a
latform should allow increased interactions with correspond-
ng receptors. The use of antibodies as targeting ligands has been
idely studied due to their high afﬁnities to cognate receptors. A
rominent example has been the use of HER-2 antibodies, which
arget the HER-2 receptor that are over-expressed on cancer cells
128–130]. Incorporation of anti-HER2 antibodies onto the sur-
aces of PEGylated liposomes has indeed shown greater efﬁciency
or drug delivery compared to non-targeted PEG-liposomes [131].
reatment of tumour models with doxorubicin-encapsulated lipo-
omesenabled completedepletion in subcutaneous tumours,when
he antibodies are conjugated onto a liposomal platform of opti-
al PEG2000 density (6mol%). In this case, and in most examples
f targeted nanoparticles, increased therapeutic effect of targeted
anoparticles is a result of increased tumour cell uptake, and not
umour-accumulation (within tumour interstitium). Both targeted
nd non-targeted nanoparticles arrive at the tumour vicinity via
he EPR effect, after which the mechanism of tumour cell internal-
sation is enhanced by the presence of surface ligands.
Although the presentation of ligands on a PEG-brush surface
nhances their binding to receptors, their improved exposure can
ecrease the nanoparticle lifetimes in circulation. Using an RGD-
argeted stealth system, nanoparticles carrying doxorubicin were
ound to accumulate faster and in higher concentrations in the
iver and the spleen [132]. Faster clearance from circulation gener-
lly corresponds to a higher and faster accumulation into the liver
nd the spleen (RES). In this example, the total amount of PEG2000
ontent was included at optimal brush densities, at 6.5mol%.
he ligands are incorporated as RGD-PEG-lipid conjugates, which
ndicates their extension from the nanoparticle surface as a con-
equence of the brush-like state. Presentation of the ligand in a
EG-brush fashion reveals the targeting molecules increasingly
o plasma proteins, hence their faster clearance from circulation
ould be a result of Fc-mediated RES uptake into liver and spleen-
ssociated macrophages [133,134]. When ligands are loaded onto
iposomes of ambient PEG2000 density (5–7mol%), what is gener-
lly observed is a faster clearance from circulation, accompanied
y a higher accumulation and internalisation into cancer cells
131,135–137].
Most nanoparticle examples that describe successful receptor-
argeting, use targeting ligands that are loaded onto nanoparticlecal Research 62 (2010) 90–99
surfaces via a PEG spacer. The rationale for such an action lies in the
extension of the ligand from the nanoparticle platform, enhancing
its ﬂexibility and interaction with receptors. Our own work has
examined the effects of presenting a ligand without a PEG spacer
[117]. Through the synthesis of a peptide–lipid conjugate, we were
able to functionalise the surfaces of liposomes with peptide ligands
speciﬁc for the urokinase plasminogen activator receptor. These
targeted systems were able to induce enhanced cell-binding and
gene delivery compared to non-targeted nanoparticles. However,
these ligands are exposed at reduced proximities to nanoparticle
surfaces, an event that becomes problematic when long PEG chains
are included.
Addition of PEG2000 molecules at optimal densities for in vivo
delivery is essential, but results in the sterically shielding of the
short peptide-lipids, hence preventing their interaction with cel-
lular receptors. Similar studies, using a RGD-type peptide for
targeting 53 integrins, also describe this ﬁnding. This report
showed that short peptide-targeted nanoparticles exhibited lower
cell-binding abilities when higher mol% of PEG2000 was included
into the formulation [106,138]. As a sufﬁcient PEG coating is essen-
tial for avoiding recognition by the RES, ligands should be extended
away fromnanoparticle surfaces, to avoid shielding by the polymer
chains.
The chain length of the PEG spacer between the ligand and
the nanoparticle surface also requires consideration. When the
chain length of the PEG spacer is longer than the other PEG chains
involved in the PEG-brush, the conjugated ligand can become
buried within the brush layer [139]. The extra units of a longer PEG
spacer are subject to mushroom-like folding, which results again
in limited exposure of the ligand. Implications of this effect have
been described with a folate-targeted liposome. Conjugation of the
folate through a PEG3400 spacer, when the rest of the stealth con-
tent is comprised of PEG2000, the effect of the ligand is not apparent.
The folate-targeted nanoparticles were unable to increase tumour-
accumulation, plus theydidnot exhibit short circulation lifetimes, a
consequence commonly accompanying an effectively exposed lig-
and [134]. The ligand-conjugated PEG spacer therefore needs to be
at the same length as the stealth constituent on the surface of the
nanoparticle.
Concentration of surface ligands is another parameter that
affects the ligands’ targeting effect [140]. Higher ligand densi-
ties are envisioned as a method of increasing the probability
of nanoparticle interactions with cell receptors (multivalency).
However, the presence of increased non-PEG-like material on
nanoparticle surfaces can be more detrimental than advanta-
geous to delivery. A study using aptamers as a targeting ligand
for prostate cancer-speciﬁc antigens (PSMA) demonstrated that
higher densities of surface ligands resulted in greater accumula-
tion of nanoparticles into the liver and the spleen [141]. In that
study Gu et al. used poly (d,l-lactide-coglycolyde) [PLGA] and
PEG triblock copolymer based nanoparticles. The nanoparticles
were composed by PLGA-b-PEG and PLGA-b-PEG-b-Apt (aptamer
for PSMA) [141]. Localization of such nanoparticles in tumours
was also at lower concentrations compared to nanoparticles func-
tionalized with lower densities of aptamers. This suggests that
higher coverage of the PEGylated nanoparticles’ surfaces with tar-
geting ligands further shields the effect of the PEG layer, hence
resulting in greater recognition by tumour and spleen-associated
macrophages.
Later studies using a HER-2 targeting system enhanced this
argument,whereheavy-ligand loading led tohigher clearance rates
from circulation [142]. High surface coverage of ligands there-
fore renders the PEG layer obsolete, an occurrence that needs
to be avoided in order to reduce interactions with plasma pro-
teins. Although the physical implications of ligand loading were
not studied, the biological effects of antibody-targeted nanoparti-
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les demonstrate the importance of optimising ligand densities for
aximising their targeting abilities [143].
Examples of targeted nanoparticle drug delivery systems have
hown faster and higher concentration accumulation in tumours,
ompared to non-targeted systems [133,144]. Generally it is
elieved that the introductionof targeting ligandsdoesnot enhance
anoparticle accumulation into tumours, but shows higher efﬁ-
acy by enhancing internalisation into tumour cells. However, in
ome cases of antibody and folate-targeted nanoparticles accu-
ulation into tumours was faster than compared to non-targeted
anoparticles [133,144–146]. This occurrence is envisioned as
consequence of recognition of the nanoparticles by tumour-
ssociated macrophages (TAM) [134,147–150]. In response to this
ypothesis, folate receptors have been identiﬁed to be over-
xpressed on TAMS. This effect of TAM-recognition is pronounced
hen the folate ligands are loaded onto PEG-brushes, a conforma-
ion that highlights the exposure of the ligands.
. Summary and future perspectives
Here, we present an overview of the clinically used and tested
anoparticles for imaging and treatment of cancer. Currently,
oth clinical and preclinical studies show a variety of the type
f nanoparticles developed for cancer. There are more types of
anoparticles currently at an early design step that may progress
n the future to preclinical development for cancer imaging and
herapy. From all these nanoparticles, we would like to highlight
he potential value of theragnostic nanoparticles. These nanopar-
icles are designed to do both imaging (diagnosis) and therapy (i.e.
hemotherapy or genetic therapy). A particular version of these
anoparticles is the “activation”-theranostic nanoparticles. In this
ase nanoparticles are monitored for their kinetics in tumours.
hen imaging (i.e. MRI) shows maximum nanoparticle accumula-
ion in tumours a physical source is applied to change the status of
henanoparticles andburst-release thedrug. Suchsourcecanbe the
IR laser, induced heat or the ultrasound induced heat or light for
hotosensitive components. The changes induced on the nanopar-
icles can be nanoparticle decomposition, or “melting” releasing
apidly and locally the active (i.e. chemotherapy). The combination
f hyperthermia and locally delivered anticancer agents can lead
o very speciﬁc tumour only cell killing in a short period of time.
his way surgery and/or chronic chemotherapy treatments can be
voided.
We have also highlighted important factors that affect the per-
ormance of PEG-coated nanoparticles, the PEG size and its grafting
ensity, based on the liposome nanoparticle example. The cou-
ling of PEG and ligands on the nanoparticles, needs to be designed
nd studied for optimum circulation times, binding and tumour
ell uptake. It is an important fact that targeting ligands lead
o macrophage recognition and faster clearance compared to the
on-targeted nanoparticles. In the future nanoparticles’ design
hould introduce cleavable masking of the ligands till reaching
he tumour cells. A thorough study of the effect of PEG size and
ensity on nanoparticle kinetics, is needed. As well as more stud-
es are required on the clearance mechanism, the metabolism and
xcretion of nanoparticles and their components.
Nanoparticles for cancer imaging and therapy have evolved
apidly during the last decade and it is expected that more and
ore will become clinical practise. Their controlled size and multi-
unctionality are the main reasons for their increasing applications
s anticancer agents.eferences
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